var title_f3_20_3392="Double opposing z-plasty";
var content_f3_20_3392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Double opposing Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3392=[""].join("\n");
var outline_f3_20_3392=null;
var title_f3_20_3393="Congenic breeding scheme";
var content_f3_20_3393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Recombinant congenic breeding scheme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 515px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    RC breeding scheme. Donor strain genetic material is shown in white and recipient genetic material is shown in black. There are 2 stages in the RC breeding program. The behavior of a schematic autosome pair is depicted during each of these stages. Stage 1 consists of repeated backcrosses to the recipient strain, so as to reduce the donor contribution to the genotype. There is no selection for donor alleles. Stage 2 occurs as independent sib-pairs from the second backcross generation are used to establish new inbred strains, with full-sib matings at each gneration. Inbreeding fixes the genotype of the strain, with most loci becoming homozygous by the 12th generation. The resulting array of genotypes is shown schematically at the bottom of the figure. Only 1 copy of the schematic autosome from each strain in the set is shown. The donor contributions in each strain in the set are map loci contributing to continuously varying traits and eliminates the need for genotyping to achieve the resolution achieved by QTL quantitatively similar, but the specific chromosome regions of donor genotype will differ from one strain to another.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Demant P, Hart AA. Immunogenetics 1986; 24:416.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3393=[""].join("\n");
var outline_f3_20_3393=null;
var title_f3_20_3394="Metastatic neuroblastoma skull";
var content_f3_20_3394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Metastatic neuroblastoma of the skull",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bone itself has developed an osteoclastic reaction. There is an intracranial component of the metastasis putting pressure on the brain and causing a midline shift.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3394=[""].join("\n");
var outline_f3_20_3394=null;
var title_f3_20_3395="Smoking and hypertension";
var content_f3_20_3395=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Smoking and hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3395/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3395/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3395/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3395/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3395/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3395/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3395/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/20/3395/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     SMOKING AND HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tobacco use is the most common cause of avoidable cardiovascular mortality worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/1\">",
"     1",
"    </a>",
"    ]. There are now 1.3 billion cigarette smokers, 82 percent in developing countries, and if current practices continue, there will be an estimated one billion tobacco-related deaths during the 21st century. The immediate noxious effects of smoking are related to sympathetic nervous overactivity, which increases myocardial oxygen consumption through a rise in blood pressure, heart rate, and myocardial contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronically, cigarette smoking induces arterial stiffness which may persist for a decade after smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of hypertension is increased among those who smoke 15 or more cigarettes per day [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/4\">",
"     4",
"    </a>",
"    ], and the coexistence of hypertension and smoking decreases left ventricular function in asymptomatic people [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With each cigarette, the blood pressure rises transiently and the pressor effect may be missed if the blood pressure is measured 30 minutes after the last smoke. The transient rise in blood pressure may be most prominent with the first cigarette of the day even in habitual smokers. In one study of normotensive smokers, there was an average elevation in systolic pressure of 20 mmHg after the first cigarette (",
"    <a class=\"graphic graphic_figure graphicRef58131 \" href=\"UTD.htm?28/38/29293\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, ambulatory blood pressure monitoring suggests an interactive effect between smoking and coffee drinking in patients with mild essential hypertension, resulting in a mean elevation in daytime systolic pressure of approximately 6.0 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, habitual smokers generally have",
"    <strong>",
"     lower",
"    </strong>",
"    blood pressures than nonsmokers as observed in most [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/10\">",
"     10",
"    </a>",
"    ], studies. The mild reduction in BP in smokers is related to decreased body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/11\">",
"     11",
"    </a>",
"    ]. Support for this observation is the higher body weight and increased blood pressure among former smokers versus that observed among never-smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/12\">",
"     12",
"    </a>",
"    ]. A vasodilator effect of cotinine, the major metabolite of nicotine, also may contribute to the lower blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these observations, smoking should be avoided in any hypertensive patient because it can markedly increase the risk of secondary cardiovascular complications and enhance the progression of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An example of the latter effect was observed in one prospective study (with a mean follow-up of 35 months) that examined the factors associated with alterations in renal function among 53 hypertensive patients in whom the serum creatinine concentration rose from 1.5 to 1.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133 to 168",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    despite a significant reduction in the target mean blood pressure (127 to 97 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3395/abstract/14\">",
"     14",
"    </a>",
"    ]. Smoking was the most significant independent factor underlying progressive renal disease (serum creatinine 1.5 and 2.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133 and 186",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    at the beginning and end of the study for smokers, respectively, versus 1.25 and 1.32",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [110 and 117",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    for nonsmokers, respectively). The mechanism underlying this adverse effect is unclear but may be related to the transient increase in systemic blood pressure with smoking being transmitted to the glomerulus, resulting in glomerular hypertension.",
"   </p>",
"   <p>",
"    Cessation of smoking can rapidly lower the risk of coronary heart disease by 35 to 40 percent; this benefit is independent of the duration of smoking. It is unclear whether cessation of smoking has a similar benefit in helping preserve renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1276922\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With each cigarette, the blood pressure rises transiently and the pressor effect may be missed if the blood pressure is measured 30 minutes after the last smoke. The transient rise in blood pressure may be most prominent with the first cigarette of the day even in habitual smokers.",
"     </li>",
"     <li>",
"      Habitual smokers generally have lower blood pressures than nonsmokers. The mild reduction in BP in smokers is related to decreased body weight. A vasodilator effect of cotinine, the major metabolite of nicotine, also may contribute to the lower blood pressure.",
"     </li>",
"     <li>",
"      Smoking should be avoided in any hypertensive patient because it can markedly increase the risk of secondary cardiovascular complications and enhance the progression of renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/1\">",
"      Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/2\">",
"      Najem B, Houssi&egrave;re A, Pathak A, et al. Acute cardiovascular and sympathetic effects of nicotine replacement therapy. Hypertension 2006; 47:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/3\">",
"      Jatoi NA, Jerrard-Dunne P, Feely J, Mahmud A. Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension. Hypertension 2007; 49:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/4\">",
"      Bowman TS, Gaziano JM, Buring JE, Sesso HD. A prospective study of cigarette smoking and risk of incident hypertension in women. J Am Coll Cardiol 2007; 50:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/5\">",
"      Rosen BD, Saad MF, Shea S, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2006; 47:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/6\">",
"      Groppelli A, Giorgi DM, Omboni S, et al. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992; 10:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/7\">",
"      Narkiewicz K, Maraglino G, Biasion T, et al. Interactive effect of cigarettes and coffee on daytime systolic blood pressure in patients with mild essential hypertension. HARVEST Study Group (Italy). Hypertension Ambulatory Recording VEnetia STudy. J Hypertens 1995; 13:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/8\">",
"      Mikkelsen KL, Wiinberg N, H&oslash;egholm A, et al. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am J Hypertens 1997; 10:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/9\">",
"      Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J 1986; 111:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/10\">",
"      Primatesta P, Falaschetti E, Gupta S, et al. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/11\">",
"      Perkins KA, Epstein LH, Marks BL, et al. The effect of nicotine on energy expenditure during light physical activity. N Engl J Med 1989; 320:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/12\">",
"      Poulter NR. Independent effects of smoking on risk of hypertension: small, if present. J Hypertens 2002; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/13\">",
"      Benowitz NL, Sharp DS. Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 1989; 80:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/14\">",
"      Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3395/abstract/15\">",
"      Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13:1663.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3866 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0322F712F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3395=[""].join("\n");
var outline_f3_20_3395=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1276922\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      SMOKING AND HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1276922\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3866|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/38/29293\" title=\"figure 1\">",
"      Smoking acutely raises BP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_20_3396="Normal saline implants";
var content_f3_20_3396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal saline implants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral CC (panels A and B) and MLO (panels C and D) mammographic views obtained with a saline implant in place. The implant capsule is intact. Normal folds (long arrow) and implant valve (short arrow) can be seen.",
"    <div class=\"footnotes\">",
"     CC: cradiocaudal; MLO: mediolateral oblique.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3396=[""].join("\n");
var outline_f3_20_3396=null;
var title_f3_20_3397="Type 1 diabetes mellitus and diet";
var content_f3_20_3397=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/20/3397/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3397/contributors\" id=\"au872\">",
"       Linda M Delahanty, MS, RD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3397/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/20/3397/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3397/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/20/3397/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3397/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/20/3397?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Diet and physical activity are critically important in the management of the ABCs (",
"     <strong>",
"      A",
"     </strong>",
"     1C,",
"     <strong>",
"      B",
"     </strong>",
"     lood pressure and",
"     <strong>",
"      C",
"     </strong>",
"     holesterol) of type 1 diabetes. To effectively manage A1C (hemoglobin A1C) and achieve stable blood sugar control, it is important to understand how to balance food intake, physical activity, and insulin.",
"    </p>",
"    <p>",
"     Making healthy food choices every day has both immediate and long-term effects. With education, practice, and assistance from a dietitian",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a diabetes educator, it is possible to eat well and control diabetes.",
"    </p>",
"    <p>",
"     This topic discusses how to manage diet in people with type 1 diabetes. The role of diet and activity in managing blood pressure and cholesterol is reviewed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY IS DIET IMPORTANT?",
"     </span>",
"    </p>",
"    <p>",
"     Many factors affect how well diabetes is controlled. Many of these factors are controlled by the person with diabetes, including how much and what is eaten, how frequently the blood sugar is monitored, physical activity levels, and accuracy and consistency of medication dosing. Even small changes can affect blood sugar control.",
"    </p>",
"    <p>",
"     Eating a consistent amount of food every day and taking medications as directed can greatly improve blood sugar control and decrease the risk of diabetes-related complications, such as coronary artery disease, kidney disease, and nerve damage. In addition, these measures impact weight control. A dietitian can help to create a food plan that is tailored to your medical needs, lifestyle, and personal preferences.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES AND MEAL TIMING",
"     </span>",
"    </p>",
"    <p>",
"     Consistently eating at the same times every day is important for some people, especially those who take long-acting insulin (eg, NPH). If a meal is skipped or delayed, you are at risk for developing low blood glucose.",
"    </p>",
"    <p>",
"     People who use intensive insulin therapy (those on an insulin pump or multiple daily insulin injections) have more flexibility around meal timing. With these regimens, skipping or delaying a meal does not usually increase the risk of low blood sugar.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      High fat meals",
"     </span>",
"     &nbsp;&mdash;&nbsp;Foods or meals that are high in fat (eg, pizza) may be eaten occasionally, although blood glucose levels should be monitored more closely. High-fat meals are broken down more slowly than low-fat meals. When using rapid acting insulin (eg, Humalog, Novolog) before a meal, the blood sugar level may become low shortly after eating a high fat meal and then rise hours later.",
"    </p>",
"    <p>",
"     People who use an insulin pump can use an extended insulin delivery regimen to better manage blood sugar levels after eating a high-fat meal. People who give insulin injections do not generally adjust their treatment based upon the fat content of their meal.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES AND CARBOHYDRATE CONSISTENCY",
"     </span>",
"    </p>",
"    <p>",
"     Carbohydrates are the main energy source in the diet, and include starches, vegetables, fruits, dairy products, and sugars. Most meats and fats do not contain any carbohydrates.",
"    </p>",
"    <p>",
"     Carbohydrates have a direct impact on the blood sugar level whereas proteins and fat have little to no impact. Eating a consistent amount of carbohydrates at each meal can help to control blood sugar levels, especially if you take long-acting insulin (eg, NPH).",
"    </p>",
"    <p>",
"     There are several ways to calculate carbohydrate content of a meal, including carbohydrate counting and exchange planning.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Carbohydrate counting",
"     </span>",
"     &nbsp;&mdash;&nbsp;A dietitian usually helps to determine the number of carbohydrates needed at each meal and snack, based upon your usual eating habits, insulin regimen, body weight, nutritional goals, and activity level. In most people, between 45 and 65 percent of the day's total calories should come from carbohydrates.",
"    </p>",
"    <p>",
"     The way carbohydrates are divided up for each meal or snack is based upon personal preferences, meal timing and spacing, and type of insulin regimen (",
"     <a class=\"graphic graphic_table graphicRef73017 \" href=\"UTD.htm?36/1/36891\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The number of carbohydrates in a food can be determined by reading the nutrition label, consulting a reference book or website, carrying a database on a personal digital assistant (PDA), or using the Exchange system. Restaurants usually have this information available upon request. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     It is important to note the serving size and grams of fiber when calculating carbohydrates. Eating more than one serving will increase the number of calories and carbohydrates consumed and the dose of insulin needed to cover the meal. For example, some pre-packaged snacks contain two or more servings. To calculate the carbohydrate content of the entire package, multiply the number of servings by the number of carbohydrates.",
"    </p>",
"    <p>",
"     When a serving of food has more than 5 grams of fiber, the grams of fiber should be subtracted from the grams of carbohydrates to calculate the insulin dose (",
"     <a class=\"graphic graphic_figure graphicRef76576 \" href=\"UTD.htm?0/2/40\">",
"      figure 1",
"     </a>",
"     )&nbsp;[",
"     <a class=\"abstract\" href=\"UTD.htm?3/20/3397/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28778107\">",
"     <span class=\"h2\">",
"      Exchange planning",
"     </span>",
"     &nbsp;&mdash;&nbsp;With exchange planning, all foods are categorized as either a carbohydrate, meat or meat substitute, or fat. In this system, one serving of a carbohydrate (eg, one small apple) can be exchanged for any other carbohydrate (eg,",
"     <span class=\"nowrap\">",
"      1/3",
"     </span>",
"     cup cooked pasta) because both servings contain about 15 grams of carbohydrate. You can also easily determine the carbohydrate content of your meals and snacks using the Exchange system (",
"     <a class=\"graphic graphic_table graphicRef70878 \" href=\"UTD.htm?22/35/23101\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The exchange lists also identify foods that are good sources of fiber, and foods that have a high sodium content. A dietitian can help you determine how many servings of each group should be eaten at each meal and snack (",
"     <a class=\"graphic graphic_table graphicRef70878 \" href=\"UTD.htm?22/35/23101\">",
"      table 2",
"     </a>",
"     ) and the typical carbohydrate content of each meal and snack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Intensive insulin therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who use an insulin pump or take multiple injections of rapid-acting insulin per day can adjust their pre-meal insulin dose based upon the number of carbohydrates they plan to eat and their pre-meal blood sugar. This requires the person to perform basic arithmetic.",
"    </p>",
"    <p>",
"     The pre-meal insulin dose is calculated by dividing the number of carbohydrates to be consumed by the number of carbohydrates covered by one unit of insulin (insulin-to-carbohydrate ratio). This dose is then adjusted based upon the pre-meal blood sugar reading (see correction factor below). Some insulin pumps can perform these calculations.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Insulin-to-carbohydrate ratio &mdash; An insulin-to-carbohydrate ratio is determined by a dietitian or diabetes educator. This allows you to calculate the dose of rapid-acting insulin needed to cover a meal or snack.",
"       <br/>",
"       <br/>",
"       For example, if the insulin-to-carbohydrate ratio is 1 to 10, then you would give 1 unit of insulin for every 10 grams of carbohydrate consumed. If you ate a meal with 70 grams of carbohydrates, the dose of rapid-acting insulin would be 7 units. Most insulin pumps are able to give tenths of a unit, so that 78 grams of carbohydrate would require 7.8 units of insulin.",
"      </li>",
"      <li>",
"       Correction factor &mdash; The pre-meal insulin dose can also be adjusted based upon the pre-meal blood sugar level; this is called a correction factor. The correction factor can be determined by a dietitian or diabetes educator.",
"       <br/>",
"       <br/>",
"       For example, let's assume that the correction factor is 30. If the pre-meal blood sugar was 240",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       and the goal BG was 120",
"       <span class=\"nowrap\">",
"        mg/dL,",
"       </span>",
"       take 240 minus 120 = 120. Then divide 120 by 30 = 4 extra units of insulin to correct the high blood sugar level.",
"       <br/>",
"       <br/>",
"       For patients whose blood sugar is measured in",
"       <span class=\"nowrap\">",
"        mmol/L,",
"       </span>",
"       a different formula is used. Let's assume a correction factor of 2. If the pre-meal blood sugar was 14",
"       <span class=\"nowrap\">",
"        mmol/L",
"       </span>",
"       and the goal blood sugar was 6",
"       <span class=\"nowrap\">",
"        mmol/L,",
"       </span>",
"       take 14 minus 6 = 8. Then divide 8 by 2 = 4 extra units of insulin to correct the high blood sugar.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHAT SHOULD I EAT?",
"     </span>",
"    </p>",
"    <p>",
"     While protein and fat do not affect blood glucose levels significantly, they do contribute to the number of calories consumed. Eating a consistent number of calories every day can help to maintain body weight. An individual's recommended calorie intake is discussed below. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Recommended calorie intake'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      General recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;The American Diabetes Association recommends the following to help manage the ABCs (",
"     <strong>",
"      A",
"     </strong>",
"     1C,",
"     <strong>",
"      b",
"     </strong>",
"     lood pressure and",
"     <strong>",
"      c",
"     </strong>",
"     holesterol) and promote good health:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Less than 25 to 35 percent of calories per day should be from fat, and less than 7 percent of calories per day should be from saturated fat; there should be minimal trans fat. Saturated and trans fats are found in solid fats like cheese, red meats, butter, margarine, and shortening. People with diabetes are at increased risk for heart disease and stroke, and eating a diet low in saturated and trans fats and cholesterol can help to manage cholesterol levels and decrease these risks.",
"      </li>",
"      <li>",
"       Total cholesterol intake should be less than 200 mg per day. The major sources of cholesterol in the diet are foods such as organ meats and egg yolks. Shrimp and squid are also moderately high in cholesterol, but can be included in your diet occasionally because they are low in fat.",
"      </li>",
"      <li>",
"       Between 15 and 20 percent of calories should be from protein, except in people with certain kidney problems (chronic kidney disease or CKD). People with CKD are sometimes advised to eat a low-protein diet. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"        \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A diet that is high in fiber (25 to 30 grams per day) may help to control blood sugar levels and AIC. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"        \"Patient information: High-fiber diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A diet that is low in sodium (less than 1500 mg per day) and that is high in fruits, vegetables, and low fat dairy products, is recommended and can help manage blood pressure. For people with diabetes and heart failure, a low sodium diet may reduce symptoms. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Artificial sweeteners do not affect blood sugar levels and may be consumed in moderation. The US Food and Drug Administration (FDA) has tested and approved five artificial sweeteners: aspartame (Equal, NutraSweet), saccharin (Sweet'N Low, Sugar Twin), acesulfame-K (Sunnet, Sweet One), neotame, and sucralose (Splenda). Stevia (sometimes called Rebaudioside A or rebiana) comes from the stevia plant and is now generally recognized as safe by the FDA as a food additive and table top sweetener. When something is generally recognized as safe by the FDA, it means that experts have agreed that it is safe for use by the public in appropriate amounts.",
"       <br/>",
"       <br/>",
"       Sugar alcohols (sorbitol, xylitol, lactitol, mannitol, and maltitol) are often used to sweeten sugar-free candies and gum, and increase blood sugar levels slightly. When calculating the carbohydrate content of foods, one-half of the sugar alcohol content should be counted in the total carbohydrate content of the food. Eating too much sugar alcohol at one time can cause cramping, gas, and diarrhea.",
"      </li>",
"      <li>",
"       Previously, people with diabetes were told to avoid all foods with added sugar. This is no longer necessary, although sugar should be eaten in moderation. If you take insulin, calculate your dose based upon the number of carbohydrates, which already includes the sugar content, as described above. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Carbohydrate counting'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Products that are \"sugar-free\" or \"fat-free\" do not necessarily have a reduced number of calories or carbohydrates. Read the nutrition label carefully and compare it to other similar products that are not sugar- or fat-free to determine which has the best balance of serving size and number of calories, carbohydrates, fat, and fiber.",
"       <br/>",
"       <br/>",
"       Some sugar-free foods, such as diet soda, sugar-free gelatin, and sugar-free gum, do not have a significant number of calories or carbohydrates, and are considered \"free foods.\" Any food that has less than 20 calories and 5 grams of carbohydrate is considered a free food, meaning that there are not enough calories or carbohydrates to affect your weight or require additional insulin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Recommended calorie intake",
"     </span>",
"     &nbsp;&mdash;&nbsp;The number of calories needed to maintain weight depends upon your age, sex, height, weight, and activity level. In general:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Men, active women &mdash; 15",
"       <span class=\"nowrap\">",
"        calories/pound",
"       </span>",
"      </li>",
"      <li>",
"       Most women, sedentary men, and adults over 55 years &mdash; 13",
"       <span class=\"nowrap\">",
"        cal/lb",
"       </span>",
"      </li>",
"      <li>",
"       Sedentary women, obese adults &mdash; 10",
"       <span class=\"nowrap\">",
"        cal/lb",
"       </span>",
"      </li>",
"      <li>",
"       Pregnant, lactating women &mdash; 15 to 17",
"       <span class=\"nowrap\">",
"        cal/lb",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     To lose 1 to 2 pounds per week (a safe rate of weight loss), subtract 500 to 1000 calories from the total number of calories needed to maintain weight.",
"    </p>",
"    <p>",
"     As an example, an overweight man who weighs 250 lbs would need to eat 2500 calories per day to maintain his weight. To lose weight, he should eat 1500 to 2000 calories per day. As weight is lost, his recommended calorie intake should be recalculated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES, DIET, AND WEIGHT",
"     </span>",
"    </p>",
"    <p>",
"     Your weight is a direct reflection of how much you have eaten and how active you are. Eating a consistent number of calories every day can help to control blood sugar levels and maintain body weight.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Avoiding weight gain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight gain is a potential side effect of intensive insulin therapy in type 1 diabetes. To avoid weight gain, the following tips are recommended.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Measure your weight on a regular basis (eg, once weekly). Weight gains of more than 2 to 3 pounds indicate a need to decrease what you eat or increase your activity. Do not wait until weight increases by 10 or more pounds to take action.",
"      </li>",
"      <li>",
"       As blood sugar control improves, it may be necessary to decrease your calorie intake by 250 to 300 calories to avoid weight gain.",
"      </li>",
"      <li>",
"       If blood sugar levels are frequently low at a particular time of day, talk to a healthcare provider about decreasing the insulin dose rather than adding a snack.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercising regularly can help to lose weight and keep it off. The recommended amount of exercise is 30 minutes per day most days of the week. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People who take insulin should check their blood sugar level before and after exercising. If exercise is vigorous and prolonged (more than thirty minutes), check your blood sugar every fifteen minutes (if the exercise regimen is new and will be used again). Frequent monitoring can help to get a sense of what effect exercise has on your blood sugar level.",
"    </p>",
"    <p>",
"     If your blood sugar becomes low during exercise, eat a snack according to the guidelines below. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the blood glucose is 51 to 70",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.8 to 3.9",
"       <span class=\"nowrap\">",
"        mmol/L),",
"       </span>",
"       eat 10 to 15 grams of fast-acting carbohydrate (eg,",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       cup fruit juice, 6 to 8 hard candies, 3 to 4 glucose tablets).",
"      </li>",
"      <li>",
"       If the level is less than 50",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.7",
"       <span class=\"nowrap\">",
"        mmol/L),",
"       </span>",
"       eat 20 to 30 grams of fast-acting carbohydrates.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Retest after 15 minutes and repeat treatment if needed. If the next meal is more than an hour away, eat an additional 15 grams of carbohydrate and 1 ounce of protein (for example, crackers with cheese or one-half of a sandwich with peanut butter). Try not to eat too much because this can raise blood sugar levels above the target level and lead to weight gain over the long term.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Adjusting insulin dose for exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;It may be possible to reduce the insulin dose before exercising to avoid developing low blood glucose. A physician, diabetes educator, dietitian or exercise physiologist can help to determine the best way to adjust your insulin dose before, during, and after exercising. People who take oral diabetes medications usually do not need to adjust the dose of these medications for exercise.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES AND ALCOHOL",
"     </span>",
"    </p>",
"    <p>",
"     Drinking a moderate amount of alcohol (up to 1 serving per day for women, up to 2 servings per day for men) with food does not affect blood sugar levels significantly. Alcohol may cause a slight rise in blood sugar, followed hours later by a decrease in the blood glucose level. As a result, it is important to monitor blood sugar response to alcohol to determine if any changes in insulin doses are needed.",
"    </p>",
"    <p>",
"     Mixers, such as fruit juice or regular cola, can increase blood sugar levels and increase the number of calories consumed in a day. If mixers are consumed, a dose of insulin may be needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      TYPE 1 DIABETES AND EATING DISORDERS",
"     </span>",
"    </p>",
"    <p>",
"     Eating disorders are relatively common in people with diabetes, especially in female adolescents and young adults with type 1 diabetes. This may be due, in part, to the difficulty of balancing food intake, exercise, and blood sugar levels, which sometimes leads to weight gain, especially in people who use intensive insulin therapy or an insulin pump.",
"    </p>",
"    <p>",
"     People with eating disorders and diabetes often use unhealthy strategies to control their weight, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Giving less insulin than required (or no insulin).",
"      </li>",
"      <li>",
"       Severely restricting the amount of food eaten.",
"      </li>",
"      <li>",
"       Eating a large amount of food at one time (binge eating). After binging, some people vomit (purge), use laxatives inappropriately, or exercise excessively.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Eating disorders can cause serious complications in anyone, although the consequences for people with diabetes can be especially severe. The kidneys and retinas (in the eyes) are at high risk of becoming damaged as a result of eating disorders, especially if blood sugar levels are chronically high due to underdosing of insulin. Missing or underdosing insulin, even occasionally, is harmful.",
"    </p>",
"    <p>",
"     If you have concerns about your body weight, size, or shape, you should speak honestly with your healthcare provider. The provider can help to make a plan that includes a reasonable diet, exercise, and if needed, counseling regarding body image.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287377230\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962995\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=see_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=see_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/47/15091?source=see_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181963126\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"      Dietary carbohydrates",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Endocrine Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.endo-society.org/\">",
"      www.endo-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     The following reference books are a good source of information regarding diabetes and diet and carbohydrate counting.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Doctor's Pocket Calorie, Fat, and Carb Counter, Allan Borushek, also available for download to personal digital assistant at",
"       <a class=\"external\" href=\"file://www.calorieking.com/\">",
"        www.calorieking.com",
"       </a>",
"      </li>",
"      <li>",
"       Practical Carbohydrate Counting, Hope Warshaw and Karmen Kulkarni",
"      </li>",
"      <li>",
"       Smart Pumping: A Practical Approach to Mastering the Insulin Pump, Howard Wolpert",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/20/3397/abstract/2-6\">",
"      2-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/20/3397?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Panel on Macronutrients, Panel on the Definition of Dietary Fiber, Subcommittee on Upper Reference Levels of Nutrients, Subcommittee on Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board. Institute of Medicine of the National Academies. Washington, D.C. The National Academies Press; 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3397/abstract/2\">",
"      Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3397/abstract/3\">",
"      American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004; 27 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3397/abstract/4\">",
"      Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3397/abstract/5\">",
"      American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3397/abstract/6\">",
"      Sheard NF, Clark NG, Brand-Miller JC, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care 2004; 27:2266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_20_3397=[""].join("\n");
var outline_f3_20_3397=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TYPE 1 DIABETES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY IS DIET IMPORTANT?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPE 1 DIABETES AND MEAL TIMING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TYPE 1 DIABETES AND CARBOHYDRATE CONSISTENCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHAT SHOULD I EAT?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TYPE 1 DIABETES, DIET, AND WEIGHT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           TYPE 1 DIABETES AND ALCOHOL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           TYPE 1 DIABETES AND EATING DISORDERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/2/40\" title=\"figure 1\">",
"           Nutrition label PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/1/36891\" title=\"table 1\">",
"           Carb counting PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?22/35/23101\" title=\"table 2\">",
"           Exchange system menu PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_20_3398="Management of acute intermittent porphyria";
var content_f3_20_3398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of acute intermittent porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Gagan K Sood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3398/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/20/3398/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intermittent porphyria (AIP, Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is an autosomal dominant disorder resulting from a partial deficiency of porphobilinogen deaminase (PBGD, hydroxymethylbilane synthase, previously called uroporphyrinogen I synthase), the third enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"UTD.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ). Symptoms in AIP are due to effects on the visceral, peripheral, autonomic, and central nervous systems. They usually occur as intermittent attacks that are sometimes life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of AIP, including both treatment and prevention of acute attacks and long-term monitoring, will be reviewed here. The etiology, pathogenesis, clinical manifestations, and diagnosis of AIP and an overview of the porphyrias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE ACUTE ATTACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization is usually required for treatment of severe symptoms of acute intermittent porphyria (AIP), monitoring of respiration, electrolytes, and nutritional status, and the intravenous administration of medication (eg, carbohydrates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    ). Monitoring on an intensive care unit is warranted if the patient's vital capacity is impaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs known to be harmful in patients with AIP should be avoided whenever possible (",
"    <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain, nausea, and vomiting are generally severe and require narcotic analgesics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      , or another phenothiazine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      , agents which are safe to use in the acute porphyrias.",
"     </li>",
"     <li>",
"      Short-acting benzodiazepines in low doses are probably safe for anxiety and insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta-adrenergic blocking agents may be useful to control tachycardia and hypertension, but may be hazardous in patients with hypovolemia or incipient cardiac failure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizures are treated by carefully correcting hyponatremia, if present. Almost all anticonvulsant drugs have at least some potential for exacerbating acute porphyrias.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      may be less harmful than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , barbiturates or valproic acid&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Bromides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"       vigabatrin",
"      </a>",
"      are safe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Attacks should be treated with either carbohydrate loading or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , both of which repress hepatic delta",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    synthase (ALAS1) and are considered specific therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Unfortunately, although such treatments are potentially life-saving, adequately powered controlled clinical trials are lacking for all current therapies for acute attacks of porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Carbohydrate loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose and other carbohydrates reduce porphyrin precursor excretion, but the effects are weak compared with those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    . Therefore, only attacks with mild pain and without severe manifestations (eg, no paresis or hyponatremia present) should be treated with carbohydrate loading [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1\">",
"     1",
"    </a>",
"    ]. Intravenous treatment with 300 to 500 grams of intravenous glucose, usually administered as a 10 percent solution, is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the dilutional effects of a large volume of free water may increase the risk of hyponatremia. Oral glucose polymer solutions may be given if tolerated. A parenteral nutrition (hyperalimentation) regimen may be needed if oral or enteral feeding is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intravenous hemin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"heme\" refers specifically to ferrous protoporphyrin IX, which is readily oxidized in vitro to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , and is usually isolated as the chloride. In alkaline solution the chloride is replaced by a hydroxyl ion to form hematin. Hemin is also a generic term for heme preparations used as intravenous therapies for acute porphyrias, such as lyophilized hematin and heme arginate.",
"   </p>",
"   <p>",
"    When infused intravenously, these heme preparations become bound mostly to circulating albumin as heme albumin, and some is bound to hemopexin. These are taken up primarily by hepatocytes, where the heme component reconstitutes the regulatory heme pool. This leads to repression of the synthesis of hepatic ALAS1, followed by dramatic reductions in ALA and PBG in plasma and urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current recommendations are that most attacks of acute porphyria should be treated promptly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , even though product labeling for the hemin product available in the United States (Panhematin, Lundbeck) recommends an initial trial of glucose loading for several days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1,6-9\">",
"     1,6-9",
"    </a>",
"    ]. The standard regimen for the acute attack is 3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of hemin daily for four days. Treatment may be extended if a response is not observed within this time. Hemin has been administered safely during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Subacute or chronic symptoms are unlikely to respond to this agent.",
"   </p>",
"   <p>",
"    A lyophilized hematin preparation (Panhematin) is available in the United States. Product labeling recommends reconstitution with sterile water. However, it was discovered postmarketing that degradation products of hematin begin to form immediately, and bind to endothelial cells and clotting factors. This explains the frequently seen complication of infusion-site phlebitis, which can lead to loss of venous access with repeated dosing, and a transient anticoagulant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stabilization of hematin with 25 percent human albumin can prevent these adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/12\">",
"     12",
"    </a>",
"    ], and is a current off-label recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Heme arginate (Normosang, Orphan Europe) is a more stable preparation that is available in Europe and South Africa, which does not cause a coagulopathy or phlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    other than infusion site phlebitis are uncommon and have included fever, aching, malaise, hemolysis, anaphylaxis, and circulatory collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Excessive dosing caused reversible acute renal tubular damage in one case [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/16\">",
"     16",
"    </a>",
"    ]. Some patients treated repeatedly with hemin have developed iron overload. Therefore, serum ferritin should be monitored and small-volume phlebotomies considered during remission, with a goal to normalize serum ferritin levels into the range of 100 to 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Phlebotomy-induced iron deficiency should be",
"    <strong>",
"     avoided",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    A single underpowered, randomized, double-blind, placebo-controlled trial of heme arginate for acute attacks of porphyria in 12 patients, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    was delayed for two days, reported trends in clinical benefit that were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, in an uncontrolled study of 51 attacks in 22 patients in which heme arginate was initiated within 24 hours of admission in 73 percent of the attacks, all patients responded and hospitalization was less than 7 days in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of a normal liver has been highly effective in several patients disabled by recurrent attacks of AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This may be an option for severely affected patients without advanced motor weakness.",
"   </p>",
"   <p>",
"    On the other hand, transplantation of a liver from a patient with AIP to a patient without this disorder has been shown to be associated with neurotoxicity in the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled observations in small numbers of patients suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    is a cost-effective alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    for treating acute attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Cimetidine inhibits hepatic CYPs, and can prevent experimental forms of porphyria induced by chemicals that are activated by CYPs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/23\">",
"     23",
"    </a>",
"    ]. However, chemicals activated by CYPs are rarely, if ever, implicated in human AIP. Therefore, cimetidine cannot be recommended as an alternative to hemin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION OF ACUTE ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple inciting factors must be addressed and avoided in order to prevent future attacks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Authoritative websites (noted above) should be consulted to avoid exposure to harmful drugs in treating intercurrent illnesses or symptoms (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Drugs and chemicals'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking cessation should be recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consultation with a dietitian may identify dietary indiscretions and help maintain a well-balanced diet somewhat high in carbohydrate (60 to 70 percent of total calories). Additional dietary carbohydrate and calories is unlikely to be helpful, and may lead to excessive weight gain. Weight loss diets should provide for gradual weight loss, when patients are clinically stable.",
"   </p>",
"   <p>",
"    If present, iron deficiency, which at least theoretically might further impair heme synthesis, should be corrected. There are reports of precipitation of AIP after weight loss surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequently recurring attacks confined to the luteal phase of the menstrual cycle can be prevented with a GnRH analogue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. If treatment is effective after several months, low-dose estradiol, preferably by the transdermal route, or a bisphosphonate may be added to prevent bone loss and other side effects, or treatment changed to a low-dose oral contraceptive.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     Hemin",
"    </a>",
"    prophylactically administered once or twice weekly can prevent frequent, non-cyclic attacks of porphyria in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LONG-TERM MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AIP are at risk for developing chronic renal failure and hepatocellular carcinoma. If present, hypertension should be controlled, nephrotoxic drugs avoided, and renal function monitored. Current recommendations are that patients over age 50 with acute porphyrias, and especially those with continued elevations of ALA and PBG, be screened by hepatic imaging at least annually for early detection of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    sometimes causes iron overload. Therefore, serum ferritin levels should be monitored and phlebotomy considered if levels increase. Liver transplantation may be considered when repeated acute attacks are not prevented by other measures and are unresponsive to hemin infusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of the acute attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective treatment of the acute attack of AIP comprises a number of components, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications which can exacerbate the hepatic porphyrias, as well as alcohol and tobacco, should be stopped whenever possible (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intercurrent infections and other diseases that might be contributing to the attack should be promptly treated.",
"     </li>",
"     <li>",
"      Hypertension, pain, and electrolyte disturbances, especially hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), should be appropriately treated.",
"     </li>",
"     <li>",
"      Bedside spirometry should be available to detect early bulbar paralysis. A falling vital capacity should prompt admission to an intensive care unit for further monitoring and, when needed, mechanical support of respiration provided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     Hemin",
"    </a>",
"    therapy is recommended for acute attacks of porphyria, since the number of reports of effectiveness is overwhelming and risks for adverse effects from hemin infusion are small (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Intravenous hemin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravenous glucose loading is suggested only for early treatment of mild attacks (eg, mild pain and nausea, no motor neuropathy, hyponatremia, or seizures) (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Carbohydrate loading'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention of future attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the prevention of future attacks, all of the following should be carried out. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention of acute attacks'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of fasting or caloric deprivation",
"     </li>",
"     <li>",
"      Prompt treatment of intercurrent diseases or infections",
"     </li>",
"     <li>",
"      Avoidance of drugs and chemicals, and other factors known to exacerbate porphyria (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 1",
"      </a>",
"      ). Updated lists of safe, unsafe, and potentially unsafe agents for patients with AIP are available on a few authoritative websites [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3398/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term follow-up and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AIP should be followed for early detection of renal failure and hepatocellular carcinoma. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Long-term monitoring'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/1\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/2\">",
"      Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998; 35 ( Pt 6):726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/3\">",
"      Bonkowsky HL, Tschudy DP. Letter: Hazard of propranolol in treatment of acute prophyria. Br Med J 1974; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/4\">",
"      Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 1980; 30:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/5\">",
"      Larson AW, Wasserstrom WR, Felsher BF, Chih JC. Posttraumatic epilepsy and acute intermittent porphyria: effects of phenytoin, carbamazepine, and clonazepam. Neurology 1978; 28:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/6\">",
"      Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007; 10:444.",
"     </a>",
"    </li>",
"    <li>",
"     Sood G, Anderson KE. Porphyrias. In: Evidence-Based Hematology, Crowther MA, Ginsberg J, Schunemann H, et al (Eds), Wiley, Hoboken 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/8\">",
"      Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993; 153:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/9\">",
"      Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Semin Liver Dis 1998; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/10\">",
"      Green D, Reynolds N, Klein J, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med 1983; 102:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/11\">",
"      Jones RL. Hematin-derived anticoagulant. Generation in vitro and in vivo. J Exp Med 1986; 163:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/12\">",
"      Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991; 86:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/13\">",
"      Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI. Reconstitution of hematin for intravenous infusion. Ann Intern Med 2006; 144:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/14\">",
"      Daimon M, Susa S, Igarashi M, et al. Administration of heme arginate, but not hematin, caused anaphylactic shock. Am J Med 2001; 110:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/15\">",
"      Khanderia U. Circulatory collapse associated with hemin therapy for acute intermittent porphyria. Clin Pharm 1986; 5:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/16\">",
"      Dhar GJ, Bossenmaier I, Cardinal R, et al. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand 1978; 203:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/17\">",
"      Herrick AL, McColl KE, Moore MR, et al. Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989; 1:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/18\">",
"      Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004; 363:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/19\">",
"      Seth AK, Badminton MN, Mirza D, et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007; 13:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/20\">",
"      Dowman JK, Gunson BK, Bramhall S, et al. Liver transplantation from donors with acute intermittent porphyria. Ann Intern Med 2011; 154:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/21\">",
"      Cherem JH, Malagon J, Nellen H. Cimetidine and acute intermittent porphyria. Ann Intern Med 2005; 143:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/22\">",
"      Horie Y, Tanaka K, Okano J, et al. Cimetidine in the treatment of porphyria cutanea tarda. Intern Med 1996; 35:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/23\">",
"      Marcus DL, Nadel H, Lew G, Freedman ML. Cimetidine suppresses chemically induced experimental hepatic porphyria. Am J Med Sci 1990; 300:214.",
"     </a>",
"    </li>",
"    <li>",
"     Available from the American Porphyria Foundation at www.porphyriafoundation.com (Accessed on January 21, 2010).",
"    </li>",
"    <li>",
"     Available from the European Porphyria Initiative at www.porphyria-europe.com (Accessed on January 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/26\">",
"      Bonkovsky HL, Siao P, Roig Z, et al. Case records of the Massachusetts General Hospital. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. N Engl J Med 2008; 358:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/27\">",
"      Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 1990; 150:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/28\">",
"      De Block CE, Leeuw IH, Gaal LF. Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects - a case report. Eur J Endocrinol 1999; 141:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/29\">",
"      Yamamori I, Asai M, Tanaka F, et al. Prevention of premenstrual exacerbation of hereditary coproporphyria by gonadotropin-releasing hormone analogue. Intern Med 1999; 38:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3398/abstract/30\">",
"      Anderson KE, Egger NG, Goeger DE. Heme arginate for prevention of acute porphyric attacks (abstract). Acta Haematol 1997; 98, Suppl 1:120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7142 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3398=[""].join("\n");
var outline_f3_20_3398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF THE ACUTE ATTACK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Carbohydrate loading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intravenous hemin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION OF ACUTE ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LONG-TERM MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of the acute attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention of future attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term follow-up and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7142|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/50/35617\" title=\"figure 2\">",
"      Heme biosynthetic pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43116\" title=\"table 1\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_20_3399="ECG atypical Mobitz type I AV block";
var content_f3_20_3399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing atypical Mobitz type I (Wenckebach) atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 150px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single lead electrocardiogram (ECG) strip showing an atypical Mobitz type I&nbsp;(Wenckebach) AV block with 18:17 ratio. The last three cycles of the group, the skipped beat (with the P wave lost in the T wave; arrow), and the first three cycles of the next group are shown. The last three cycles had a PR interval of 0.36 sec while the first three cycles showed PR intervals of 0.23, 0.32 and 0.34 sec with a decreasing R-R interval. This demonstrates the importance of comparing the PR interval of the last beat before the dropped QRS to the PR interval of the first and second beats of the new cycle. The PR interval is the longest in the beat before the dropped beat, shortest in the first beat of the cycle, and increases in the second beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3399=[""].join("\n");
var outline_f3_20_3399=null;
var title_f3_20_3400="Patient management following extremity fasciotomy";
var content_f3_20_3400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient management following extremity fasciotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3400/contributors\">",
"     J Gregory Modrall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3400/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3400/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3400/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3400/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/20/3400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H443284462\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremity fasciotomy is the only recognized treatment for acute compartment syndrome and may be limb saving. Reperfusion following fasciotomy causes local and systemic effects that can be life-threatening and can complicate wound management.",
"   </p>",
"   <p>",
"    The management of the patient following extremity fasciotomy, including management of reperfusion, wound care, and methods and timing of fasciotomy wound closure, will be reviewed here. Preoperative management and the indications, diagnosis, and techniques used to perform fasciotomy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link\">",
"     \"Lower extremity fasciotomy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443283570\">",
"    <span class=\"h1\">",
"     ISCHEMIA-REPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local and systemic consequences of ischemia-reperfusion occur after fasciotomy. Increased blood flow in the muscle following restoration of normal tissue pressure usually causes muscle edema. The extent of extremity swelling depends upon the duration and severity of ischemia, the predominant muscle cell type within a muscle, the location and mass of ischemic muscle, and the status of the venous circulation.",
"   </p>",
"   <p>",
"    Animal studies show that cellular damage starts about three hours after a complete ischemic insult and is nearly complete by six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/1\">",
"     1",
"    </a>",
"    ]. In humans, the level of tolerance to an ischemic insult varies and not all ischemic insults are complete. Patients with underlying peripheral artery disease may exhibit less than expected swelling due to the protective effects of pre-existing arterial collaterals that lessen the severity of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/2\">",
"     2",
"    </a>",
"    ]. There is also evidence from animal studies that ischemic preconditioning in skeletal muscle may mitigate the severity of muscle injury, remote organ injury, and mortality after major ischemic events [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Swelling may be limited if there is incomplete reperfusion due to microvascular thrombosis. With prolonged ischemia, a &ldquo;no reflow phenomenon&rdquo; occurs that is characterized by capillary occlusion from endothelial swelling, plugging of capillaries with red and white blood cells, and increased interstitial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Reperfusion may occur at the macrovascular level, but there is no tissue perfusion. Clinically, this manifests as myonecrosis with minimal extremity swelling.",
"   </p>",
"   <p>",
"    Successful reperfusion liberates the byproducts of muscle ischemia and cell necrosis (rhabdomyolysis) into the circulation, including potassium, phosphate, organic acids, myoglobin, creatine kinase, and thromboplastin. The systemic effects of these byproducts may include hyperkalemia, hyperphosphatemia, metabolic acidosis, and myoglobinuria which can cause acute kidney injury, elevation of serum creatine kinase levels, and disseminated intravascular coagulation. (See",
"    <a class=\"local\" href=\"#H443284400\">",
"     'Management of reperfusion'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Muscles differ in their susceptibility to ischemic injury based upon the predominant muscle fiber type that is present [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/7\">",
"     7",
"    </a>",
"    ]. Type I fibers rely primarily on oxidative metabolism of triglycerides, making these fibers vulnerable to ischemia. In comparison, type II fibers use anaerobic metabolism of glycogen and, as a result, these fibers tolerate ischemia to a greater degree. Differences in muscle fiber distribution may explain, in part, the higher incidence of compartment syndrome in the anterior compartment of the leg, compared with the superficial posterior compartment (",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"UTD.htm?41/27/42424\">",
"     figure 1",
"    </a>",
"    ). The tibialis anterior muscle is comprised primarily of type I fibers, whereas the gastrocnemius muscle has primarily type II fibers.",
"   </p>",
"   <p>",
"    Although fasciotomy leading to reperfusion is generally limb-saving, crush injuries involving large muscle groups (eg, buttock, thigh) may be prone to life-threatening complications from reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The magnitude of the reperfusion insult may be so severe that sudden cardiac arrest can occur as a consequence of hyperkalemia with or without severe metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H428236833#H428236833\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Contraindications'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H443284400\">",
"     'Management of reperfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Interruption of venous outflow due to venous obstruction or surgical ligation after trauma may aggravate swelling. In the injured extremity, venous repair of major veins of the leg, such as the femoral or popliteal vein, is performed whenever feasible to prevent increased venous pressure that can lead to prolonged muscle swelling and compartment syndrome. When the venous injury cannot be repaired, prophylactic fasciotomy is frequently performed. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H443285312#H443285312\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Prophylactic fasciotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443284400\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF REPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of reperfusion injury is focused on restoration of intravascular volume, followed by prevention and treatment of associated metabolic abnormalities. The most serious abnormalities include hyperkalemia, metabolic acidosis, and acute kidney injury due to myoglobinuria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia &ndash; Hyperkalemia is treated to prevent life-threatening arrhythmias or cardiac arrest. Treatment is initiated based upon the presence of peaked T waves on the electrocardiogram (",
"      <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"UTD.htm?11/50/12068\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations of hyperkalemia in adults\", section on 'Cardiac manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Peaked T waves in this setting are an indication for",
"      <strong>",
"       urgent",
"      </strong>",
"      therapy of hyperkalemia, since ongoing release of potassium from ischemic or necrotic muscle cells can lead to progressive and life-threatening hyperkalemia. Treatment of hyperkalemia in this setting may include multiple modalities, with intravenous calcium having the most rapid onset. In the absence of electrocardiographic changes, hyperkalemia can initially be managed by ensuring adequate urinary output, but careful monitoring of the serum potassium is warranted. The manifestations and treatment of hyperkalemia are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic acidosis",
"      <strong>",
"      </strong>",
"      &ndash; Metabolic acidosis, usually lactic acidosis during reperfusion, may exacerbate hyperkalemia and induce hypotension. The initial management of lactic acidosis is focused on volume resuscitation to restore tissue perfusion, with a goal of achieving a urine output of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. Severe acidosis with an arterial pH below 7.10 to 7.15 may be treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      . Issues related to the treatment of lactic acidosis are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H15#H15\">",
"       \"Approach to the adult with metabolic acidosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhabdomyolysis and myoglobinuria &ndash; Rhabdomyolysis presents with elevated serum muscle enzymes (including creatine kinase), red to brown urine due to myoglobinuria if there is persistent renal function, and electrolyte abnormalities. Peak serum creatine kinase levels depend upon the volume of muscle breakdown and the muscle mass of the patient. Creatinine kinase values should be measured twice daily until decreasing levels are observed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Aggressive saline hydration is the primary initial therapy of myoglobinuria, lowering the risk of induction of acute kidney injury. Other treatments may include bicarbonate or mannitol. The prevention and treatment of heme pigment-induced acute kidney injury is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443284358\">",
"    <span class=\"h2\">",
"     Role of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A late consequence of muscle ischemia is capillary occlusion. Some authors have recommended high dose anticoagulation with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as a means of limiting progressive small vessel occlusion. Because many inflammatory mediators are generated by the activation of clotting, heparin may serve a dual purpose limiting coagulation and the associated inflammation and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the risk of anticoagulation after fasciotomy may outweigh the theoretical benefits for many patients and there are no convincing data to support its routine use in this setting. Anticoagulation is warranted for acute ischemia and compartment syndrome due to thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443283577\">",
"    <span class=\"h1\">",
"     WOUND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fasciotomy is mandated by the diagnosis of an acute compartment syndrome, the wounds created from the fasciotomy procedure are associated with significant morbidity. The goals of wound management include identifying and debriding nonviable muscle and avoiding further muscle injury from wound dessication. We suggest leaving fasciotomy wounds open rather than closure or graft coverage of the skin in the immediate postoperative period to facilitate assessment of tissue viability. Premature wound closure before adequate resolution of swelling can lead to recurrent compartment syndrome. Nonviable tissue within the wound may lead to other wound complications such as infection. (See",
"    <a class=\"local\" href=\"#H443283633\">",
"     'Wound complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the first 24 to 48 hours after fasciotomy, we prefer sterile saline gauze dressings which allow frequent wound assessment. Thereafter, we use negative pressure wound therapy until muscle swelling has regressed. (See",
"    <a class=\"local\" href=\"#H443283584\">",
"     'Skin closure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H398898525\">",
"     'Negative pressure wound therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While awaiting skin closure or grafting, a variety of methods can be used to limit skin retraction and promote apposition of the dermal edges prior to negative pressure wound therapy, or for patients who are not candidates for negative pressure wound therapy. Among the simpler, less costly approaches are placement at the time of the fasciotomy of cutaneous sutures, or silastic vessel loops anchored to staples on the skin edges (",
"    <a class=\"graphic graphic_figure graphicRef71739 \" href=\"UTD.htm?10/55/11120\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Commercially available devices for this purpose include the Sure-Close&reg; suturing system, Marburger Skin Approximation System, Wisebands&reg; device, and Canica&reg; device [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H398898525\">",
"    <span class=\"h2\">",
"     Negative pressure wound therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy, also called vacuum-assisted wound closure, refers to wound dressing systems that continuously or intermittently apply subatmospheric pressure to the surface of a wound. Negative pressure wound therapy decreases tissue edema, enhances local blood flow, promotes granulation tissue, and decreases bacterial colonization. The general mechanism of action of negative pressure wound therapy and the placement and management of the negative pressure wound therapy device are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no randomized trials comparing negative pressure wound therapy with standard gauze dressings for fasciotomy closure, retrospective studies show a decrease in the time to skin closure or grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The larger of these studies compared 458 wounds treated with negative pressure wound therapy to 270 treated with standard gauze dressings. A significantly higher rate of skin closure (83 versus 56 percent) and decreased time to skin closure (5.2 versus 6.5 days) were found for negative pressure wound therapy compared with gauze dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81875569\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies and case reports describe hyperbaric oxygen as adjunct treatment for the management of wounds following fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. Further research is needed to determine the appropriate role of hyperbaric oxygen therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443283584\">",
"    <span class=\"h2\">",
"     Skin closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the viability of the muscle is confirmed and muscle swelling has regressed, skin closure becomes the primary focus. Skin closure is usually achieved by bringing the edges together, skin grafting, or less commonly, a myocutaneous flap. In an occasional patient, the wounds may be left to heal by secondary intention. Appropriate timing of the closure is important to avoid recurrent compartment syndrome that can occur by closing the skin prematurely.",
"   </p>",
"   <p>",
"    Delayed skin closure is appealing because it offers definitive closure soon after fasciotomy. However, delayed skin closure is often not feasible due to residual swelling. One study found that delayed skin closure less than five days postoperatively produced an undesirable increase in intra-compartment pressures (&gt;30 mmHg) in 7 of 12 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors suggest that measuring intra-compartment pressures during delayed skin closure might avoid this complication. Skin closure between 8 and 14 days postoperatively may decrease the incidence of wound complications and decrease the length of stay compared with later closure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More extensive fasciotomy wounds, particularly open wounds associated with massive post-fasciotomy muscle swelling, could require several weeks to achieve closure. These wounds are candidates for closure with a skin graft [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Myocutaneous flap coverage is a rare adjunct that may be needed if neurovascular structures or vascular grafts are exposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443283619\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications related to fasciotomy are multifactorial. Most complications are related to the underlying condition or injury that indicated the need for compartment decompression. The acute compartment syndrome may cause further injury, and the lack of timely diagnosis and treatment of acute compartment syndrome can be catastrophic. The fasciotomy can be an additional source of morbidity.",
"   </p>",
"   <p>",
"    Technical complications related to fasciotomy technique are largely preventable. Persistent or recurrent compartment syndrome can occur if fascial incisions are not adequate to permit complete decompression of the compartment or if selective fasciotomy has been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H548658803#H548658803\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Technical complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11098771\">",
"    <span class=\"h2\">",
"     Persistent neurologic deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent neurologic deficits are the most common complication of the treatment of extremity compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/33\">",
"     33",
"    </a>",
"    ]. Following lower extremity fasciotomy, impaired neurologic function of some type is evident in 7 to 36 percent of limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Nerve injury is due to soft tissue trauma, nerve ischemia during the interval of increased compartment pressure, or as a consequence of the fasciotomy incisions or dissection. Nerve injury as a technical complication during fasciotomy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H16956529#H16956529\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Neurovascular injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common neuropathic symptom is altered sensation at the margins of the incision, which was documented in 77 percent of patients in a retrospective review of 60 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/37\">",
"     37",
"    </a>",
"    ]. Chronic pain syndromes developed in 10 of these patients (17 percent) at a mean follow-up of 59 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain management is a critical issue in many patients with persistent neurologic deficits. Appropriate referral to a pain specialist should be made if pain persists after all visible wounds have healed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link\">",
"     \"Prevention and management of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443283633\">",
"    <span class=\"h2\">",
"     Wound complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound complications after fasciotomy may occur immediately in the postoperative period or delayed for months to years. Early wound complications occur in up to 40 percent of patients following lower extremity fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29,34,38\">",
"     29,34,38",
"    </a>",
"    ]. Risk factors for wound complications include the presence of vascular injury, greater than an eight-hour time interval between the injury and fasciotomy, a lower extremity site, and prophylactic fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/38\">",
"     38",
"    </a>",
"    ]. Issues related to prophylactic fasciotomy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H443285312#H443285312\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Prophylactic fasciotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wound infection occurs in 4 to 7 percent of extremity fasciotomies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. Prophylactic antibiotics should be given at the time of the fasciotomy procedure and discontinued within 24 hours. Wound infection is treated, as indicated by positive wound cultures with antibiotics based upon sensitivity testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H16956492#H16956492\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During fasciotomy, muscle devascularization may result from soft tissue debridement or during the fasciotomy procedure. In one study, repeat debridement for muscle necrosis or invasive sepsis was required in 16 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many authors have hypothesized that early closure with a skin graft decreases the risk of complications, but data to support this notion are limited. In one series, a significantly lower rate of wound complications was found for wounds closed with a split thickness skin graft compared with skin closure (5 versus 51 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late wound complications are reported in 4 to 38 percent of limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29,34,37,38\">",
"     29,34,37,38",
"    </a>",
"    ]. In a retrospective study of 60 patients, 26 percent had tethered scars, 13 percent had recurrent ulceration, 13 percent had muscle herniation, and 7 percent had tethered tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/37\">",
"     37",
"    </a>",
"    ]. Poor wound healing and late wound ulceration are more likely to occur in the presence of extremity ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331922656\">",
"    <span class=\"h2\">",
"     Venous insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity fasciotomy may predispose the patient to the late development of chronic venous disease. The diagnosis and management of lower extremity chronic venous disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 17 patients with a history of lower extremity fasciotomy for trauma, 8 had signs or symptoms of venous insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/39\">",
"     39",
"    </a>",
"    ]. Comparisons were made between the injured and uninjured extremities in these patients. Indicators of calf muscle pump dysfunction, including significantly decreased mean ejection fraction (32 versus 61 percent) and significantly increased mean residual volume fraction (59 versus 22 percent), were found in the injured limbs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331922541\">",
"    <span class=\"h2\">",
"     Limb loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lower extremity compartment syndrome is associated with a significant risk for limb loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/33\">",
"     33",
"    </a>",
"    ]. Five to 21 percent of limbs treated with fasciotomy of the lower leg will require major amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29,34,35,38,40\">",
"     29,34,35,38,40",
"    </a>",
"    ]. In multiple trauma patients, combined orthopedic and vascular injury, other severe injuries, or systemic factors may contribute to the need for amputation. The highest amputation rates occur in patients with vascular repairs that have occluded [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the mechanism causing the compartment syndrome, limb loss is generally related to persistent ischemia such as incomplete fasciotomy or severe arterial disease, underlying systemic disease, or other injuries and not usually from a fasciotomy procedure-related issue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H548658803#H548658803\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Technical complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amputation after upper extremity compartment syndrome is rare. Two of the larger series reported no upper extremity amputations in a total of 233 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/38,41\">",
"     38,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443286216\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported mortality rates for patients requiring emergent lower extremity fasciotomy range from 11 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/31,34,35,40\">",
"     31,34,35,40",
"    </a>",
"    ]. Mortality is most often due to massive trauma, cardiopulmonary failure, or multisystem organ failure and usually not directly attributable to the fasciotomy procedure. In a series of 36 patients undergoing lower extremity fasciotomy for a variety of indications, multivariate analysis identified age &gt;50 years as a significant predictor of poor outcome (death, amputation or extremity dysfunction) following fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/35\">",
"     35",
"    </a>",
"    ]. Older patients were more likely to have undergone fasciotomy as a result of a vascular procedure. Trauma patients were younger and had better overall outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/35,42\">",
"     35,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate following upper extremity fasciotomy appears to be lower at about 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/41\">",
"     41",
"    </a>",
"    ]. In a retrospective review of 139 patients with traumatic brachial artery injury, there was no difference in mortality rate for patients who required fasciotomy compared with those who did not (3.4 versus 2.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3400/abstract/41\">",
"     41",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443284217\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle reperfusion following extremity fasciotomy can lead to potentially life-threatening systemic complications and profound tissue swelling that complicates wound management. (See",
"      <a class=\"local\" href=\"#H443283570\">",
"       'Ischemia-reperfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of the systemic complications of reperfusion injury is focused on restoration of intravascular volume, followed by prevention and treatment of associated metabolic abnormalities including hyperkalemia, metabolic acidosis and myoglobinuria which may lead to acute kidney injury. (See",
"      <a class=\"local\" href=\"#H443284400\">",
"       'Management of reperfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      closing the skin wounds for at least four days following fasciotomy to permit assessment of the severity of swelling and viability of the muscle (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Premature closure before adequate resolution of swelling can lead to recurrent compartment syndrome. The presence of nonviable tissue within the wound may lead to other wound complications such as chronic wound drainage or infection. We prefer saline gauze dressings in the immediate postoperative period to facilitate frequent wound evaluation and interval debridement of necrotic tissue, as needed. Once the fasciotomy wounds are stable, they can be managed with gauze dressings or negative pressure wound therapy. Negative pressure wound therapy has the advantage of decreasing edema and may lead to earlier fasciotomy closure. (See",
"      <a class=\"local\" href=\"#H443283577\">",
"       'Wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound closure is typically accomplished with delayed skin closure, skin grafting, and, although rarely needed, sometimes myocutaneous flap coverage. The decision to perform delayed skin closure over skin grafting depends upon several factors, and no one closure technique is appropriate for all patients. In an occasional patient, the wounds may be left to heal by secondary intention. (See",
"      <a class=\"local\" href=\"#H443283584\">",
"       'Skin closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent neurologic deficits following fasciotomy for acute compartment syndrome are common. Nerve injury can be due to soft tissue injury from the inciting traumatic event, nerve ischemia during the interval of decreased compartment perfusion, or as a consequence of the fasciotomy incisions, dissection or muscle debridement. &nbsp;(See",
"      <a class=\"local\" href=\"#H11098771\">",
"       'Persistent neurologic deficits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound complications are common, occurring in up to 40 percent of patients following lower extremity fasciotomy. Risk factors for wound complications include the presence of vascular injury, a greater than eight hour time interval between the injury and fasciotomy, a lower extremity site, prophylactic fasciotomy and premature fasciotomy wound closure. (See",
"      <a class=\"local\" href=\"#H443283633\">",
"       'Wound complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/1\">",
"      Lindsay TF, Liauw S, Romaschin AD, Walker PM. The effect of ischemia/reperfusion on adenine nucleotide metabolism and xanthine oxidase production in skeletal muscle. J Vasc Surg 1990; 12:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/2\">",
"      Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischaemia and claudicants treated by revascularization. Br J Surg 1992; 79:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/3\">",
"      Eberlin KR, McCormack MC, Nguyen JT, et al. Ischemic preconditioning of skeletal muscle mitigates remote injury and mortality. J Surg Res 2008; 148:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/4\">",
"      Vaillancourt C, Shrier I, Vandal A, et al. Acute compartment syndrome: how long before muscle necrosis occurs? CJEM 2004; 6:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/5\">",
"      Brooks, B. Pathologic changes in muscle as the result of disturbances of circulation. Arch Surg 1922; 5:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/6\">",
"      Menger MD, R&uuml;cker M, Vollmar B. Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary \"no-reflow\". Shock 1997; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     Steinau, H-U. Major Limb Replantation and Postischemia Syndrome: Investigation of Acute Ischemia-Induced Myopathy and Reperfusion Injury, Springer Verlag, New York 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/8\">",
"      Malinoski DJ, Slater MS, Mullins RJ. Crush injury and rhabdomyolysis. Crit Care Clin 2004; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/9\">",
"      Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med 1991; 324:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/10\">",
"      Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 2002; 10:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/11\">",
"      Zorrilla P, Mar&iacute;n A, G&oacute;mez LA, Salido JA. Shoelace technique for gradual closure of fasciotomy wounds. J Trauma 2005; 59:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/12\">",
"      Berman SS, Schilling JD, McIntyre KE, et al. Shoelace technique for delayed primary closure of fasciotomies. Am J Surg 1994; 167:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/13\">",
"      Narayanan K, Futrell JW, Bentz M, Hurwitz D. Comparative clinical study of the sure-closure device with conventional wound closure techniques. Ann Plast Surg 1995; 35:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/14\">",
"      Janzing HM, Broos PL. Dermatotraction: an effective technique for the closure of fasciotomy wounds: a preliminary report of fifteen patients. J Orthop Trauma 2001; 15:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/15\">",
"      Barnea Y, Gur E, Amir A, et al. Our experience with Wisebands: a new skin and soft-tissue stretch device. Plast Reconstr Surg 2004; 113:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/16\">",
"      Singh N, Bluman E, Starnes B, Andersen C. Dynamic wound closure for decompressive leg fasciotomy wounds. Am Surg 2008; 74:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/17\">",
"      Zannis J, Angobaldo J, Marks M, et al. Comparison of fasciotomy wound closures using traditional dressing changes and the vacuum-assisted closure device. Ann Plast Surg 2009; 62:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/18\">",
"      Yang CC, Chang DS, Webb LX. Vacuum-assisted closure for fasciotomy wounds following compartment syndrome of the leg. J Surg Orthop Adv 2006; 15:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/19\">",
"      Wattel F, Mathieu D, Nevi&egrave;re R, Bocquillon N. Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation. Anaesthesia 1998; 53 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/20\">",
"      Strauss MB, Hargens AR, Gershuni DH, et al. Delayed use of hyperbaric oxygen for treatment of a model anterior compartment syndrome. J Orthop Res 1986; 4:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/21\">",
"      Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/22\">",
"      Weiland DE. Fasciotomy closure using simultaneous vacuum-assisted closure and hyperbaric oxygen. Am Surg 2007; 73:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/23\">",
"      Abdullah MS, Al-Waili NS, Butler G, Baban NK. Hyperbaric oxygen as an adjunctive therapy for bilateral compartment syndrome, rhabdomyolysis and acute renal failure after heroin intake. Arch Med Res 2006; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/24\">",
"      Nylander G, Lewis D, Nordstr&ouml;m H, Larsson J. Reduction of postischemic edema with hyperbaric oxygen. Plast Reconstr Surg 1985; 76:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/25\">",
"      Uhl E, Sirsj&ouml; A, Haapaniemi T, et al. Hyperbaric oxygen improves wound healing in normal and ischemic skin tissue. Plast Reconstr Surg 1994; 93:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/26\">",
"      Kolski JM, Mazolewski PJ, Stephenson LL, et al. Effect of hyperbaric oxygen therapy on testicular ischemia-reperfusion injury. J Urol 1998; 160:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/27\">",
"      Greensmith JE. Hyperbaric oxygen therapy in extremity trauma. J Am Acad Orthop Surg 2004; 12:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/28\">",
"      Wiger P, Tkaczuk P, Styf J. Secondary wound closure following fasciotomy for acute compartment syndrome increases intramuscular pressure. J Orthop Trauma 1998; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/29\">",
"      Johnson SB, Weaver FA, Yellin AE, et al. Clinical results of decompressive dermotomy-fasciotomy. Am J Surg 1992; 164:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/30\">",
"      Papalambros EL, Panayiotopoulos YP, Bastounis E, et al. Prophylactic fasciotomy of the legs following acute arterial occlusion procedures. Int Angiol 1989; 8:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/31\">",
"      Jensen SL, Sandermann J. Compartment syndrome and fasciotomy in vascular surgery. A review of 57 cases. Eur J Vasc Endovasc Surg 1997; 13:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/32\">",
"      Sheridan GW, Matsen FA 3rd. Fasciotomy in the treatment of the acute compartment syndrome. J Bone Joint Surg Am 1976; 58:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/33\">",
"      Ojike NI, Roberts CS, Giannoudis PV. Compartment syndrome of the thigh: a systematic review. Injury 2010; 41:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/34\">",
"      Rush DS, Frame SB, Bell RM, et al. Does open fasciotomy contribute to morbidity and mortality after acute lower extremity ischemia and revascularization? J Vasc Surg 1989; 10:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/35\">",
"      Heemskerk J, Kitslaar P. Acute compartment syndrome of the lower leg: retrospective study on prevalence, technique, and outcome of fasciotomies. World J Surg 2003; 27:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/36\">",
"      Lagerstrom CF, Reed RL 2nd, Rowlands BJ, Fischer RP. Early fasciotomy for acute clinically evident posttraumatic compartment syndrome. Am J Surg 1989; 158:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/37\">",
"      Fitzgerald AM, Gaston P, Wilson Y, et al. Long-term sequelae of fasciotomy wounds. Br J Plast Surg 2000; 53:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/38\">",
"      Velmahos GC, Theodorou D, Demetriades D, et al. Complications and nonclosure rates of fasciotomy for trauma and related risk factors. World J Surg 1997; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/39\">",
"      Bermudez K, Knudson MM, Morabito D, Kessel O. Fasciotomy, chronic venous insufficiency, and the calf muscle pump. Arch Surg 1998; 133:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/40\">",
"      Ritenour AE, Dorlac WC, Fang R, et al. Complications after fasciotomy revision and delayed compartment release in combat patients. J Trauma 2008; 64:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/41\">",
"      Kim JY, Buck DW 2nd, Forte AJ, et al. Risk factors for compartment syndrome in traumatic brachial artery injuries: an institutional experience in 139 patients. J Trauma 2009; 67:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3400/abstract/42\">",
"      Kosir R, Moore FA, Selby JH, et al. Acute lower extremity compartment syndrome (ALECS) screening protocol in critically ill trauma patients. J Trauma 2007; 63:268.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15660 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3400=[""].join("\n");
var outline_f3_20_3400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H443284217\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443284462\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443283570\">",
"      ISCHEMIA-REPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443284400\">",
"      MANAGEMENT OF REPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443284358\">",
"      Role of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443283577\">",
"      WOUND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H398898525\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81875569\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443283584\">",
"      Skin closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443283619\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11098771\">",
"      Persistent neurologic deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443283633\">",
"      Wound complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H331922656\">",
"      Venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H331922541\">",
"      Limb loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443286216\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443284217\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15660|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/27/42424\" title=\"figure 1\">",
"      Muscle compartments of the leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/55/11120\" title=\"figure 2\">",
"      Apposition of the skin edges following fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15660|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/50/12068\" title=\"waveform 1\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16312?source=related_link\">",
"      Definition and pathogenesis of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=related_link\">",
"      Lower extremity fasciotomy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_20_3401="TB granuloma and immune recovery";
var content_f3_20_3401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Iris granuloma due to tuberculosis followed by immune recovery tuberculous uveitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+Al0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD334k+OtO+H+i22p6ta311DcXS2iR2aIz7yjvkhmUYxGe/pxXAQ/tGeGpjhNB8S9cfNFbLz+M9P/apZk8GaAyAFhrKYz2/0W45/rXnXwd8AaX4t8M6t4i1rX9Zsf7MvnjDWkkSxpGkEUhch42Ocu3Oe1S272RaiuXmZ6QP2gtAJOPDvibA/i8q2259M+fjPtSS/tB6BHN5T+HfE3mbd+BFbHj14n6Vxnwr8DeB/iNpV9daB4g8aQraz+XLDePaLIpZQQ4xEwAIyAQQeDXh+nyXv2GxlvYSI5ow3nOhcyZA5Jzz1zjtScnFalRhGT0PqD/honw2AS2h+IkA4O9LVcfnPRD+0R4fmk2Q+G/FUjf7FtA38pq8B02a1t79UURPOo3K7xkg9wQNtdG9+NRwY7iJTv8AmVcqi4HUqev4+tZuozdUIPa57E3x90JCRL4e8RxEDdiRbRDj6G4qRPjtpEkLTJ4Z8TmNereXa+3/AE356ivIbWGX7YDbahoONu5U2hXYjnJONoPt7VU0y4u7azuJrWW5SISb5JYVwrMc4IJ9s9BzVc7IdGJ7WfjppXzH/hFvFRA6kQ2xH5+fSp8dNHeESp4e8QMh6Yazyfw+0ZrxO0v4LuwUx3txbOu/zZJUOxhkbeAMj0xz60Wk+l2byfar20nU5Dolqw2NjgqxwCD69q0TvsQ6aR7WPjro/nmFvDviGOYAkpL9jQjjPRrgVG3x50dI/Mfwv4qVcA5aC2H/ALXrxIeJ4jZ+RpWjxQK5xNKUYlwDxn057ita38SWvlBNRvDbqwTbDb75HxuJx852rxxz9RRe7shOC31PYB8bNONt9o/4RXxQIsA7mjtRwenBuM1Tf4/6CrbT4e8SbuwCWpJ/8j14vJrUovj/AGb5RBJclgAwUcj5icZA7ciszUNWge5kaVFlWZyfMmhDEHPO7bgBvcVLk0UqaaPeD+0HoIV2PhzxQAn3sw2w2/X9/wAVMvx70RxEU8O+JGEy7oyFtDvHqv8ApHP4V88yQSXLiezaaW5cszAy7SR7E8N9DUQklijMe1hERu8hsAZPdT0x+INLnYeyTPolvj7oa+Zu8O+JB5fDfJa8H/v/AEJ8fdDcAr4c8SnIyP3dqP8A2vXg1rNPBbfaGur6zLEHEcQmiI9c9x7Gi4k8m4imXUrZjIA4ljibd7ZQ8EHHSp9pI0VCL6n0EPjhpJK48O+ICD/EGsiB9T9owPxrQT4rwy2ouIfCniOaL/pk9i5/Jbkn9K8FF/dxSI0yQvCwCpLZ5AAzkll9R6EVv2mqapo4ivtMENxbu29lU546f8BOPwqJVpLYpYeG12erxfF21liEkfhbxEVLBCC1kCpPQMPtOV/HFWovid5vkbPCHiTM7OsYL2IJZRllwbnggc4POK83tPEGla1ayxahYNFPMWHnE8BO6hxjI9j07Vea4hktxpt1ORfpseznZ+LiMH5ee7L93d1xipdeSL+qQfVnXXfxhtLTy/P8J+Jl8xd6YFm24d8YuOas2/xTS4hglh8JeI3jnIEbB7HDE9v+PnrXGXwOoRrBMHa/JaaOQ4jeN/4kZQMfQjg5ql4fuLtElikAkkMw8y3K4WTPUf7EnH0NS8RJbItYOm+rPQ7f4m/aGmWLwh4k3w/fVnsVI98G56U3/haIF59lbwf4mW4zt8tzZKSfbNzzXIag8JmiuSbgxMpDSqCssYA+9/vKeGHcc03VIbi5s0vERZ72Bv3gUYEq9jgcg9DkUfWZdh/UYd2dtafEl7uUx2/g7xIzg4I32I/nc1bPji9EqxnwT4kDsu4Ay6f0/wDAquJ0uT+0Dbz+cgL4jkVDtkLYO1jjvjv3xXS/bjsAadlkg+ZcAnevRiM9/UULEy7ClgY9GaK+Obxo2dfBXiMqvU+dp/8A8lVF/wALAuArE+DPEgCrvIMtgDjOOn2qqenTYS4tVdJCjbUdRgBTyP5022fznVjtC+WwLg5BYNyPf/61H1qXYPqMOrZpxeOL6ZEePwR4lZXztIlsOcf9vVKPG98c48EeJflOCfNsOD/4FUmmTssLqxVATlUUn5R0PH1H61alO2R4GdjE6/Oexb092xT+sSSuYywsU2iH/hMtR3BR4H8SFsZwJtP/APkqmv41v4yA/gnxIpK7hmbT+n/gVVy3doWSB2/djBjyOXB7MfX+dS3H72UCLHm9fnGMDoQaf1hkfV1fyKA8Z6jtDf8ACD+JQD0zNp4/9uqZL42vomjWTwT4jUyDK5m0/B/H7V19q2Ipdykj96U+VkC/KMUsixXVo0DI7eaMliduMdCM89auNVsl0knqZH/CZ6hvVP8AhCPEm5huUGbT+R6j/SqRfG18wJXwX4hOM8C404njrx9qqe3lkiuFsNVIMqDfBcqPvp6j/aHQ/wCBrWjdnJEUcDIP41Iz9OOhpqq2EqKiY3/CYansVj4G8SgNjGZtPH/t1TH8aX6LIzeCfEYEf3/3+n8f+TVbjfaGLrLGrOnCIpIBHqahnxBvSWZN8ik7SMru9PU8Ue1fRCVJMy08Y6i6hl8D+JCCMj99p/P/AJNUz/hNb/ynkPgjxIFT72ZtPB/L7VWr5cQtHEcshbb8jHOSPb27ZqrbRNKWljgMkhXB85uB34Poan20tFYpUY2buVR401A23n/8IP4l8rBOTLp44HXj7VmnJ4w1JtuPA/iT5huXM2njI9f+PqrNt5xmjuXuEMDn7u7AbsPxFSPcrAwhkRo4GbEW+PIUn19Aaft9Lg6GtkZjeOrxZCh8FeJNyttOJbAjOM4z9qx0qKT4g3EcbvJ4M8SKiSCJyZbAbWPQH/SuOo5qbU5wqiFnRI5GMW9F4jk6jOO3bPvWNJdC4sp2jtP+PqVrW7Mh3Kvy5Bx9T19xU+3ZosKma9t47u7mJJLfwV4kkRwxUrLYHO04P/L11HpSv46vEcI/grxIrlS4Uy2AOB1P/H171z+lSNYala2l1M0zMQ8VypO0MflKEAdSB171vS3FtHqCSSzznyo3VmEbNwT0A6Dkdaart9AeFinuRw/EOaaeWGLwb4kaSJtjgSWGAcZxn7Tjoaq2/wAUlubfz4fCPiRosBt26xAxnHe5rMbXdPtb6/ESuUWXzN8kZXcxAKqDjAxyMmsvQ5wbe3eaLzjtaJIxggncTye/Ws5YmSdkjWODg9Xc6b/haaCMufCHiUIOpLWXH/kzTT8VohKIv+ES8SFygfAayOARkZ/0ng+x5rmb+SFGdrqRY7S1ZmKsdokkHr3OOBj1rBi1Z7aMGxiTzZCXe4mG4u57InXA6ZNP6xLsDwlPuz0Kf4tW9uFM/hbxDGGGRuksRn/yZqv/AMLnsNxX/hGPEeR1GbPj6/6RXkGu3TzSATs88pyMTtlw5GdoVRhfXH51zc95cIkhmdICwyypIGYY4xgdz71ftZmTw0L6Hvb/AB00eMsG8Pa/leo3WRx/5MUyD476LPL5cXh7xEz4zx9jweM8H7RivnqXUoym5ryN44x+7t2+cscc7yAMA0pure9sZPMngFyQDHGsezYM9Ac9OpOPSrVSTV7ESowXc+jI/jZpbqCPD2ujIyA0tipPOOhufaq9x8d9Htyol8N+JFLDI+W0OfyuK+dUmsbe2NrNPb3dsW35lyrqxGM889O2au2sltaypvsrpkbGDayBgGwcdTj071qrsycIp7n0DH8cdLkMYj8MeJmaT7qhLTcfw+0ZqRfjXprbseGvEWVGWUmzBX6j7RkV4Haa3NPdNMsctukSBXWCzMuw+oO7Bb3ziqOq6tFdf8fb6wozjdPtTnB7KcjnnFPUm0e59BSfHnQ45vKbQde83GdoayJ/S4qbUPjdpunhzd+FvE8ewgEeXak5PsLjmvnKPV7VkWCys4FcBFN1KDI7nuFXgsfQGprW/kUPEJpY5CpQxmNEjQZ5yuC3t7UkxqCPfB8f9CIkJ8O+JR5ZAfclqNpPQHM9IP2gfDxcJ/YmvBj2LWY/9uK+eNVvBLqCzT21u9xKxDLGhbee3z8c/SqdjfXavIslom0LtZ2O8KSfUjI9KnmsP2aex9MRfHnRZc+V4d8RuB1KraEfn9oxUq/HHSmhMq+GvEjIM5IFocY65/0jivnqx8uNWS40opJMPkn3MYzk8bRgFD2yPSugWPT0DfZ/PttQBUm3dGZVJ6KrcYbPqCCKE5PYOWC0Z7Kvxw0x4UlTwt4paJ/uusVqQfx8+oLj4+6Db583QfEAI/hBsyfyFxmvKV1OVlXypon8pfmLrswcnIz378+tZ1xf2N6snmafZyOw/wBaGKhT7P09qOZoapxezPXR+0X4bMnljQfEu7rjyrb/AOP01v2j/DCsFbQvEoOM4MVtx/5H4rw3UdKsrJD51uLWRl3gufM9PujP5Zx3rldXhuFbzd7BtwAi3AsFHzZJHcnt6UucPZH06/7RvhldudC8SHccDEdsefwnqvJ+0z4Sjco+i+JQwzwYLf8A+PV8sSy3QfKqSXyeFyx9iP8A61RxlZ+JVWOU5BBYgkevpQpsTpo+p/8Ahp/wd/0B/EnH/TC3/wDj1Pb9pvwikKSto3iQRuSqnybfkjr/AMtq+ULmGPJKkt2IAAwcd6hu2WOFUVS6KmMtjcj5zke3t3qlIhxsfWJ/ai8GhC50fxLtHU/Z4P8A49XvNfmHLuEUoGQNp6fSv08ppkniX7WRlHgXQzbuscv9sphmPA/0a4rj/hNoWt+KvgR4v0PQLqzt72/1hoJJ7h2CLCbe28zG1TklQVxjGD1rtP2qoDc+DPD8K7d0mtxqNxwM/ZrjFfO1p4eg86cano0c8pPLKhjIIHQZBFZzmos6KdP2kbH074E+GWoeB/iFLqWlaot34fu9Mis7qK62JOJYQFiZVijVCoQBeeeSTmvnPw1YWJ8K2ztiWN7SHziWZTGcBiAfu57jvxTrbwxoIkjjEDWsr972xVkz6ZwePeu80rwxapYrLPCroq+W720cbxcdDsUfIOvbtS51M0jSdPU4HVNPn3BtJMktoVWUNNtJyDgYI6c9qXS2vJZ0hk0eW4nnCsxsm3TSLnPy5PXg8Dmu/wBS0qztVaLT7ISwsu0SPbsx57/K4OB16Y9qwR4fl1CYxPfWJICosUgaFwRwPlYbiR6DNLRFJN6i6fPZiFJbGC8BjbZLFPZCSSMHo5BPPzcH3ps3inTrm8C3UF1KUBV4piwRX9VQng8Z9Kbd+Fb21igS7eWPaXCSWk3GD2Kkggk4GelVf7OktlDTwG9V1OTNIfMQkY5zzx6Z5ptxBRkXbrxDp9xKZktXREPJLN8w75AIz+XSraxyXlok9nLZETxhQCkSlUHUDc2VJHXjP0rG8P2OpRySRWupwae7ITGl++3dgfw7gevTrVC8slsnSSSOQgKoMjIJBGB0Umqil0M5XejZV1MyaZqTT6dJHFNG20xxzhwTj0BOevXpVYX1vfBTL5iytnc4kC7jkdQc4P8AOrEltYzoxU2ysQXw0ZUr7jaeDWdqWm2BZWS/tkfHJCEKR69Tk0X8gcOxatdVh0wOLWZo2ClZFdA4YHowDZH4jBFVl1bznVQbmclSy7jgI/rjuPrWa0oitktQvm72yxEfzAjpyfvA/n9aSFIgQ08ZZ3JV92VEf9TxTsJJtmkup2m6MLYYuNhMimQupb1x2/pVmDUQ0SmSwRoXBG2J+TjrjdxVWyNiPJE1jDJHkp5iyujde5GcflWgky2tyBYzRRpjcWWQSED0ztBz+FRuVHzLltY22o86fFJGu3eLVZiHb144GfX+VPCHTdyWQmhBU74pVyAO/JGCfpisy6l828e7hu5I7lmJ8ryThxj72QP0OKP7W1GW42fabp/K+84nCjH0PaoaRrzXR1FndTQeQr2pM8kihZbecbZOOFZemffvTbSxvEllu9OtrqK1QEz+WQyx+5Hcew5Fc7PqMcsLLA7yQ5GYZEXluuQw5Bz7Vf03XGtlH2O8kVwQfLaIFV9cg96iUWUpF5L250e6N3DdW8tsx3yRqo4/2lU8H1rcfWrdrSOWW0HkNh28nBUN2kQdj6r0Paublurq6SUKizRnJKqFTB/2Rg/lTdNWfTSJLK4ENtJ/rYW/eL9COo+o6VDVzSLPUrbULHWbaBlkleVVBilt2O+PHde4PqjcU+/f7ZCb2AGK9j/d3KZ4nj7Ejt7Hsa8+ju7fMc0EHklz8yW8uPLbuynqM+nIres55LiSOeK7dbpMny5D/rB6E9xWTTW5qtdjcku7lI12TJOhO5fNXmXHDRsRyHwSM9wK2vD91E1pHKXeJ0bCFzkOnTaf9penrWPF9i1FPLSN7adsCSJiAZPbHQ+xFR6Y0unLAskZuNMuTujxgurjjDA9ScdeDxU3uWn2NW50o2Wtu+nfu4533oFbaA5OSue3PK+/BroLa9S8tyGhd3ycTIAoJB53jqrdiOlZzTtPDu8gtkASQuOSP8abZ7zeiSIsUlP7xTxyOMkdiB/KquWo3GvfmynZJHU3MAaPOPLEyjBX6MM8evNaOnSh4IWVHxC2Z16kkjlgO571z3jKSJGyxO2RAroDks6kFfp8v8ql0W+u7CZ44SJraAj5SMsgbkEHqw9vaosVe51qzBNSkCFfKkwfMB/i6Ee1aEGGiaOH5JIGDByT155J9wSMVk+bFIiSxv5qqfMAUfeB+8Pr9a0Igskw7AD7o4yPeo2IlG6L1vcJLaHZtKgbWIGT17e9Ss7JIkyhBb42Fm5JB9fU1Ss223MqcoCfMBxxg9cfiKkIjDXEasW+bdknOM8gjtiqjLS7MJQSkWEuJ7W6lWJ0TzDu2k8dP0qyZ7zzt8WJmIHDDbg+1ZAuZo3ZAEZe6kkAE+/+RU8F4yRAm4WNQfmDsFIPp71qp9CZUutkX9QtVvLVEvYw0i/PGQ53q3qp9falsnMgdbhFtrhDsZoeN4xw2MdxUdtcb4A9sy7QcMyNkg/jUCsHmdo50eXGXCEsWz0GOxrXnsjBQeqZYC58pYkE02ciYnGB7gGppxLciMFlQu25X4Ocd/bFVLaYxyHdAxLZ+WRNuz1OR2pHuonLSNMkrE4+UkjP8wP51LempXK3LQtu8aRbnmbcSEC8KCfQe1U97+cFKBmztZQxEeOvJ74zTTKlxbmRYiybtpIbIJ74FWEuS0hWORBlcFuu0D0B45qVO7HyuK/r9COKeJpECx4bBMbghBjuAPWo7gJPEI3uJDbsCswk5OM42+5+lUp0VLZwS7PHIWywxlc8cd856UXJNxYoRasYANw2nbkd8kdDUyl0ZqqfVP8Ar5lVmtxZX1kGDzxrvjkkQ5IH3ZF9ORgn1HvWQYpJbvUEil+0SXIWRrYZjAYKoJDeufwrUu7iRZ4YyAp2kggBt0Z6gt+XB+tV3kgtby4ea3t4YoYy2HJLsMAgAjucfrQtS9k3vcrWEsGp2jOkzM8R8ht427R1z7Ecc+orZ0rULqOOQXaQSzw/IzeZ8hx1IHTnrXI2F4UumkS0igkil8uQsPMDg84Oe3Ix3FaV3erFaInmJ5jseDjai5ySfw/WmnZ3TFNX0aMzWdQlF1LeX+50uUdnQElQBggAfTj8awIZbm1kWWBktVl3Dy4yRgsc/mAKvalqMlxIjFk8snES7fnVRz19yB17VTMqiRpp1UynjcxzUt6miVlogvJFnMBjhw0SkRGb5vm7yNWHdGN4jFAszqBtacybWbHXbjt79B71JrM5EbvdzOyn5VjiBGfYAcmuXvbx3RjcztHAy4McZ+f6HGTj8a0imZTdivq+oWcMC22nsxZpPvxPhc9+epPuayDc6WmIljaMx5LM5HX6d6h1FvPwkNsdnqw2ZUf0rHcfZ4jIfKlf7pU8FfTA/rWsV3Odye5s3exwpiZQrED58Ju/IdPrVGaNp2JzbxiM/K8cm04PoT9elZkNzIZEcy+WR1LKCv0xWhY63e2gaaKSyLDK+ZJbo+QeOAw4/KtkkZNtlu30OKYuq6lp8lxjcPvyk9+cDg+tS2KywOY7RYr6ZAfkWLEcZ+hxnHvxVI+J70oB5h8tcgKqhFb2wuOD3qudWmuofIZWtoI8v+4iGSe5Zupq9DO7NeMzT77aaG/mAJYxi5wo45ztwPwFXtJa5sYStvo8dxcRAnese4hm4XLEkke3Wudsp7mLdN9oZlX7olk2hvXuKt2c04kkcavtRfnJt5Nyq3vjj1HWhXJbRrw6X52oznUQZ3ZW+Xz0s44WIByznDeo28dOtWtPtmnuntLO+gnVYPs6i3hNyUUnOFOMDB/jJOPWsXUdRs7idIr6TzYFIbzUj3kD0/H61YttcuZnk0y1lij08KWWN3McQPbIGS30P5U0yR4+yIY/PkumijfLmSNGVz0yQeAMcYA5q3LrEZnnSxW0hiLAb1jwXXjkLnHHXgY+tVvMs7Y+ZqFvdazdGPdDHETFbgjuwHzED8KiDXLXKOLKG1aUD5Dbm5MY6hR6D+lHMh8smas2oWMk6yTXavciMxm7lkaREXjaFGMEjnOO57VDPPp9w7n7Tcag6sJHMsSwxofUHk49BjrVdoGluFlvLyWeaNcQo9lxCwPUBjgflToxZxKY0W9knf72SqKxzkuecde3T0qrrqHLInbUWeG8hS2WHzUUuHieTAHRvM5P8qpC4muw7/YUgtYkHyWyhIl9DsOck+tRI91KoW0tp5nfP71SdqE9MAYB59zTNYi1W9uDFeebGFA+W7kVWBA+Y5ArOVno2axTjqkV4pUecGNmuXZSFh24Ynp0x79TVi5m1BLcpd2llbyKAx+UyyKp45HQH61VEE1ravHHI08eCS6/KAfXce/0qmGmYEJd+Rtb5iWLtn0x3+tZ6dCrNak17blHEvmeWzdI5kJLDHdmOawpfM8liwARuchc7fcVbn+1zusbPcDvtbcTjvUBSXeuwu5BI+ZQSPrRdC5Shu2Q+TlzznBHBx/LikuTEyK0ZZmHUMOR9CP61Pdx3DEM7R7eVXOFI/AdKgtg6K6t5BA5bP3v+AmqXcyaKN0oaGUn7wQ8g8Hiv02r8zrqNzaXLCPGF+cqcgV+mNaoye55F+0na/bfDfhy38tpN+sj5Fxk4tLk8flXjGk6RNaIY9xvYjk/ZiTHOv0ORu/z1r3L4/Kr6X4VDyeWDrX3/Q/Y7rH61wJs4ZbNpVjW5EbZZowQP94DsPauevJpndhYpwZiaNdXIBijkuVdPlEM2CVI/hO8Z/HNdDpDaeLieaaKS2nbPGDGrEngkfdyM5565NVFLCaaeYkSAZXcC7qe7I3B+ozWpHaTXI3m7S4OBtkZxkgjI4xzxxz3FYKd9jqcLE7nypGhkMW44LYOFYgceoB9wR3qzdfvxZxawBIhQMhOGwDx8rHqRis+JryO0kQMtyqsdpP3lwejAenY1K9z5lqqXNuXgyQSgDxgnB5Ucj60nLuUoaFp7WOGVfs+yWOMGMIVKttI5G1uCPyrPkiSJPJNooXJZo3bouOqg/e78Gp8IHd7S8ZYnPMRk8xWX0IP+IojuGACSwxyvGQSd2VI/mMVPMwUEU2t7e8VIYLuFYCMPBGnzD32vxj8qyL7wzb5kZ7EzBuVZv3QI7Zx1H6V0F1GHjSSeEqHGVDncSAfbt+tVpAkEmP3i5XAAlOw/T29qfP2H7NM4/U/CdxfCHznxbQgqohUAoD2wQAevUc1SfwTFGVd5Wlh+6RGgwPqpA/nXeIXXAVEV2G35iW/HNKNqyh5bltoOWEKksD75qo1H3IdNbHA3HgssI3clokBWFJIyPL59M/jxmsy98HzRS/uLrzXX7hQHkehr06OKK5lUYklGdwVAE/n+FTz6fHDhWhnVHyQFZMH/aLHt7cGtFN9CHBdTxo+G9RtV3LazzNJ024GD6dcmqgv7iFmjlgCv02yEYDZH3sjPY8Zr1u6s4DG4BWRkO1SgL9B95TgCsi+0PzYI2VD5nXc7AZ56hcE/rVKfczdM4FbrTJYctDcSSEEkRhVVT2GMEn8TVCDBkDvHE0akHbIh49c45rt5/Ds0jP+9AZOCQoXC9wNvX3NMTwnAGMnmJNuxhizZH0H+NDl5CULdTmdMgmN00lnEiIvJwu7n2J5FS3mkXEyx3qBnnY4wsYAz6ADk/WtefQWjkzbXR84jID/ACgjP6fjTobW6ttQLwvcwg/OzsM4Hbpxj8AKV76l8q3MjTbuWJmV1jB6sZi2VPY+v4Vtx3UN2m66t1IHBaJMH8efTvRqp1W6uY5LqFFRfuLsC5B6YxwfXis5Fd0kSK1ikcKOTEeMnkg5/nxSdmCTtc1lSzkQpI8kcb8RMBwR2x6NVkQRQFVmRpHQZByCwXsQwOQfqKwZb2WCPZDOJId3yq4wfz+tW4tSVU8y4jjGCNzEc4qHEuL1Oo0/UbdnRJPNeM/NF5ih3Htwa1bVo0AgeJfKOWDOcYOc4x/WuRW7hTc8SkKdoxgLs9wfX2q7aaqd4jliYMFJU5zu7dO1Z8popHbW1+d6NEyjblS4Y5P+97e9asd20bEsF2sPlOM8+prg/t0rYeKP94pCukRyHT/a7cetaNjqRk3DaEHQIXwAB6+/vUu/U0iaGvym5R4ppleNyAAB91iQBtI/Gi3aVIkufmZIQYZARyy+o9SKgnuEuIjFOu5XXnBwufbHcVLHOYbdNhjfkAAjOAO4qGirnV6bOptUeOQFOD05YHufStCGUi5RIQ2CCMEdCOR9e9c/pXzKqs25sYA7NWoZRGylkLoTtxn7v+fesmabmrJIowyopYYyc/wmrG5ssMB8ADArHSVXCAYweTu6Af1qZbgJcqQ5VXULnntQpCcLmi7hH3MwOcKVHr/jUCSbLxTuDoc7mZQSNo460wuM58wA4OOKj8vz54ir/d3BgF5Ocf4VSd9g5dNS60FtcSRu8konxu/d/Ljn1zipUW4yzefFC6j5JT94j0PqKjYwuEaUsXHpkkjsNooni6M8jxtjcgK/MKtS1MGrqzHD722VSQzAeYI8r+Az0+tWkghIDFhGRwHI5I/w+tVJJTG7Lcgru/j2FifqO1TRGIxM0R2qMBmVMgHsWz1+goWuhMk7aEl7HIiRzQ3OewcJtXHfr60xzIIYhcSKDtyixkcD1JI/SiW3VgTOwkkZcB5m2BfdU7/jVXzI44PLt0lmlbqR0H4VT01JjqrfoFvNkKHZIi3Jl3DDjsMdj9aeLpYiZYFlVt247pBj64HSqslxdCJ0ncBlB3KoG/A9u2KxjcvOZI43J/vnaenYk96nmaNVTUtS3qSrHI0THy8ZkUqwJR/7wx0HNYt/cyXUMa7g0kg2SdjgentxSXM0EaJHmWNmQqxfoPYDrWVd3TTFNqMAo743ZHpRdjSJrudYYpneRdsknfPoMfyqpNdteTEKIzbrj5GPf3P1rM1i5m271wwUKVwoAwDk/WqyahGC2JEiJ+YbhkGq12J03N2dpgpkdMDHAP3T+NYeqasIoXhjMUMikNlRuJ+majm8T2wjcSSlXU4UHkY9QB2rj9W12KabYGO77yuw4/TtVxg7kOZqXd+ZJpW8tJZCuGd+CB/Suf1O5lVRGWiYf3UBBxWbdasskJjSCJiTnd8wJ/EdvQVUhklujxbM2wdQxG33rWMUYSbZakuBHmN41MjHG18sQvs1Z8smJ2IJCHJ2xkHaKtuqukkUp2luQyjcM+/fNJDps+0x26lt45ReMj371rZIzsynDJbq6kwGVsjBztBOfX0pkdtA08gkimMhByYipOffPb6VoLZOkm17eZMHDIMbW46g9zTbiG3cDe6IQQuCSrZ+nT8apPqJxtoVvsFgkQdri4S5C7mjNv8AKT2G7P64p9wqI2yKZGQHIZ4Cp+nX9KfqK2kNxvaYMcDhgXJ/HPp6VYtDDEjSpCuwrjKxsSO/IPAodRAqUiKZp4oFRdPhcbAC6w5K5/u88Z61DDCjAmOKVsAb8rx+Q4xWtbLZ3Nx/rGtFPKoFKqPbP/166Kw8tVEivbzSr8i/xY9+B/KlzX2FyW0ZgafpkbIGWO0XGMkJvO4/yxn3rRsPDLxMFsHuBNJkuwAUD8T0rr7SK2IUbCRt5EG1uR6k8jnvRAV3MBNIvGRuQjfn0X+ppORSgtzPsl1yyuGuP7RbJTBJICHHQEAc/SocagRN51z5bSEFwgIyfc/0roI22yK4AfKlgxfIPY4ApGuh54Nwi5Jyd4yoHqAP/wBdQ5stQXY506a3ltI96x3jBjcdff3pU0uDfuuVLDHzSNtC5/z2rojCt0C8aQeTgs8hkx0PoeQKZ5ckTbf3MQfBwxJUAdCOpoch8qeqM6zs33b47USouNrmQIAOxxTdT0q2VWlhtUeaMkHzH4Zc9sdMf1rRcpv3OGlQgjcDsz9fWoAql22BJCQCc5I56fWmp23Dk1ujmpYROWK6Yxwd2IVKxgH9aWCwlwxgjtbJS2NqwF3+uTXVSyebLbwlQp4LbzwW6c47flVa6e6jaSNLu3iKjHyxggc9jnGam4+UwBpMck0jXVzdsXX5o4sRKB36dBUNx4c00WbslgXYd2fjOeBkd62pWvmt2SC4SGJhtKpb8vx7nNZEumzXLRrJK7DaDndhQPTjgelFxKJhXOk6Tb/8fUipL12Y3KP8az7mDRw+yKSFy3IOzbg+5xXTG1ulZ0S2hKRfcJYDnt25rP1GxuA6mREEhXpGoU4NCkKUTjdY0+1+yXMsMu5xGzfKOPungDrX6NV+e+s6X5GkXTu+144GOGbcSSDnGOK/QiuqDucVVWZ5T+0M6JovhhpQpT+2eQ3T/jzuq85tFsfs7TQzzRsybX8qZlAHQpkfnzkfSvRv2hedG8LgBTnWgMMcDm0uu9eUWxhSdRPDAUBJA4wcewwTXPX+I68IrwfqaxtfPVjFc3Uv8ccgwxIxyCMdv/1U/T4AiKYZRISu/dG2HQdzjjINZ8PkM4Nszo7c+WAfrnBzzWg96RCDJCyRkg/IgDoP9nB6msOXqdqZoxzhZTJAPMkA2+bExDE92x247dKHvi0pkZP3hX5zJ8jH3JB+asm3vXaRxbXknmHGwqiqWx2YZyD9PSq1xqMk0j7lM/lnBcoTvJ/z0pWC+pqzTLcMPI+Z8FnwcH8SMUsuoZYb4/KlQYJCDke9cpfa1FbSqt4z+dIx+S2YMenOV9vr1qlc61qE5YW+nIUyAGuUVAMe5PYc01BicrHYvemQB3K7Tzuk+UkDjoetRS6xbeWrC5L4fBiiUrsx7t+vFc0dE1x4RdXNxbx71JQKNzkdjk+tSz+H9Os4oLvUZLyeG4HlSTXDbYoZSRtb5evoc+uaqNLUmdVIuT+JbSKNQCGOeofknqAw7VP/AG1qGpSRx2lhdyzSNgMmSMDgYY4GB0zVzRrvwraXFn9nXTmjyfPgLDbFEPvFn7sTx3yOelZL/EQ2+qCK3EbaWLpnN/KCpnjU8Jt6hMZGa09n3MXWu9DYn0/xJ+7Z9M27zgB3WPc2cYAXnFPTQ9aE6yXQsLdY1yQ+WC46naOScn86zoPiddzRyGxt1h+yfvmuzKTI6gkBQrcKpBHToM4qO6+IN/cW0r3U6Ndui+TBaqEEeMHccDOfXoACe9NqKI55vVo3LbwrrrgvDqsVwnLb1iYqF9VGcBQevoajvPCHiC1iguDqFrJFMVUTIGkVuOML2x3/AJVUsfiHEbK5UWsUMs0kblkcvCi7gQpRuGx8xyepbnpWjF4802db+KOylX5jlFkPlsFBwxA5CZ5IHUqKpqBKnPexk3vh7xAkqpFqcTMq71QRBGPb5AeP1rDFrrYl2JIkikg/MpyT069M9q9Bt/EemzTppthqMN1AjJsF78iyTMpJZeMhR0Ibs1ak2kafqLz2sED22bY3HmcMIj1YNjjZ2BWplBte6awqxfxHm4hv42jjnt4pkRf33lSeWMgcKM8t6nNM0+6t/PVpluLdichZ07cnGTwfzrpr/R57SGOa5RUMeBlD3HIJ9xxx0INNF8kl7I09lCIrpPKuINmYmB6MF9jgjFYqaW50ezurx1KTSJeDa7SmMHKguAoXsFHUc9hxTL7S45ERXtzIM4Mmc49Min6r4efSr3yrcrbxSMcG4BKxHAzuA4B6HK9Qc9qdaSCbzUWKJZomxIsfA6dQDxt47VUr3bIjbYp3GjrMDttE2MAowF+UjqQAf51kXXhiG3BLbxKchd/X8vWu7jjkupVeMMzSbWK7QjsPb246imrHMkbeTcLG0ilJOV+6e31qXUsWoHmyaNIZGCvIiuPv4yB781Bb6fdw7vKkAYEgPuyxPrXol1aJKq7NpZflBAKkexH9apy2IVlHllgF6F/lz65Hr70cye41Bo4+1DRfJJJszzgHkH3NXrW83qFKS+crc/4/StqbTsqOcQqeW2AgH0+n1pk+ntOd8ixyq38advqO1LSwakUd3H5gDhvmBGGwNp7c1o2NwcDdtBXhvQ/QVnfZcDy3beMcMw5HsfU+4p0KNFOvm7FGAFcsSOKzlFGkbHVCcsgBx8x/hGfpz71p28xwFLAHsv8AjiuYimbBKED1xzmrkVwXxt5I6+lYtGsddTooJMOWO1mxz2wKtxz+ZIqqu84J4P8AM1hLK0iqrYGOgHc1YUkKxHG3ruOCTUmiSNq1lXLRurkfTgVcEjAOUkV+20gjis22dQqCSRS2Pl+Uk/hWlaurSIwkbcgHCpjI/wAacdBTJbS4iK7w77FbGIk6HOOM1bi3lZGaJ4VHJ6Fj75zVLT7dn3bhMyF2KKYz8vPt1NXWhBUyrDKRjaZWjOF+n+NaxRyztclkWFSPLQM/HzSTFmGR0IFK8+cCV1UIQw2R42/Tp+tUpJjBGnlSRj2SX0+nU+uaqTXsanLSwdBkgk8+49c1TkQqTkXZnVSy53BmJLO+0tnufQfSqUlypEkcJlKLglYlOD7knnH1rPn1QQo+8NOSRu35Cj8O59zWVNeSAM7usQduULYAP+7UNroaqm1uajzQ/K7vN5R4KggH6/l3rNe5KphF3t91fn5UZ6DHFULy9Qj5ZhKc42JGQQPX0rNvL95IWeXywFbAVnG88eg7UJMGyfU9WkjhETNtjBy/ygknPrXNale+bdyCz81YAfleThyPcdOaS9vmBk2EfTGawbu7dQY18wEj8VPp9K1Ub7kc1i1PfOkLlZCqMuDxwD9K5u61OSSYrkHtgjC/571PMhZsyKz7uSGJJB9qni0wCEtIAqD5hu/p61aSRlKV9jGEdxc7Tv8Al9FH8varUWmhpf8AScZ7EkfzrXjsnmCeWCSTlnPQ1rwafDtAcByuf9lQcdBxkmq5rEuPc5mOykR8LEkgzwEHP+fpWqNMsJQqXLMhfGHYfKPy7da3JMW6qsLbIhxu4BJ+v51iajfqm4/dyCSDyOO5FJNsfLYo3FvBA6q8asF4Xbzn86xL6+SCXYHeeVsECLOcdME1vaHpGq+KovNtI5TYq7QxXPmbGZ9u5ggwdygcsa7LSvDmmaS6iyhF55OJVlkQK87HgOwHIQn7iDkgEnrVtWJST3PNbTQNW1ORPMX7JbgZG7cP/HT05rpbD4exTMYgXnlRWJZ+AAOeSOPWvRrXTUt5Bc6zM4jzlFQAvK3fP91evP5A10TSWVufJndLO0nJh+zxvukD43bT2jJ4+Zuo44pKEpbilUUPhOG/4QXTNP0Z7iVZYZEKxRLKEy8hx0AyNoz+I9K028MWKPbgwvHNNMiiDbl8Yzz0C7+2emenFVb7xZdxWT3qaelzp1u4eOfIEcTBSoOAOW3fmOOvNcbrvjrVbO/Dvr0T3tquIvIYuk6SAEEYGBgcHPIIArZU1ukYyqTejZ6TNoNgt0tu0sE2n3G9XjmmUxqyHaRuHzAAlV3YzmucvtM8PpZTW8bWvnt/x7x7hhmJIKMwwQRj73rXld14s1S8t0souZFuDcxyogVtxJPHfqTke/sKzBdXYu5jOgl81BIcPgKSckn646etW0rmXO+rPYtP8JWE9ydPjkuElilhiz5m1iGOCO425GA3pg1Q1fRdU0q5EUN400TvIkcczMoAViDjHXAwcdq4G48QavZ3cNwBPBcvmORiuRNjGDgfxDj+dX7HxtqX9pXGqSStJdxht8U3OGkG2QsPUip5dAVRpnRXMl5Z3nl6lZb9iqwCnGeeMEYOD+HQ02515EkSJXeNpF3bVRmCn+6SRkn61R8O+Jbe4S4OrSym8VCIyQNiICMAD1GTn06jrVt9Vsrm4sUtEaGZhhy/CI+eMk9uOtKSsWqibJo9ajuA7vJvjJGRIi8t0wT/ACpyX8QkxHLvzkF9oA6ciq2rWqyC5uLgoskxx5MXCFen0PTNc1qGlxxoJI55kyMMFfbj0NZu1zZM7MXkNztmmAk4CLtOSPw6fnUSXKncQ+1TxgsAW+mOK4R1vbRVkhmafB3KHYjI/wA+tWNJ1tp5CjsYnjBkVMD5Mdz649qOW+wKdtzuknjMAibJjJOXccA4759akEkhxkqzqAueDkH0rBttTmnVs3CkBfm2cAfge3c/WrjXTylhIirgfeVvT0Pf8alxKUk2aEkTF/3kzqCDjAzg57k+1VZRHHFlbjzQvCxOoH8uMUxWiYyO03mhvmb5hwfYZ6ZpkiJsZY8MmeA7El/QH0FTew0U7m7la3kaOKd58bVbYAqc9sVkXF5PHG0jwyfIMcnH/wCutdZJFPyozMByCOB+PWs2YTykgspdznceFUfSmmTM5/Xrhp9HuUkhIYW7t+8O3HynoK+/6+A/ES7NDvc/PIY33MTyODxX35XVS2ZxV1Zo8p/aG2jRvC5YIV/tocSAlT/ol11x2ryeYrGrFIo0hYAAk79xxyBn7ozXqn7Rx2+HvDR2eZ/xORhc4yfsl1XjolAmAjREbdhgef8A9dRV+I3wt+TTuXZr8RzMokVlKAdOFqOfUV3sqxJcBTu8xUKAZHJJ7dOntVC8v7hQUdYjtGEOwEqPcjqKwrmTULhFE1y8EZwNquQ7emO351kops6HJpE2oeJIoD5ZQySSMp2RryR68+vvQLjUNUUiSZrO3DEpAshZgPTPasrQdOAvPPmLCUkAhgNpI/w6V0zyrbiSNWh34ySjDI56e59hSfZApPqOtFgsjG80TqSu0SNz+AJrRkuLZhDBNL5UEoYNgbhj6iuZ1TU1sbk2u8yTDAdt4Y7f4sH14x+dcve6zc3l00jhckADC8Edhx6CqjTb1M51V0O3uvEJ0+KIafNIkcqZWKcbxEvdiPQ/wjrWFqXiG8vZYY2uGMIHmBc7Rx/GQP4j7elN0bRb3VfKnleS3tCdr3Mnzb2HGFQcsR0A6e4rrbHwRGssWxHuLlcPLK5wiP6EjjgfwjPvWnLYyc7ux5rbyTTxP5UDPAx3OqLxn19quW2nTXqm5u5REgOPKC7i/GVVV7++eBXuNt4WtbKxkmkhjCgf8tV+8e5A9OnHTFcXrNkkU7zXjo8jcqirtGP6VaTk7JalStDWR5xFYyh3MfnLGxwW5VeO3/6qlt7N9wMMkkkpUmR0JPy+ma3dRupJEaKPaqDr7CqkUjp8y3AjkH8UZwa29lFbnPzyexUt2uI7GS3huFETHqIvnH+yW9B1I96tpJqigG2laBDGINijaXHQsc9zk5NXpLybyCjag0sSO5VVIHLYDtj/AGsfjT01u5SGO3eQvGDuKsAckjHXrjGOM03CL0BSkndGJ/aF3pt/C8qRs1upAeI9M8En1611mheLLuCys/sFxNE4mzLJvKqBnOFHZc84FZqtBdQiEqoVj8xPU1YfQlayJs2IUHPl9s+1c9Sk1qjppVE/dkej6X4rtNdkhW6uYrC+niK3E2CIjHnCR4wcMRzn+VW7i0iu3ie3VLVUPk5YHBUAc++PvHuBXjKJNpU8cp/1cZ3tgE4OOtelaBr/ANtsX85sKH/drydr4GBx1zzj0PWuar7x3QhKnudAzSyefZ6y8pubVRLEIl3CWJeSf9ohSWU9xms69sJ9Ma2uIiRHA+3zYyOjAN82OvysDnpjnsRWrk3T2Ra4jS/jIeK6Tk5z91z3x6ehxmntE8lpLNaqqQWsyBVfISPLElFzzhcnj+6x9KUJpu6InF9dChaLFuwkFyrqRuQMd0Weecc7cHgjg8VdWRvNAV2XYeWKkknpkjtxx7VXaFHuHXTg0NyP3kDqTmZDjdBz1Cc7T024zVuOaK6jkljk8zzBuKyQgqoIHII5Bz1H506sLaodKbekhksWRvkzIMkog+Yfn1ApqIZA6rEysD8wCjI+v/16kwAT8m3nAByeB3GetSvGVXazoehxksx/KuW9tDrSRTazRWVmQhx1VgBn8aoyQRo4IQq7HkgYK1siMoACUBY5weP1FE0JVggTj3AAGe9HMJxMGW23k7X3YGcZxmj7JhE2hQmccc89+tajwlNpZCcZIOBzTDG5GQvy4ycnFHNcOUrGJDtwWKIMZYdKmiIdV8slMjnjH/66s+WNilhv34HoRSi3Z1QAIMdSB3qWykWLZFMYJmX02qOfrV+KFTtB+Y9OvUVWtoEUxlSBu5CgE8dzW3bQhsAheRyRxgen1rNlJodaRRIJGECBduBjsc9fxrZt7Z8oYt8bS8qy9vb35qnBsXA2sQR93v61pWwIChZVB5LFhyrEfw1rTt1OWu2loJCjqBEHlD7uSG2jHscetRXKBJcSHzQv3VdsjPv7VPOZFZSQ4CjBBAHB6/jURQsrDPlx5GEDdOO59atu2hiu5mT/ACkuXKoz9OhP4dvrms29KeY5Cqy4+UYz364rckhU/Kxy4OAUwQBUd/HHu3RLs3jknkispNo64SSaORu4vmAjRwrcs7kk59axbsyxxsWVl8wEPkjJx9a6m5j3nH8YOM44H0rE1S3y2BwNuQSckn6dqIsto5rULlmgEiKx2jbjGMj1wKoRH5HJAj2gBjxnr6Vq3MWGfezIBz9O+AKynUuwZwrEjGe4AraLOaXYz7+68vItXVXU5yPvH39OKoqvmvkgkucHd2Fa81quSIkIGMZbDVGts7tk4J5wM+natL3M7X3KMdvj+ED13c4/KrttYBnRWBGejuCTj0ArQisgFwVA46jr+tacCxxgHcxGdpK9/YUrlKJTsbZbUHKpI3T5gPl/pU886iFjubgZBxkZH/6+tSzhFAUFXbg7WHTnrxx0/Gs+7lCiJdwBbnG08Dpmkrt2BpGTfSonms+XAXIBPH6/yqhomkzaxev9sVhZRYeSM8Fh15PsMHHfpWhZ6fNqerhUlVEhUTSSIo/cgEDp0L9MdsmvRbDQorXS447OOS4gmlO8rgyJ/wBNAW6v6E98t6CuiELK6Oec0nqVhbx2+kpa2gSJSxM0eCgiU/djXtls7mA9MdAau6bapGk4jSO4itVa53BlCSY48xieW4Hyp3APIzVO81S0tJprW6ea2tgWUXkWJtxIwykg5OecuOCTnjOK4XVtVm1i8jSzh+1TB/MRYovmZM7QSB02rzk9+tU172gXtHXQ6fXPG1iZ55dOkZjGsUlzdgEPOrjLBgRhQvAHHHbgVzY/tjWNNvV12+exIiF3EZyWkljY/u2A/iXKjk9MZrvtN8Br4Yh+16hJFcXzqBKG5jCZHT/bXoD0NeceM9Qgu7pFyqpCu2JQOUA4xz2/2a2UHI4Z1ktIdDAj1Ke9eG2SD/VxCPy9xbecn5wO5Oew5wKyrnRUd2YXEUPyFyH4H0APOee1S3V5OyhkfY6kEyJ8rYByORyPwrHlBBLgu7E5Yk5zWijGO4k5NWIZdLuJZhJ58RdclXV8Nx3/AMKQWFypQtMGUD86mYlM5PAOM00TJtbZJ83oelJWHyPubXha8trCWaC+s2uILhSjsyl2QHuo9QcHIr0B/DVp4ntRcWe6fUUTy1uVjJLJ/tjgkfXNeWpLgjawz/hXd/D7xPNpmpwvvKruwfmwCPSqW2hjOLi7mTc+BCius91Ja6mpyYJlJEufR+g6d+o/Ks1dBu5bYiG6jkv4W2SxGT5kHsf4l6EHpX17Faab4m0qOaVY5N68MFwT9fWuR134ZafdI0kVpC0gBCsEwSPQ+1S42IjU1PmD+1L23XypZvniO3aBjbg5/Q5q/pWpR3ZkjnaMXGQ5lkPpnp7+v4dK7/xB8P45JBAd8EwBUAR5BHb5hXnOueFrzSpys4DDnZIi859896zaUtDpu0X7q8glZBGUbcCu5AQWx3YdjWNrlkspWRFUhfnVgeR+VZ4DJMQ4woxv25wSB1PerMc5mjwicDjep6/XNQ4cuqNo1Iy0kbWloj2xkU7ICgx8u4hh2/xrUti4YBQSIyATySR6euPesHQtsd6IQ/E+cDdjDem49vyrqVgmhdCkaxFMAuM5JxnGfpSltYuKJEl82KOJGRy24jHAUehPWlndoZFWSUDYAu5GDe46f0qPyVCHesiTA5bbwfb8KUu0oRoyEjHB+T5gffHHWs2zRDJn3hmjV2Ycl92P071QnVyXaRxv9+AMew71Zm4SSR2UA4wByR+HrWRcEKQQJWPQk8d+tNbikY/iGc/2dfAgZeNs9hnBr9B6/OrXXdrO5AU7fLbn8DX6K1009jirPU8o/aIkki0Pwy8P3xrHH/gHdV42bZ5YjGqxLkdFH55PU/nXsn7Q/wDyBPDHOP8AidA5x/06XVeQyma6jVWgZPLG35SBuHsB/OsK9uZXOvCfA/UrTDChLqQNtGMnkgjoPSs27cW0cl3IXmU5CqcdcY/OtW7iuMlTE0Py/KG2glR2zkce9ctrl9Ko8toVEC45RxtOPfpULXY2loVf7Sa2jKKxJIOeBjJ5rEvtVmuWXAAX7pKjsev41BqtwbiSVUneZV5JT5YwfQdz6ZqBt5AChl2gAA1sorc5pSvoiUZZyseTI3yZ/r+Vdp4P8NfaZUMmFH3pDnlRnA2+5PP4Vh+F7EjUbYMNwJ3DIzkfT2r6J8B6HbfZbeRvnnfBVSMgAdzRfsaexaV2h2g+D1eztzFAhWIeWHccKB/dB6n1NdVYaG1nvfbE0QyPLYfmT/hXUJPHFafIUK4y4UDg9/8A9VYt/qirceXDMkiMCxb0/wAaba3MoqetkcN4luxBFK7uWhjBGTxk+n0rxTX9RknnfLc54A7CvRPilfN5gtk7Dcwz3PrXkV7IzShf1Nb048sLmU5OpMrOXkYDBJJrW0/ybe0iZo2ee4JA6ED/AArHZ+DtyOeoq9piMbiMqzK+4YYetNR5nY0lLkVw8mRVLuEKk525569/SoJEIDEEEA5IJ65OOK980X4Zaa3hCTV7mRbiRoi5U5+U/X1rxnX7L7BdgRMdob5eORWkqaWzOaFdOVnuZcZxIF+YOOx616H4fdW0OKUJyH2tkc5rhk07FnJdzzCMg4jDctK3ov06k9BXoXgBBdaA8cik4lLZHU5rnk2joVlqjQ+wRvG2EQxygghh1bFc1No01tMsunArvVpViPAC55z24JrtLBxJJc20YDeXyFz6dfxqWewElykyhjGIyJImJO7kdx0NclRcrt0Z6uFftYN9UY+gX9rNP5OpRSxAxMUUcFWI43e2eeK6Pwvdw3Pn6dqErYmOJPMYLjjhgT6eo65x3rD1u2t7ye8mt1KSw+VtdeQV2ElTWfbTnVUhTdsMY4Ufwj6+tYP901JbGjpuatLQ6m2s47rT1EMrW95ZyO6yrndIMZjIz0wAeO43DtUqRy+cLlUiKTqsjxbztPYyDAypB4Pvwaq2N5PKY0WMBkxgx8AnfuUPkYwWLcg9GIq7p7bLibfIwcMCkZUjcozuQf3mC4bHfBPNbRlGS0OaScZNssNtCMR5yuBhtx8wrn9SPcdajtY2fiHBkAwSi9B/n1qWKBoblURxuiOJEDccjIwewOfofSr89rIv79vMO0ZIJBKgYyCB1x7e1ck1qdcJWS8yv5ZkH3m3Y4Vs4Hb+VMNufLCnaRjOD6HjOcVsNB8xY4cYxuDYb8h2x6dKYQxR/mBxjliMnHTn0OakdzCEeXcMMLjI5/UUwRibqQOxGeMfStOeDFsCmMAgnd0OfTv2qhHNGbiKJCQWOdvQ49D7Ur6lehKUcvsLb2GPxHpUQA3O7YIPJBOOKurk7nQliR8uPrzioBI3nEJkoRgsvYdc+/aqtYm5Nbx7XGFKlR0PbNasJ3rujACKO/b/APXWVp6M5+YYXqQO5roYI1KDOFVeRjoo9fc1LV9AcuVFi3h6MUy4HTv9T/jWlDG7LGQUWPBw44YnP8Oe3v8AlVK2lTymbLCAtkAn5nPvVyO6xIHID5GA7DAAzzgelawcVucNbnl0JJraMk7WJbuWbcSfb0+lVNgBy2NpJHSrD3cZGWG7B7DatV5JUkVhglc846LUTkr6CpqaWpF5aNkJlV5IJ61XnRDHkkA+4p9znGY9uM/dz1FZ87OqkADdj1yGrFyR104t63Kd/ujACkByPlJHFY12wfBkUHOSccflWjc3BC7XBKjjAPQfWsi6ZNhcEqpz0OTTjqbyWmpzmolftDqc4PQkdfes0sWk2khQeBzjGPer+phpS8mTk9Mn8OPyrJ3LuK7gM8lsV0xOSe5JLGGYMXDEngdcGpIow3yqrbQ2SQP5VWt2Rs5HP949q1beP5NwUYXkAnBHPrTk+oktCTZEoEhb5sdSvIHpipFdgwVUZSQMHHzE+oPGKc7M2du3HQbVwSPTPpUEjYII3dsE8nH1P8/yqL3NEtCNpHiQtDHtjyQGOSG45C471UOnz3cixpuZAQHk3D7x5Az+GT6AE1oWtk97coiyeUp5aUnKR+x9T1wPeuvs9Pg01YYTGVMoyjysHZARliR0JPUn0wAMmuilHm1Mas+QztN0iCytTChhkeHEkwROZpM/KRnkKAScenuareJ9bTzXtNLmcy+WyyNKECLu+ZuemccGr3iLxJHp+y0t0LzmFt83uxyR65z1J/SuIs4n1BhbpGXedhHGqD756ce1a1J/ZiYQjZc8/kW7HSJde1O2stLs5Jdygssrjn5OWLdlz/h2r2fwZ4Gi8OWkccKQicqEln25d16kfTPAHp1zmrPw88PJotq2QrXAHlyzAcSN3x7Lwo+hrszW9OPKjz6tV1H5Hk/xUvV07TrraNzKME54J7DHbFfNepSAyu78yOSc+9e5fHi5aLUI7OIKsbqHPtivD5YUupZYom/0kgiPPQt2Fbp8sTOCuY0sm+RWlJWMZHI5P0FPimj3f6tdhG0K4z1759fTFUZJJJJGMrEsTyW65969O+Cen6Fe6uy+IHCQLkJkcBvr2zWa1Npy5Inm19c/KAtsYnDDJJO0r6YqkuwPIyLw3IHp6Yr174jaVpZ1i8GjqGsgSV2jjH+FeS3MKQXTwqMAMMegB/8Ar1U4pK6MqdXnnyskIEiq6EL1P/1hU1nOyPuVioFW71LSwsntpVWe/cDO1vltx3Jx1kPp0UdeemXGW37Tx7VMHqbTd0fTPwR18z2q20sh2E7QM9DXtqAEjPOa+TvhBcSLevEhw2AyjOORyK+qNOffBEWyrsoJ+taaHBPRmVNoH+mLKQGXJOccg5yK5Px/4fsZbZkuY1KS5HTkH616fuwowMk1wni6Z3gbcg4B4HYetYytE6VJy1PlnxL4eNvdusbZ8phtZWwxXPT0rjZVntZmKrjDEDPQ/UfSvZ9ehM905VAxDHI9V71xniHQZYWLwKN2dwJPUelSpJSszd0+aPNHc5Gxv4pfMjmaKJtoaMnn5h/Dntmu407Ube5VWE6qwAzn7oPcHmuFlnu4wY2jYxhiHUKuQ31xVixvpiypb3SRsU2SAoEL85y3Zue/HSlKCYU6jWjPRTOkkb5lQ7s5IYbf/r0RrEkWFjkZcZDBsCsHSpiQoNxb+Y5/jyMfiev4VvSxPCijcDwQWjUYz6daw5LbHWpdLFeV8R8gIemcA59ePWubvo2bcwI2k7clq3Lp3UKrNwynJK81zmpqifvDIGCc8jtQtxSMbWlU2N1sKkiJssOh4P8AnNfopX53au4fT7t1CruhbgDoMV+iNdNN3RxVlZo8p/aH2/2J4Y3LvX+2eVyRn/Q7r0ry544ZVVoojvfpGkhcfn0Uexr0/wDaJVn0PwyqKXY6zgKDjP8Aod1XjM8i7ktkSLzFBOIAdkR/4DyW9icetYV1eR14PSF/MtammnWtvm+ihVAc7IRvmc+mCeOe+K871qRrq7aW6zbqThbcuXZf94/0rqNU022VFkEbwZGHkeXdMf8AdPRB9MmueMNuT5kNvGI42BWIqWaZs9D6475I61nCWtludM4tq70RzUqmScLApIY4Vc133hfwHd32kXV8o85baPzJWJACZ+tR+GtHSaeZ5hFvOTIyrlYh12L9Tx/9avR9PQLZNbLLtSYY2BetU5puzegQpOKvHc4vStNEWsRNhTsiCKOgJ6/yr2vw/BC1shiKhk42oSWB9D7VwNhp6xzCPBV1bDMeuexrqtKtWtLRQkrLPFkqwY4Yk5yR3+lE9NbnpRipR5b2Z1EdvcSswvHMY3EkZ4P/ANb2qydOQgnap+UhE6KPwqla3d2+HldFK4J4/hPpWhNLKIXLOjHj5gT+gqYO+5yV+dPlPFvijC8WqeZghJVGP94DBrzC7GZCMY9s9a9q+INhPNDcJMfM2sZIsDt3FePXts4GV+bntXbTmpRPJlT5J2ZUitZZHcBQGVckHiprWRonDDhgc1Au5+SxB6Hk80q5GAOpqoyaY5QUkd5YeMp4NPFuWZosY2ZOK5fVr03kofnrwpqoWC5UNkdai5ZjgcH1q5VGzCOHUZXJ5Gn1G7A/1s74AVOgHpjsK9N8M239jaC4OWllkPQ98fyrnfDzRWNvOhhCShgC2MNjr196249bijs51EJLtynPAOO9RKOmprfWyLfg2Zn8RDB3Jh93vxgV3Wt6dHYWqTgt5zjLjPUVyPw00/z55rqZvLjwU3no2etelatFBeRRGFdyKNqOvcd65MRK6Z6WAbpyv0Z5XY2qWupyq7loptpkTOMZTH6VnzW9zC0EttAsS4+YZ+8OnPvXoGoeEybkMJA0eFkw3HPI4rnNRRFvWWFsDBX5Txnv+NccJfZkevWlCtHmhqZ9lc+eo2yEW7YWVME4K5K5H14/GuqWYG0jYP8AaZ4HiZo4yQJR02KByGAcAcnhjnpXGybLe3mTYvnGYMZQcNs24KcdRnn61u+GtSRhDYgC5i2Ps3NsCs3ZjjPUcehbNawSj7rZ5laLfvJar+rnYW0UKeWm1nhX9yr+XjCNzGT+OQQeRgjtWvCitIkTM3z5CqhyCOm056f/AFhWVJFF9kFwgk+zkgmJhySSOGX1D8HHQk0sU6GTbAXw+WODtKlc8epAGeKdRqMmjKmnUjdM1ooxi0WYIC8ZcuBgjGc479B0NUpIGXZsw0Sg7W4GT/hU0DgwRs7E7VYlRwSMEkYqd4wQBMMFYycoOSuSx/DkCs5JNXRcZOErMp3MJSxzGhUNjduHBbHIHp1rnWgCXm91+ZRweyn/ABrr7vzGtkGza7EcdG7f1IrlNSAE52opUtxJnqBwfrzmolpLQ2ozvHUcXKLj5hxz6jPQCoirZfcrFVwrHOCTSISqEYOV+ZSemf8APFRl1DOuB855U84aknZDdzRtpDEUBYEkZP8An0rQe6UFVwC3B56H3P8AhXPwzFWw2QqHjJ/z+VXhN0cEMuORxzXPN2NoxvuaQnAQyXDGYk8Aj5fyq0twHZst90fePXFYkfmzJiJSgzjIOMe1XBx8jsGZeBtPX8azUmVKmi1DIWf5mLIOiDofxp5m80mHhRn5h2FRRSNHaln253HlzgH24qKWQE5QgYx9Oexq7kct2X5gscWM/Re+aqSS7hhXUMD370ZdpCsjJ9zHyjkZ/pVQRGE7ZWzjoSvGKiTHGNtynes5gJCDYevqa5y7k28hXC88NXR3iyrvJ2nZ09PwrmtQI2FnGSx//UKuDKexkSspZRknOcYGCD6VmTnMTPyCcksAAM1bvDskxjcG68457GqeBJCiZRSSfm+8R6nFdlPY4ahFazF5kTgRsfugdD0Ga6W1GE5IxjqV6D61xsR8u5jZiSM4+bPPNdfEfMtgF3DIABPelVQ4ak0zbVDMVx/ET0//AF+9QRKHbfMW2tzluSBnil8v5QHYFD8pDGrMEAmK/dJ4DnPzMcjGO3SseayN0jqPB1hD9s8yIIJIV807zuYkDlwDx379O3Sq/jO7+ywRwxRWzzna0c5LKyjJJABx6k8jrz16XrO4FuXaBWEpCmJXGQCOArH0x1Pv9a8n8WakTfyWNgGE9wp86UH5lQ9s9t3511xqWhynJ7Hnq83YmFzNrcwhtD9oBOx5WGFVV9T3+tez+APC0cWnWl7uUz9UnK4Ygjqo/hXHA/E1wHw6tLaDy9PkWPCcOoxliecn1x29Oa920eFYrSFYv9WF+6fX1HtVQVjixTd7M0IFWNFjQABRjAqU0ijFIxwCcZrtjdLU4Dwf46wY1l2kXIliXYxPcda+fpyUuGAyAGzxX1V8YtBfU7BbqFD8mRnHt+ma+YtUgMN04YHPIx9KpPmRpB2Y/wAQRW2oWlrewIE1Qx7bhFGFnx0kA7PjgjvjPXNY2lalJp8xIchG647VPKWRfkJyPunNZ1yDkNnIYZPsaSnyu6Np0lONmbc3iR0ilSKVyXUqwQkbgeoPtXOSMzu0hOXY5/GkDEk5ADEflUalmI9ulKdRyM6WHjT2JUz2YgCnoCZM5HOM0zGOCADjJ5yasWiM7qMfMT0pQLm1ax6b8HbZptbU/Nwe3ucV9TOwCoF4fAUHpmvFvg7oMdjZC4kJ8wEM2fX0r066vBDmQ7ztGcE/pSnU5dTl5eZ6Gx9sdWZF4AHeuI8W3rrHKxb+E8A5/H6VqXuoQvZedHkkAEtngf41xWrvPdI+7jPX6Vze1lJ8qOiFNWuzl8q125ABXaTn61c1oW02mWlu1vCuyPazgYLZ9fXFYtxIRcMikrGv32/p9axtW1maNgC24HhVP8z7UVZ9Dso0epyXifSmhu3KKPs4QbWJ5QE9D6+xrEktl8ry9hUjBBH8X4n+XrXWT6kLhmBijYONrBhww9PpWXMJbW3jmjbByQCvOMDuOhxWkZ8y8yZ0+XZaGXYS7Qy+evy8iOVMj8PeughZJFCgyZxkeU+QPaqAt4LsRhliwV5eI9PqKnjguYVCZDqozkfNxU3WzLSdrpkzNtAPmMXbJKSZBUDvzxWVfkT7wjRuW4BY4x71fae4aMwSSlol5UMuQo/Gs6UoSOAw5xtUdKd1cTTsU9cZf7KnQRquIWyc5OcV+h1fnbrDp/ZtyEgwfKbLE5z8vp0FfolW9JWRxVt0eT/tFRiXQvDKMzIp1oZKdf8Aj0ueleTi8i023XYY4oiDtf1z29Sa9b/aDGdI8LjJH/E6HI6/8ed1Xl0tiI8zSBcJ8zO5yWIODj071z4hXkd2BsoNvv8A5HN6lHeXpLR23kcBfmxnnpgdvxqJLBLRJLbSpxLIUYPcFc4yPm69fQDoO1bTGRg0JAiBYupZctjkAD0BB59aZDaR2dtIPMTagDk4OWc4GPr2rnvbSJ3KN/ekUtDtH0y0jQqwGQNwbrg85Hc12VpPHxNDvbB+81Yt8pS2htbciVgjXDxqd0oTAJ354TBzxyc0uiTsyOHzcEn7yuAI8e2BTlEqErs6aWTFwtxHhjjDgDrXU6eq3SRLDtBdTn69Tg1yKOozgl07gdjVnSr59PvEKy7oh0OM7c9fwohUv7rOh0uZXidJqKztMkFs4EjoSWPPHtn1qjLJdXME0UySRMFwNrY347g1r2UaXF/M4xIJI1LS5yQOeBTtdhQ+RaIyGWfkbsjAH0rTkvqivaK6hbU4aQXF7AwuWceUCQznLH3riNWtRl3iUY53KK9J1WwnhXykV1jTkNjP1WuM1myvYglxCiEOcsv96qhU9mzLFYaNePNE4GSxC3ICktGepPatS40+1W0LRZDAZyT1rWiS3vTtU+Q+fnU9RV0eH4SgEl1I8Z6qoxW7alqmeRyunpNHDJEWwADk1dhja2ZHKguDkAjOK7/TvDmiIoMhmJ92q7JpWkw8RWpfnILNWnMkZavQ4m033EpEhYuR16nNbum6PPOoVgu3qc84FabfYLXDPHHEfRetXtPEt8ii3UxwgZ6YJHrWVSsoo6cPgpVnrsaGmWqr5dvFIUSNvlB7nuSK6xJJfIWOFtjJ1cc8+mKybHT0VSJMsi8gf4V0+nadIjkKUUABgcfriuN3noevWdOlFRXQqzeehWa4V5GAyTjOBXM6hCJ45Cqo0hBOQMEDk5z6YH5V12q40+QshZo25bHb3/8ArVzesaqiTSz2KJGDC8DtJg7lYAHA9feqUVezMYylKHNCP+Rx1n4fnvLxEkDRmZQ6qSCxQ/xY7Z684qDT/Ktr9UgMxt/tAR8JnGTgH657VpaVqzxOJC0L5Vo1TkPHjgEnuOvA65OahvY4Z7a9lLJbea29RGCuW/uqucAA96TSbSQe+03I6rSDM8zWsixyMPMRiSWCyA/MAcZy3BH0FWmK7yYN+MKY92CQGbBBP5/nWeLrz5bbUnRkWVEmm28eXOpCsD/vYIyfYCt67dJN8u0LAJSDGB8yoRu4z3z/APWqa0Hv2OejK263JrMTNDFNtyCWZCp5HXK49gO9WmWRpf3/AN5sICM8bQDj2yW/8dqvp6/u4UGdwGdwyCF4+Uj1OD+dXrpt1kfNfvlnXgDcMdPX5j/3zRCyVyKsnzWIJZQWuG3DcE2MQeQO+PQ/N+tcddSGS6BBAA5C4wMDgf5+tat9elbMvGyxvMTgjso6EDt3rnrMu7M2Tu6Ducen0qJyubUocty5K2xOMnPIHuarlSIwzMS7c8DtT5pTkg5z0OP6VEzlsbRyOSR2rM2iSqpkZcLtC8HJ6VeTYFG4jjk8D5apxjeCWygHAIwPxHvVlnC2w4yp5wp5rGTvsbxLEdwYkLzvGyn7uOM/WpVuo3QYXcgGTg7eKzCnmRbWO5Sd5BAJJ9M1etS2zIAAxtAxjFY3sXYuhwId6JuDdRzyPrUcbFHUhFCr3A4b+uKeybhhQwbGcdzUM0ZSVUjIEhHTuaq+hKSehZQsLlyWC5ADHoPqDT53JRkBDp1464qkUHClmZlXkDilOI5M7flZfmUcnH+FS9QcepWu2YllUAkdFYdjWBews2Co4yBg8Ae9dBdSJtUL98HaT/L8KxJpVaWTcPnUH5DxnFVF20FLY5bU4AjuRkc4wO/vWWzGOQ7Mr6MFzg/Suh1EY+ZclQecDGe9YsqYO7fgDkYGMn+tdtI4qq7mZKuG3uzMeuQACfeuk0q8VoQCSxHHXqO4rGeMEYJ3HHRhnFLYTLbTbASiZzgHOPetZbGUZWOw8sFC6qhC5JJGSP8A6+Ku2pMe9NoBUglGUjjH3vYVlW1whVTnjjgdjW+BGV8t5nDhmbdIp5fjAPoMZ/Kubkd7HRzaGT9tldGZGZ1dwQu7Ixzxn2z1rlvD+k3Lz31/cRrIfPYXBBGSpOMc9PQV1mnrDIxlhSMB2cCNsk4zj/6/4VSv7OVbjz7XdFhPmki6gAY+Yd+K6I8tveIk5J+6IpXTTa3EMqrLEQMJ1VSc4J7mvbPCOsJd2ETOjKzgsjEj51HU/wD1q+foLGe7uVLySsG+YsTxx7V1OmnULF4E06WSB1LSIQxOSccFTwc9McdaunJR1ObEUZVEktz6CB47Yorxyz8ea7YN9n1FY5Vj+UvHGAzY7Aeo9OK62w8dROitPCGRuhj4YfVTXYq0H1PNlhqi6HW6jareWksDgFXGORmvnD4neDvst3I0SPtHzFv9oent0r6CtvEOmXC5+1LE3dZflI/Oo9a0ax1m0ffHFI7A7JBzg461d+sTNXTsz4purZkb94CAPXpms0W6C6yW+Qg53Cve/FHw6Frfbr6KRrVtxM1uuTx0G3+teaaj4VmW0lubfiEPjynYeYBkgEj/AD3+tCtLY2VTozh7mzEcmY38xSM5UdqgCMgBQBc9GJ5robrRriMiOZNpxu2k9Kgi0nc6h3UZyAACT+VKyW7HzX2MiOB5JHLA7s8+pNegeAPCk1/qUL7coD8zEcJ/9er3gzwHfarcoxiNvaH70zD5vwHavfPDnhq20q0ghjX7oxk8E+ppcylpAxm2tx+lWEelQQ2tqhZGJcuCP8mpp9OtroEyqHjR9wBz19a1bue0s4gZp44gO7EACuU1fxpp8YZLHNyynH7sfKD7n0rOpBW95jpRnJ+6WNUSOO3bbiOI9ewx6gV57rmridGism2w5OZfU+gpmu6zdaoSXYlRz5cfAH19a564dvIEm1GMoLRpu27selcznbSmepSwtkpVCrdyiONgWwg5GR1+tcnq95LM5aOWNgVyFK7QPoa1bm4uo5Asx8rzBkMBuA9z3FY915Qk3RzL5+Msozzx1BNKKNJIrWty3lFGU7e5I6n1BrX0+MBlIjLq33kcZVuehrPiCPuGCkocFWXAQpjGCPXNadoskau6c8/MpGCPfH+FOV0/dJe1mVNVtksZ45LSEeSxzJbN1Q5PepYYoWk/d5RieVYbWA+netq4t0mhBISSMtlDnBGR/n8qzLuGXbvkUvgZL45OOB/hV3UiElfQoXtu6jYSoONuehNZVxHtU+Zv4OBmukjdJG2OVGTuUBsAe3NVb7m4csWEgwSwAwfw9aS0Im7HG6wcadcqrDHlNnB46Gv0Tr8+PEEKjTb0oVOI3wcY42mv0HrqpbHDX3PLvj5j+zPCwK7gdaxj/tzuq8wnBfbGcSHG1ccAAcZx3PevTvj8obS/Cyt0Otc/+Ad1XntmvmOzAEsxAG4ZAAHeufE/Ed+At7N+v+RVhiMEhkl/eLnhj1BPqapS7F1FAyFmA3Ev0PdR+fT65rWuvMkhkjH7wjgF23AvnA4/EVUntFS/SOFgzIrPJ5hz2659T2rnS1udr1dijayfZ7ny2Gd7Zf5sbskZDEdvbvVS9ebz5Hs5F2mWQQgRbk2qfvOvUZzwPetJ18vUGChZFGMptyuAuduO/wDjyau6PLDcX9tcCPc7PkxNwroykZZuAOMDnHtWytsSk17xXs5ZIpJYpWWRVCYWNcEZxkHsOOlaQwudgXc4wO+K5q6sGgkWeSBWtd4G4vt8zK5UjP1zWpZX0caxWst9ARkuAqEKDjn88VhOPU7Kc+VI6HTdQl0u4R43EihcMmeMHsPeumtNUtbu8t7hpiLeM5JAyVbpg+1cWJUePepB46EcflVeGWSzvEbLStICvC/dB9fX+Yq6NbldpHTKnGautz1PU7Q3ERkQqFcAAEc+lcrrOlJGFZMkocFPcCt3QfEMF9ZxwTyL5ydWHOcVrXtukqq0ZB55+lbzjF6xOCE5UZcszyfU/DEEzI+Qkjj76HofWsCTTr6wk8uGY5JPI5DV65d2EbM6gq3QAdMccmsO60jbOojK5wdp68981i7x2OyEadX4jhAdWKgZTrjpUogvpNyzzHcwABDfKnuAOWPb0rpWsJ4ZYRcIrxtJgt6VqLoG5TNCMyLlSAeCKOaZpLDYeNuY5XTfD4VlkkBnZmCEOc7ea7vRoPJgVVThSO3bPNO8O2jXjzxyQpC1s4DKCSp7jmti4v8AT4FKJIjyt91IzuO7t9KFBpXbMMRVSfsoovWlrGMzKo2cn1BxyKS/vIdPhCu6mZhv8odR3wfSsAa/PDZRWu2NYwSrop+cgeh7f/WqhHY3WoyFoyPLU4LE52HqMjrjrmk5LaOrOL2Du5VpWijTur2/1MPveOAHptGc1z7WKee0U8sLnBAyuAD069s+tahV2Z49St7u18sbQ8UOMtjKjPTn86xZ4J43y0qux7BR3Hqeo96l80dZG0HD4ICWekxRS3NmXWwTaGfdgk4PuclfYGs22gYR6hBcLEVfCQzhNxU5ztU+uK09StZprzduN1OyBhhDln4Ax6/pgcnrUyW+2+FsQCqD5ihyqSHqFP8AFjpuqa9eNCLlPRLuZKcGrtlTy2soreGaJlgndiysQMgjpnvzn6ZzXS6ZC81uqeSEmTaj7jnPy8fpUGrsRcabIYw8LMY1hOOSRgL+ZFX9LjSIJ5ZKxuuxgoC5CnAIHcY3H8RijDVo4iDknpsc/tE0nHqaemh18zew2r8occlu5we3XrVbVJlSzGUOzgBCMZHUn88AY9Kuy3JtkT51MhbDJtHU9voPX8q47xBqSzTsgGWBxkMTu9T6+tVKXKrBSi6k+ZrQzdWuXuXRQQwUY+U9up/GkgUqilhweCPWoYYiF3Y4z0z1qdWbI5yMfgPpWV9DsSBUO4sOSvHJxxTlUFiAcj+6Ov40R72faAAq9Oen+fWpxtjclQC2MY7/AI1kzRIeN7RAYUsM454H1pIy6Q4YFEZTggZHvmpSpLnb0z+dJJLuCRB1+nTd9KhmiI7eRWO0uJSjDgcLW3AI0UsUBLcbjnj2rH+ywwuSjnc3bp3q7HN53O5hg4AB61D90qST2LhkBIRssPY9+3NVCoBDMfnyRlu30qxcOTEygbWAznGSKzXB3N5gO4NnzAeT/wDXp9BwRaiG12eQjf057ipHjDkscKAMDknP5VV8xXYpgfNwd3FT5eGDaZlKA5AXmkn3CXkV763WBG4JkPzLzjOKybkqUBl4OOfb2zWtPKzqFmAcsMjJ/nWDqbRrC2V2Hbu2knmnbWyIv3M28A2blG5BxknvWROh2gjABPTGQKnuZpGhLZbPoRjNV2Y5UyAYI4B7CumluctZEAVw7HZnGeQOmPWq0kBLeYCd3UDqQKubS8hAJwoz15FI28Hay7iw5Kkgge/sa6Nzje5Np10TJjocdQeprprO4SK3YmULuYSGQ4ZgORx7Z4PfpXGoPJkVo+uMYPYVq2d6Xb97ksT82MemMjsO1Dj1LjI6KKWNIYwI9435RQcck+vboORxV9Y4LpnTlGlAyU6BgpzuHXZnHPUHsRVCAqU+X5yvDY/TmowWgLSxgoVx8wH3uc4Prioi7O0jbl517r1NeysVUovmyLsXMiBfmiHoAeDnOQPY05dIkj1JhC67XTKSFWVVycAHPQ/1plpqAMTI8aR3HnbprpyW4PTI6YA+pB6da2XuBHK9zK05XCxQy7y5LHDJleCucZ5yMmtvZRaujCU6kXqY2o6ZHZxCe+muBHKm+F1jzmQNhg3fjBNZEkd7/aUkiy2doqrhvPkby+R13Doe/HFd6JFlsIreXy2faYU8w8SOGPyj0PqTxwOtUotOx9lgmSMCQusZYbSq5b74x8+OR2UcGr9houUzVdq6lucdHrF156I4E5EZ3CbgY7EdMg8kd6sprMluh8iWSOMqAChwCTnuD09PWut1PSftM1qjNGZ0iLYgcKqBBguRjHGeAOmD1Nc1qkczXz3Km4j0vyy6vFIhkmfHyblI5yVZgCM49OlDg4alRqQqWuiW11nVWNrHDc3Mkc2VwGBLt3xuBGR0Paq2tXkGo2MU32Cx80JhpWUB2AByWAOAc+gyfpxWbZ3gu7SOKcSmW2YJLJcOSIif3jOq9RwcMvvnOeKoeJQtnb3F9aXNobWNo7aVlGxmOfvLjqexbv0OKabS3uZ+yg5XasVby1ijk2z6fBljlQj9vTgmp7CeGzKSwaXZ+aM4LZOK2Yra2vFS6sIM3SoUitlX5JXOQzsrdFHy/KDkFgcmsPSFsdWkgtSbi0vhFLHIS+2PfGAwZupJcZ4GBkcdaz5JX0ZX7u2qZuQ+LNVC+XbrbICcLtQk1DceJ9XcNF9sdD0KxgCsCC7Ntb6TBcQwzSC8kjmZQyTOCBhZF6BRzzkEfTmlmu9R0W/ur61tfPs4CbW5iJWVSj/wkg5J75Hp1FF59ZD5KWto6lu7uJHHm3TysZFzvkYt8vTPPbNU7W8W7uY7K0kEtzK5iREOSzjtj09/Y1Tiu5MzsIXn0W4C7jA/zFByMrnJXPXH4VmX1nbPDb4X5WyyeScAg8Ltbqp6jn0rNpbtnQm1oka88itG7yqIvJbaZEOVbk5GO7HBwKwruR3ik+zupxkKHUjCnpweh+nemxyS21u8WohntWUqkuPmQjuf9oY/rUn2jzI0WPl34cnv0PFLmtsUtdyr55FqjO8q3CkB0c5B96yp2Z5FeRFRd5QOowMc9feptTjMd4WQ70zzxt4PYClhCS27gJu3HJyeQfUinHTczlqkTW0GUfeMKi4Hqpz+tb+nQBIwEPEmOQM7SO2DVLTLMLjzCfKAAx9f8K6BLKQxxIFG4OBzxg+/5UdbksqxWxAZdmY5wdqZOAwPOPT1qOOEqk4UhY3UxtkZBB61rXdvsWRScMCOhIAcdcfh1rNuHMbqFH3mKs20Yz2/CtNzK99jnLmza3lUxk7DyQemfbNVJh8xYDAyQCTya6S5zO6xoAwI3/KM8DqP51l3Nsqq0yxqyBuHXnjsfrVWtsZyZyniLB0+9x0ED8+vymv0Br4F8Rxj+y7/ACckQOcgcH5TX31XTR2OLEbo8x+O677DwovrrX/tndVwPykFcAxjOdvGB/XnrXffHY7bHwoeeNa7df8Ajzuq4GLEnVWC8jaOx9K5sV8XyO/Afw36/wCQ6eBRDExID7ss2eT7fh1J9TVGWJnjPkj95JyeO3cj+X41oyoGQAnLbNpxyAM9Kakb7mVfkVvkPoR1x7Cua56HKUnit1e2lkLGFc58sknb9fQn/wCvVhIXt51LNAI0QNtUgpn0A7nqB2xVj5VRPKBd2PC5wAPUn+dN0+IkwTXIVysiySFQASw6ED0Axx09a1Uu4lF9BmnQf2grR3EZZAN2zcRuKqVyT1AGUOcgcdDUT6bBpNtpl7Zr8kkYW42DfkjB3MScKDlgM/3a6bRrRRJPdRvlizoq7NwYE8ux7cHIH4mq00Nu3hq5tGeN4458RmTAEo35Acg5YAk4A74HJ4rS3NHXczlJxleO3U4v+0vMunCQCSNn+Zx8kaqP7p9O9aNuy3XEUi5Kgj5sEjpWfrtvdGVAY2ggVvKG9MyO6jHzdt+OvoeKZpvmwztcGTazRsr85JGOc/T+lc0l3O2nJ2Tiahs3s50jhwpTO9kJzkn2rbtPEmoWWxXPnLkJ8/B575HasC21RZ4vIR4VkbLsrY3qFIwCfx6fn0q1p17ZTXcKXE2ImyXdwR0GcD15wM9KmLkn7rKlVg17x0w8TRXJkEls5lRhKzryqqOtXV8Q6aQiwWtyRIu/Hl849V56da5NmTyI2MwaWRyHhUZXHGAT65zx7CrSRR29zE0x8t3wwbeAAv1HT0q/aT2J5aclp0Ne78QWk0ai3s7iUblyzABc+lPXUJ4ZVe3jWFZRkRod34nPT8KyLdrM2RaOSBpg6tt2/NuY8r6YUfwkdeea15r+BIoJbK3trgSKSsSZO04wGcHqwwTjkdzitYqW7aRhKukuWMWxbXSr/ULu4SzSWRZTneNyxsR13E9MjpVqbRJ0inlvnS2SzRVZwhDOSeAB3OeM9KzrjxfMslxqcF/PJZsnl3E2w7ok7/IDhSvJBH1rnr3VmWdZndGuLlVnWZHJ8jKEheevIHXoaclTa11MYyxE5J3S2/r/AIc66yOnI6rH5jCb9yrSxnBc8sSfRcHjvz0rQW2iliZ4riU2kBKwywhd0jE/N6bhn5cn1x2Ncp9umulgDSyfZjCdrIdp3ofMwSB0xv59c100IurO2W9jlaeWSMRm0jG8eSBlXQdAV49Ax75qoSi3ZIzxEZRV29fX8tP+GKWuak4nQymR54pk22crlY9uP9UHGQfUkk4OcYAOXC+s5oxZQM6XUu2S8kdSxRNuQp7bRxt7YweSa07DTxd6TJPA0CGNSImLAxpuGC2ernsT65AqKPTYFhVbdJCRzub5WfPylmOOWwCR14GOB00XM3r1OduEdI9CuIX8p7e0iUTRqBNubair12Z5AHQknkn9K0LyRIPJtcyP8jL6/MACvrk9MVqC1eSNETzWszh5WdwssgHzHIB4BJ55JPOMCnGIzSoER0kkGVwNoTjlvoF4x05ry8fldLGyi6zenZiVpptoz7W4lu7zm1VViM8MWcMqODtaTd1yAW5HHTBrVhYQRMblJA2QudvzdPl/FQM/lS21tHbiWRExEir8oHPXIBPoepx7Vm6lqDq0knygueCr84HGMfzrphShhqapw6GlOmnotiHWtUCxv5kqux+7tUgj8fp1/SuadTM+/aA23gZyKfdNJK+5znHVfSoxwRvGRyTWXMd0Y2Wg6P5UYKCysMirAQlwDjI4Ge3tUKLuwFA4xnHOKs43gDbnrjBqWzVIegKp/eUjBJ68UR4Rfujc3OR2pCVPADDB7d/8Kc6qqHGAxOdoPH4ms2upotBMLs2xOw5557f1pJ32Oflzx1bnP09KbbZdn3DP8Xzdc0l0VCR+Ym4AnCbqVtCkCEMoDAhVOcAk5NXLd0zjGE4ySP0qj5jLnywAAcdKtQNkM/lllwORxz3qWrl3sWd2QNjYx0z/AFqv5rSHy1UttY89B+dWWKHIdgNx+4OoFU5Q8K7I1yXyMhug9aC4jWhYxjaSTk9/u0/zcyCPcI9pzkj7xqMuFyCGZsAdcDHpUQKqMqpZmGAKAZJNM6FllbtwOc59Se9Zl0ROSXwGVec9KsSs6nfkGQjBUnGPpWfeyYwcbSwDFvWkjGRk3aFGIcZEnPHPfrVWRgAI5MnnK960JzujcI2Vxzu5wKzLhNxXa2Nh6k9K6oao5ZvUkP32DAFOg9frmlQlFKtl+Oc8H/8AVSJuRcKRgkZBokDbW2njPr2rSMjmkiOdVeMKfl5/H8DUSHYduwEdOe49KmL8N8wLHuR096ilbeFBYKgOR6fX9BV31ISsa2k3bLIFkcJGDlW67vathpN8YmWIL8wALchfbFcghYMGDfIoIx6D2rYsbtVjRGw5HQMeg96mSTNoO2p0FvcPCFCk+XyQp5VweTurVS9kddgj3+YodY2QkgkYG3nnsB3HPFYltKjB3hcKrE8fdAzwNvatNS0gDB5HyvT+6OMjH19KUXymskp7mikqwTRoZwjSEwvIRujkQLkxup5DZz2z6VJHrjWksYvrWaV4WHksE3FM5DFieSCMcYx2rN0+4UXEm6KT7UCHikGHYlT3z/8AWOKuyt5RW5BeFyQ0b+Y0gYYOC3JYdvbrnNdNOrfqcs6CT1RpC+hFvZrPFcriTb5+xXJ7oGCnGGPO0dhziqsssv8Ap+tSiG3tm+dVD5Lkf6sjHQ54I6/NWfJb2pMT2sAtrbgvLCRiNv4lAOeTg46YouIrie50yUSW8jFhJllKHg8IVX5CMndnrxzitXO5iqKj8y1f6TDdQxG7lWQ2yGdpiwkZ53JLoWAGV443cjA5xXPX9vIdPGn+ZGls8TROk6gqzEjAHGBjqAfu/jU0L2yzXPmFU3zMBJJEfMY9MAZxjtz+dJLMLhhPcX0e+MASRq+5inI2lemfxrGTu7o6Iw5Vyt6GJ4ZLGwiLCWa+iALPKC5kXJU4HQJ25PNUtXspI/GEkqXJmlbyZFZsKEwjZAPAOMYyuegxWra506WZrCaNFM7hhjIKONwVsnsScVQ1bzPtUW638hgyl2z0CjsT0yajm93lK5dUxuvaeLKyW9ih80uY5pI5E3x7Cw2yHJy393HfPtVS3heaaRby4DRo4YmNtu8jO0ZHA/wFWWzcWZgnw6yptTzVyVHUY56DFZYzvaNtpw5cdiO/PrWcp6KxcYasZpssum3yWyJ5tsGV7WNlGAH6qfX5s4z7VHfRi2eSTbtjZiJQPXPDD3z1qzc7ztltmDYU89CCDuH8jUa3QcplN7MuWLfXp+Xepv3K9CJyl1CI5SFzklhyD3Fc6h8mUxoSOPlyOVwelbMkUsZ8sD5cEKc4yOvJqrHYNJcK7ZIIw7beGJHQU32I63RSeAy4AwQTlRu696t21kguFfGOu5uzc9K1rTTVdcImJMgBVGf/ANVa1vY7QDvQHG3GOmfX0oQjOhi3Al0Zf4W3Djpn8+K0JBJHGBK4cfeypycHt7VatrKREYPho3U8E9R9fWnTwhY13Qt5AXlicN14BHqD/Oq5rEMz5BtDxK5kEoDRyZ+6RxsP8s1n3Z3IH8xSrdMrtKsOx9q0LpJFusLwpXB4zx3/AMarzuLgoMDJPmBifvMOo/KrTM5Izn80/PIgJU5DAYx+Poag2E/L5jqpGWx6delWZVYWbiIkJKcY68Z/mOKpXA8lZfk81W+U5GCrVd9UZM5rxKm3Rr4kBW8mQEY6jacV96V8I+I49uhXzAnd5EoIxkfdPf8AOvu6umlszhxHxHl/x7LDTfCxT739s/8AtndVwcRUJtRgQAOvfvXe/HkZ0/woMZ/4nXT/ALc7quGQLKMBSBjB44+g9frXLivi+R6GX/w36/5Elq4ufmQDyw2MnufpVhQqORyxAPB6k881HbwhEfadqZyT04/xq7ChKhpFDEnevzEEdhXHseloUY42ZCszbBtJbYMHHp71Ise21nhceWdhyEGSwJH5D/CpyjZyCWCDlvX/AOvT5YhO/wA6HeOrdeD0rS/cFG5bMrW9hNId4V0ACDkszfLjHQ/TsBWcglu52uIAkOHVlIb5Ux/Ex7k469u2OtT6kGuLa3R5HRGIRiSdwHII/p9DW7aRrbWUay8RqylFIHJ7Lj05xWim9iHFK7ZXj0u2ewSSW3Yu1w6q27hX3ZIVO3HQ9+uea47xVYvaRym3AKSKgeRVwS+75semAeW/Ku6ut620iyoilnIgjYYPzjkOeygDgCs1lbVY2LRiRX+fG0gBBgIM9gxGcfzq5uEjGkpxfkecjTF02xmupFdIwvntLg5I/wDrntVC0hvLbSX+0xss8mZpl64AICoPqxA/A16le2S6gZIrkRrGiPIyEna6LyM9/vkAD2zVO68PwQ2SI5JkjkiEhPHO0sxA7gEt+JGKxdFtOx1vEQuk1ucTply8t1dIIz5cYVS5YkI38Xt1PX8Kzri/8ppI5GyEvmRFJzhQNwx6jJBr0rSdNsPLSG2R7hZQFRIwMyNzlmPbLEnPpgdq5HxR4cEOqNL+5+zP5Uhkb5RGyko7enO0DHuKPYu4e2hpcydNa4GnrcSGSSSeRF8z1UHI5+grRhtdRvZrk2ZMLRzEIV4wHADc+mcV1el6MltHZRTAkRQkmM/NlnVRgH1wT7Dk9q0bGFrYuIkHnXnDfMG2Fs7+nJOCAPYU1S6thPELaKucLYWV7dPr0KOIYvKRpY0bg7sIyqO/Jz+FdFo+hW/2BYbxh9o8kxt8uSJIztfHqdhjbHqetWtKsZLXW5DEwnMERt4ty/uwf4SP7/JY49fbFa1xAYdTjMKZjJX5n5LH7rnGOeMHHcjPYVvThFI5alacvhLEVobnRLW3swsc8S5iGBtjkB+Uyf3jgAY6cn3NaOhPAtostxGxCg/u0YDA6Esf97oPp06VJYWkSp5QMhhXLFdwAYjtn0BOSB175qoqG1vJ4oQDHLNnIUhY5COVHuw5A/h5PUitNtTkfvJxLD3bwT+ZbiOK3bDNGo3RoAclj3I9SO+SKsS7TGEwGkKsuAB/FztBzwOhJFRsscJMQTMgKvJJjPT09h2H4VVUPA0cWAIDvMOeBGTyUJ9P4v0qZT0KVMtwovCl8KV+fJPzY6bfTJx19qf5jFA0gVVIJYryQoHA9Mk598c1U2cFN0rL97G7mToSv+znqT6Gql1eSSSvIzjls4A6dOgHQelZudlqaKnzPQL2+PkDJwo5wg7+pzXO3lwxfcWBY/eNW7y4DIUBL5yfm9e1Zj5yxJzuP4g1zSbk9TsjTsrIYzFm5OeOc9KexJXAUkg9xweKM7WyuW4xnt+FOVPLB+9kjPrk1DNErDrePchbOEzj0GKtL94McqvA6dfc+lVLf980m9gAuCADn6fhVzImQlWCjG3jkNUMpXRHKwBAYnLfMW6d6QbgAcbj644FPS3+YyEE5OOegpsrhShTPcc9qUn2KdrC7yoYZ2jksx61Wd8rkIeeME8mldm2thgckBjj7xqk85SUn7uO47U7aCvqWQw85RKhLKME56e9XElAdVQlixwRnhfes6CThtzHc3JIHNXLYBLgF2U5x9CP8ak1RdwAuVYNI3Jx29qRo1RCS2Cecg9faknlEsxVgOPu7adclPJ2BxtHJQHkkf0pOJV+5HLCNpZjsfPrUChQPubtp9ev0qF52nO4qAOmAO1TRhXChJFUj/OKLWB3SKsqeekuw5UkHOelZl+7wsybHZB1wQfyNaFzuVHfaRGxzisfUhHMqkKyn/PWqjbqZMoXErbcjdk8YPQVV4yCAxB6insNnnxEgnsx5/CqY3iUbmwOCfUV0RRyzLkZ+b/ZB/zmrUqKq4PG/ke30rPtyTIztjk5zmrckrbBggYOcAfpSeupnuV7hCWB4UnnIqu5xjK5Yc59KuMcrhlUemO9V9wdW2kbgOM59apMlohDNuUEDbntVqBsO2QcAdB1NQKg5diNx4xjge9T25CSK8se5cgsA2MjPQEdDVXuFjU0+6xIGlJKFhz3HHbtW/a3EUiRfunxkcHnPr75/WuPWSMXs8cbmSMPwxGA47HH860LSZlWQsW3ZGAPXtUt2NInUtFJG6sXaQDc4Kvk9ux9j+NXCrTWqMSu4HG3HB9Rx0/CqOm3w2KD80g4VlGCMDjPqP1+taVoAJJ5hDHC0gMqJCx2EAcso9OvHXmmvItz7odayzxRytDKZPLJYhgu4qcA+uee/PFJbFRM32dDAvlnKls73xgbs8HqeRjGac0aKsTRAFSSSCgYAEdDjr25HSrARZIEjQATKCWjkXGOcfK+eR9aq8iJKO4kVnCti8MSsAhAeLI49Bz1555+neqt5bxwjBSHzBgLIqZGeuCMcnn2qXEc2Jlil2hdhQZIDHpk9QD+XapduUOyQTRxr8occ+4I/wA+1Ca6IXK7mLd6QqC5kt441kZQfkTA4/ug9j6dazr22KQlZGLABSQQMLkjGR165rqjtRB9oWQQvyoUd+5FQG3S4j2RupcNvbd8uRngZ/ipcw35nKLZXUMATbsfIULj7u7vnr0qnHpU0VyJEECA5UKDnJ9B612Zg2hW2lIxu4DZw2OSD39Kpm2KRqCMg8gnHXpwPWpbQ0tTmXsGwGkRWCnacPk56VXtNPj+f7QQhjO4ADt2rsLiCNjG21dx5TaOAR/Oqxj2ASmNGC/6z5Dj8R3pJ6h0OaurMzwAOGcou0HpgE9cdx1xTobLMpIiycD7hwo7k+3pXQJGJICoViAMqPT/AD7fjUaWeHKRlVYLjYOMn6/3jTUiLGaojSQtCoZmxubrtHof5UsMShAQqkEnB67h6g+varU0IeNSyeXMnKle/OOabJaFEALMj53EcYYHofrQ+47LoKkaxyCGTcAxICluMEetQKjRnJDeSOVwe/f6VJKGkQRzEiQHByeOehHoKjQBGQYaIDq33gfcilfUhoo3EEeI2yVGcZwSCR7dqyLtFZHj24dWHXoPx9K17mUSBwqMo3AeWxz16EHsfesp2OQkozk4OeAB2zWkWjJruVpA5EUSORls4HTNZ84kdmDKSJBuAPUMK05gq4iaHsWUg4x/+qqN2XeDcFbYp5cHnj/Ctk7mErnNeJN39k6gwzzbyZH/AAAg19318I+JDjQtSXoPKkPB6/Kea+7q6KOxxYjdHmXx4gu5dG8Oy2Vhe332fVhJKlnbSTuqG1uE3FUUtjLqM47ivPI3kODJoviUANnaNCvfz/1VetfFfxxJ4D0Owv4NNTUZLu9FoInuTAFzFJJu3BH/AOeeMY79a82i+P8AqUjBV8I2WT2/tlv/AJHpVKMZu8h0cTOjHliiCO+mCgHRfEncc6De/n/qutTtfboz/wASfxKARjadCvuB/wB+aevx81Nh/wAijZA56HWX/wDkanr8eNVaRUHhGy3E451h/wD5GrL6rSXU3WYVb6Jf18xg1IgKP7F8S4740K+H4D91Uw1IcZ0zxMCTuONAvs/+iamPxr1levhLTwepH9svwP8AwGqsPjvqpOB4Qsi3oNZcnHr/AMe3Sp9jR/mNFjcR/Kv6+Y+fVBNIito/iTy1yc/2DfDPI/6Y+1X21qBlLnS/Exl6ZPh++zj8YuPw4qnJ8b9YjVWk8I2C7hlFOtPufnHA+zZqrP8AH3UYbgwnwpp7vnAMetMwP0xbVXsaVtyXjazduVf18zTu9bjeGZY9L8TlmcYJ0C9yBjBP+p9OKkstbt4IWQaV4mQyfM3/ABIL4gN0H/LH07dKym+O+tK4T/hCIt7Dgf2pJyfT/j2607/he+qLNHFJ4T02ORgSVbXeU9mxb8GhU6S6ieKrtW5V/XzJRq+b26mOjeIcOwSPdoF9jYg4ziL+JiWNRNqrtsZtK8TO5Qby2g33LdwT5WSOB+Qq9F8ZtYlGY/C+lHPT/idvz9P9Gp0Hxh12Yrt8J6aFI3bjrT4H1/0bihqindyHHEV91Ff18yPTNUt7MK66V4kSUjYSvh29AVT1I/c49B09ay9dvVuyTDoXiSV1Uj5tBvgrnOcn916gEeldS3xK8SB0VfC+juXJxt1yT8z/AKL0qW3+IniadCy+FtHAHXdrco/9taE6K+0J4iu7vl/r7znrDWEi8sy6B4jCr/B/YV8d2RyCfK6Z6+1WLLVLePfNcaV4kNxJlm2eH74Y56L+54JwOfSuhTx14odkCeGtDbd3Guy8fX/RKlXxl4tbGPDGicnH/Icl/P8A49Kf7n+YPrFf+Xf+u5zt5rcE8tj5ejeJIo0kPmKPD178g6lh+579OOcVe1LxFbXJ+XTfEeUUNGf+Edv8ZHIU/uenrjHWtb/hL/F2P+RX0Trg/wDE8l4/8lKk/wCEr8XAgN4a0FSTgA67Lz/5KVXNS/mM+esvsnPWniVUht3/ALK8RRzhApU+Hr4hD6/6nHHtUja7Z/ZvIOneJ2jGRgeH78E5758nrnnPtW23i3xauSfDWglR3GuTHP8A5KUyPxj4skj3x+GtCbnp/bk2f/SSlel/MV7Ws9eUxIvEUTDE+meJSF+9/wAU/f5mPZv9Tx9Ka+vW5H/IK8SttYOo/wCEfvuTnv8Auf8APSulh8TeL5d23w3oAZcZDa7MD/6SVZj1rxpJGXTw54dODjH9vTZ/9I6ajTlsxPEVY7xOIutfZxKi6X4mcMcs40C+UyH1/wBTx9Kp3OsOQfL0bxKxxgf8SG9H5/uq9CXXPGJcqPD3hwYbaSdem4P/AIB1GPEPjHOP+Ec8PZyQB/bs3b/t0qJUaW7ZccZWjoor+vmeZveSNkf2N4kI7f8AEhvf/jVNF06MSmjeJAemf7BvcYPX/llXph8SeMAjsPDnh9tpxhddmJP/AJKVF/wlfi7JB8N6CNvU/wBuTcf+SlQ6VD+Y0+u4h/ZX4/5nnP26YABdE8SAE840G9/+NU03sxKs2i+JmPQj+wr3j3/1Venw+IfGEzbY/Dvh0nOP+Q9Nx7/8efSrEereNXbA8N+HR7nXZsf+kdUsPSezJeYV09Yr8f8AM8wW94/5AviMHGONAvfyP7qhNSeEOE0PxKQev/Eivfm/8hcV6bFrXjKRGP8Awj3hxdvUNrs4P/pHUqan41fp4f8ADX/g+n5/8k6SwlJ7Ng8zrLdL8f8AM8vk1N/KCponiUA9R/YV6AP/ACFzUD3khRT/AGP4k3gdtBvf/jVertqfjZevhzw57f8AE+n5/wDJOmNq3jdSwPhrw9kDP/Iem/8AkOn9UpJ7sSzKt2X9fM8hnvbxnO3RPEhzj5v7CvePb/VVCZ7wvgaJ4kVR66Fe8/X91XsDa54zVFc+HfD2xuQf7dm/+Q6f/bHjTzNh8OeHQcZyddnx/wCkdL6vR2uP+0K615V/XzPIUuLnChtD8R4A76Fe9fX/AFVTNdzrgpoviQtnH/IBveP/ACFXrB1fxoAx/wCEd8O4HT/iez8/T/Q6T+2vGnlCT/hHPDxU8ca7NnPp/wAedL6tR7/19xSzOuvsr8f8zypb+6E5b+yPEYQjG1dBvQP/AEVmrJvnRvk0rxKxIwXOgXvT/v1Xp1vq/jScZTw74cA99em/+Q6RdX8bHO7w34eUA4y2uzAf+kdH1Sjvd/18h/2rXvsvx/zPLBcYkDLo/iQcYJOg33/xqh7t0bMej+JWJByToF6M/wDkKvVTqvjUAn/hHfDnBx/yHpv/AJDqCbXfGkU8cZ8M6A/mdGXXJiPx/wBDzQ8JR6t/18gWaV29Ir8f8zyW5muZI1xo/iMkdR/YV8Af/IVUpZL91z/YHiQMeoGh3mPw/dV7cdU8bAAnw54d57f27Pn/ANI6R9W8bI+1vDfh4en/ABPZuf8AyTp/VaS6sj+06z6L8f8AM+f7q11KVRt8P+JAQc/8gS85/wDIVVRZatvBPh3xIfUf2Jd//G6+in1bxqqKy+HPDrhhkbNdmOf/ACTqRdR8bMAV8PeG8Hn/AJD0/wD8h1osPT2uZyx1V7pf18z5yWy1ZDgeHvEpHY/2Ld8f+Q6vCPUyTu8P+I8H10O75/8AIVe/rqXjZs48PeG//B9P/wDIdA1LxvwD4d8OA+n9vT8f+SdP6tB9Sfr1RdEeCNBe7Qv9g+JGA5AOh3nHt/qulVGtdUDHboHiQjdnH9iXnT/v1X0OdQ8b/wDQu+G/r/b0/wD8h01tT8bKSP8AhHfDhI6416fj/wAk6l4Wn1Y1j6nZf18z53e01Rzz4e8SLg540S7/APjdItnqvfQPEoweP+JJd8D/AL919AT6/wCMYZhEfDnh53wCQuuznA9/9Dpx1zxmMA+HPDwY/wAH9vTZx6/8edL2NJPcr65W3sv6+Z4AlpqQcf8AFOeJOud39iXfH/kKr8EV5GBnQPEp9R/Yd50/79V7f/bvjIKzN4d8PKinG5tdnx/6R0n9veMvK8weG/D5XtjXZufp/odL2FLuNY2t2X9fM8bt5L6J2P8AYXiMrwNp0K8OfX/llWpBqFwVRG0PxIiggMW0O9bcB3wIuD7jmvTG8SeLlbafD3h7OM865OB+Zs8VBL4s8XohZfDGhSAEA7NclPX/ALdKPZUV9or65Xl9lf18zkk1mNl/eaL4iYEAureHb1dxGccrFweevfFRR6jAMBdJ8TR8k7v7Avtw/wDIPX/PFdh/wmHiwY3eGtCGRnP9uTf/ACJUkfivxbIG2eG9Ayozg67MD/6SU2qL+0SsTXj9n+vvOQstdEM373Q/ETqVKM39g3xLDPB/1Q/yTT31W3kDSLo/iKOTbgA6Df8AJB74hOcjiujl8beK4w2fDGiMV/hGuS5P0/0So08e+J5ATH4a0Ntv3gNclyv1H2TNHLRatzA8VXvfl/r7zn31tURUi0rxM0bcvG2gXwCn2/c/lUUurAOMaR4hlVTwDoF8Dj0z5PTmuhPxB8TAHHhnRTj/AKjcvP8A5KVC3xK8RKQD4Z0bceg/tuXJ+n+i1PJR/mH9br/yr+vmYB1IRovk6b4l24yUbQL47T6A+T+tNfWJMAroniFgCFCNoF7nA9/J4roP+FmeIt5UeGNHOO41uTH/AKS0r/EnxIsaunhfRpcjJVNckyo9wbWhUaL1UgeNrreK/r5nOJqpRCi6H4iyxyxbQL3B/wDIX6U6bUYpVCnRfEqsed40C949Rjyua10+K+vSRyNF4X0h2Q42DXJAx+gNqM1Cvxg1wuynwppylM786vL8mPXFrT9lR7i+uVt+Vf18zFa8KtuXRfEbHOQBoV8PxP7n+VV3uZeGTR/EmOfkOg3v/wAarcvPjNrVqRv8K6W6t9x01xiH/wB3/RqrP8ctXXy8eEbFwwLMY9Ykby1HVmxbZx9M0/q9La4vr9Zq9l/XzMX7RcAYGh+Jj6E6He/L/wCQqDcTbTt0LxMCfXQ7zj6Hyq6Cb42asoVrXwxpF7E2PntdeLhfqPs4I/Ksx/2hb9RJt8JWLmP7wXWWyD6Y+z5zR9Xp9w+u1v5V/XzMef7ZJyNI8Tkj+9oV5/8AGqes+oRoXXRPEZbGNn9hXoyD7+V2rRb9ojUhtH/CFQF2GVX+12yf/JfFVF/aYvcsJPBMcTqdpWTVyp/9EU1hqd9GJ42r1S/r5lRvtDHB8P8AihVZdvyaHefKfX/V81lT22pybnHh/wASluAV/sS7wcdwfLro4v2lbySLzB4Nt1G7aQ2sHP1x5GcVOv7RV+So/wCEPtcnt/bDHH5W9V9Xh3M/rk+yOS+y6rs2/wDCP+IyoO4A6Jd5yRyP9XUFzZau+9Y/D3iby+CudEusg9x/q67s/tBaiACPCNkQfTWW4/8AJeqdx+0ndwBt3g+2YjqF1ds/+k9V7GK6kvFTl0R5jr2heILvTLqKHwt4iaR4ZI0UaNdDBKnHWP8ArX23Xy/P+1XLCSH8FLkDJxqx/wDjFfUFaxgo7GVSo5vU8Y/amGfB3h/HX+2V/wDSW5rzDwlpHhy2+FPi3xhr2kXOr3Wl6gIY4k1O4tAUMVt8uY2wPmlY52k16h+1M23wd4fP/UaT/wBJbmuA8BSeG9a+EfjLwrrXivSPD9xqOphla8uI1dUENqQwjZ1JBKEZz6+lFtSLm58NfD3gTxpreqab/wAI7t+xQwz/AGvTvE15e27+YM7N+5MOvcYPfmvN/CUBn8PafcSnzLhoI3SSZj97aCT717T4TuvCOl+NJfE+sfEnwrfaidNTSoo7S4htYlhVg2WUzOWfIHJOPbpjwXQL2OHw5pjTNho7WNVGcDBjGT9ayr6R0NqCTlqa17PAq+c7MUAwdx3eYc9cdu9QWs8kRMiYjEv3ZpTk4Hovt+lc9d38JuQLdpHj2cJ6LjnOOB+NEt4GKrp6GcHALyALuPcAE8KO3TP1rGnTaV5G1Spd2idALlroyfZ5ggf5pGLbTLz0Z8foOBVywlaASzxtaxQ/dMgbr6gE/wA/pWGs73cyuLe2LRAbQBsgQ+ir6+vWtHzYoLVp7ya3Bk/dDzjsHPOFVTuYfXilLXYS0WpBd2c135lxbRs0Jf5rmVyAx7cnAB688mrVp5samJNkqkjdtJZT9MAZz+FQyfYr3ZNPqEbQqdp3KcJ2PloTtz9Mn1q9pi+ZdSxIhVcDy5JXLsSO6qoA59MVLg7FxnysvWgKTpLNcQsobCxw7TsA7ZGc5PX0rrLG0gkh3Tu+zIby1Xlj/u46duayYzDaWSO629tLkRRrKwHmH0JA4/AGm3mqXQkb7LcfaXIGDbrhVJ4zzk7ffGa53Ta32Nfa82iOmN59neOSK2GHA3B2GeehPtWnJdPGyxzx52gfJFJxg98+mO1cfpt6LW3lee6R1X5pcfMqnHO48gH8fwrRlvoN0YtiuCQV42Ajv16/XFS6XKrr+vvBVE3Y27fUo3YQW8MjsMrtU5UZ75rYtLp5GVGdgV+UKg3AevTtXNQossIlIkZtxACxbIxg8cnqfeta1MkbBp5FjQgjbGPmb8TUKLRo3F7GzFEsaqJshgCGLPjjtV2QnYsYdTtXdgmsVrq1DKBHuwM5ZgDkd8cnNWhNIqp8kcecEFx97Pp3qloS3c0mTccv5YJ+6w4APvUOXEYZGQdF29cH/D0qIzLMY3WIgrkMzAY//VSWzRymPdbyqjKQTH0z1GTn1oZSbRo2amO4+ZpirngLjgen51vae+IQkjiOYksAU5+vvWKI4WCFkkMbfNls9f8A61XLSJYijYDjACAcgHPcevFb0/dMalpIuSyjzDLK6FQApwMgn39Kzb0sqsvzFWf5jkHkd8irV1czOqIFiCsPnG/I69TVGeDZOYwxLNyNnADY60p67Cp6bhHOyneAXO3IA6IPp61GjxsFCZDqecc4PYmoUuXH7tyu5slSeBwO5pVJHlnbgsOx5z71kzY17eQIqMp+c4MpI6j/AArVSVNuwFQidOOBnpyK59GUqfMHJI2kDG72NPjnlsZBuIliLb93IA7YraFTlMJ0+Y6FmQMh3b4ycKw52kVJFuaUK6AFR94Dg57Cs+KaFo4m2AhTuIHG3J7ipby+8uFGVFcsQuQ3TPvXTGaV2zmcG7JIluf3Y/ePvDMCA3GD7U2R1hKblYtjahPRs+9MWXzQQikx56leWPfFEKrLEXwxTnZn16VLld6DSstRlsFSEbGyCfuY53Z5HNT27HLEEeVjOfQ+hFVkDYV5+FPCqTyGHfPvViIeXPlDlZD3PA9amL2HLqMkZIiFDbXUkgsM4z6H0oVXGBITu+8xXgH396lIRmZflJAxlv4s9vpVeVoooP8ASGYxlgEZQTx6HFNoSfYmjt4mlyrDDL82w/ePY0t2eNq8R4IJxnOaaiSrsRW8uLg/JjjnpVouQjGRMYPAHOfSqSTWmhLdn3K4jVwohcKFIB759jSsnnySR7fKkAxuHpSfZUicvEGDk7iu7Gfen28sUyB4XDITyG4NNR6ML9UJG6xRoXkGMBd5/iOPXtQUeUK3y715KA9/UGm3BKhwQogxg5GMZ/nUMvmIUkLRqin5STj5T7+1JtbMaXUlS4UbYDhXztIHY/8A16llImKxRzKsiN9enUYqk67is0iK/wA2Fki6j3IqCVoZS7MGhmchxIASDjjJHahTa0Y+Rbo2R8i7dvI4yBUSTLHNIN4LY3FBzge1VvtUjQKYyHIfBHBwvr71UvblY7qO5IBYfIyLxu5HOT9auVSxKptmzDcR3EAmj5XqMjFVWkmdC7R+WHPKOew9T2pEZ/mg3GKXBCuf4h14FQyOZkSKFg4MmXdwQCB1xRKd1qJRVytHOIomN2+UDAK20nj6D+dTR3UEmGQskrkENtx8vr7iqt1eyl2trMo7v8zMx4Ht+NZl+USItMYVkPARGJLH09D9BWHOkjfluzQmv4QsslrzIuFRpPm3+4X+vFRSXMrWar5iB2wcAEHj2rHXyJJ1aQsm7jzAAA2Oqr7Z7mpLu4ZnCyMpWJc7Y+DWcpvc0jBItXFxIYpo52ZkbAyFyMehHrWfcLICptZ96L/Co4B+lQT3LnJhlPkqAc8qyn+WKyLm+mjlwUkGDxImMn61nJrqXFNGsbxFZ1uY/Jw2VG8jBx79arXkhllR/MkDHrg9vbFZt/qkT22DMTkcpLEdy++PSsufUoY3ERuIsHO2SCbABHbnp9KlpvQpSSOiuL0KC0bfvMZIxuH1welVHud7KSBHKP4wvX+uKx3vXkUQF5XVmADxAloz744qUXTWTn7XKZoZR/CgDqB7HFNU53vYlzRtzyiWRv3ce7HJhPA98HpWTdA7izvLIUUKAkanB9ef6VUur6CZoofMO5iSr/d57Dd6/pVcaxNa4ilt/NO7DYBWQe5B6/hWyi76mXN2M+6R7iZJoLa9e4Y8yFgobHsD0Ht61FDqix3MyMtrIpXBfcylc9j6enzcVBPfae0s8VpIkdyMsELFOT25yKrtBMkKyXMbzF0zlMOTg54U8EfjQ4tO7Q1JNWuXJ9UnaRvtFglzaDnouceoYY/AkZqCa50+aaNVkeCRc4kd2V1PBwQPm/EZ9xUNrdRTySPZtB5xUgI+6LJ9QG43DviopRA1wtveyCznZAELkXCOevKmqim9SZNE817Issj3Cvfwt83mxhWdVHGSVwGH4ZrnJNYtraYGxaB5QfkkDPFKM9SvI/75PHapr/SZ7dV/s+5t7rzH+VopyEyPQEBgPbNY8upie2CX1vA8kLFXeWPOevXHOM98+laJNEOz0Zq295p91c7hAbeZXId3+aKQnH3gQCh49vxq1PaJdMY40jV1PzbMSlV7bh97A9eeO9c2uqW8VvdWtxaTIy4IEMnmFMDtjDYOc4ORUUNwk/lL5/nIoWSNSwglT1APBX86hxvqWnYs63pP2e5KNawPGepDkq3upxx196w7rTbUbgdkAQdZGfj2J5BHvXTrrk7XSpBqFvcuVKtb38GCw93Hy59xzVW7uy2d1nHE6nGxZ2UEY/hJHOewzVJtEuxx8zCGCNnaIxLnawYPuJ79MipIpmWeMRllYnf93Ib0K+3sa2blnkZo5Ytkm0/I8mNoA9VHJ9jWWkIkdGtUZ5Nu51tgzEHHXpg1vCXcwnE0pLiKYAuDbyEn12v7AdvpVG6VgVkWIHacHd3PvWjZzLLbETQCNm43dQG/vYPINUZZykQR40Y4KMfX3rVq5hB2djjtfMj3Ery7QzAkhBgDjsBX6ZV+a+poViu3bB+Qhc/Sv0oprY0Z4z+1KFPg/wAP7zhf7ZX/ANJbmvBEmSNYn2qsqjdjbkAf417z+1QceDfD5IJxrSdP+va5r54uBJEQy8l8EqRlgPT2FDIauyxJckFlPzFuSCAFA6ks3QmseW4eSQyqyEEYYNnKj/ZH+FR3l1uDI83mpuyURgo47H2FPiklDpJGUAVPv+Ycj354HpXOzpSdiCWLJVYpHjTOFj27Rn1x3q7b2pgR5EttzjPzTsFQDsQTUU95JAwZ5o422gMI5Mue+Tn+VJaSi4mkIieQyHK+a7Zyeyk4GfrxUyehcUiaeOe5Cl7lGU8loMKiY9WIH6VYstP0+1uSYZULkfeQFzjvhj/So4bwWJlgls3aJsF1EnBA55wOeewqyksY8i906J4XyVbyhhU56MG6k+9TYpSfY6bSEMm5YRKpOA8kkJ8wH0+bjHHp3rZnja2xb2DxiSQnckZ+dM9uOT69sVy9vcX9+jujSlosPI+9So56sR939a0JL66tLXML3l2kpDSyyqpKtn1TnHfB5qvdtZMy96+q/r7jU1ZTpW3zjaJcspUAxKzgY4POeueeKo/bXvTLFdXJkgjw7GFW4IH3uAB6e1V/tiyEFvs8+BlwsI8xj2+ZuQPzrUWG/kIkkQwRLg435bd2zk4/D9KTUe41KS3SLdjDZiKJI7W8edcEEzYG0+o+6vA570lta3Fnu82WKDJ3h1UOQM/dzk5+vas+eaxglRbhpWuXXEpyFWDdySwXPH4/l0qsdSg+xK8WrFI92z/R4HKA4yBvIBYn0qXT5ivaOPc6+0jlkQSNdSBM53MSXKjngY/rWkn2JT5scU06htw4JH5k157ZXiPJG8azvL8u64LmQhugHJwPXFaragjL5s+oRzRqMjLMy8dto4B9qh0PmUquvY7QapGnyrDFCQOSXAyf7oxVhNWmmUtHbDOBkkYx9Ca4P+2hbhZYUVJAu4HIYA9uD60L4mlKyyXE00qheWjAG0dOc9BWLw8lsaqtE746o8BWO5ukBIwOc5z2I45+lXLDVhCHuDJGsP3TIj7+O2R2+tecLri/ZxI0KSQgfMSh3NngEEjjmktdTaKTMWbOQDCiFXAYn/x0/Ss3FxdzVe9oet/bUubX91NJIow/7vG0/Q5/SpGv4on8xWlhUqG8sNhSfXn+VedaXeyieNL2Vra4cf6rYFjlJHBVuxzzj9K6eHUrgy4n8ySROdvysCPXgcj86pSJcbHT2WqeZMkZS2SKU5WUkjBx78dat2soZ12KqAEv8h4bPGB2/KufEoCkwosfBJjI+7ntVSy1GFrxbXAjuGXKLHkDI7AdM47VXM1oxWTOhkbypJICMs3U9f59aJAFZpIFQDAHysRz6YNUZ75VybmMS56GIfrio49ShkAALh2PygnBzj0NQ2ti0avnSwochnIGGAOD7YqeG6jlCD5hgfcft+FY0eoIEfzwHYEdwCKtpcRlg6gjHChhgH3B7Ur3G1ZmuNzOGMwBUYQr39qfM2y3kkdyvlfM0eOC3+NZsN5GpAYsDj5t3Qj+tWp3/dhJCpGDhvT60+bQSjqakV408RKSgKwA2gYH0A7VNHM6uFKt83Cjtj/PesNroAxrIQOM/IANre+Ksicsh3M2TxgDnHbH41ftGZumuxovcIpQMWaPnGR39PpTTK2OTiLps/u9+D61RRnjRSWUyt2xwp9RTJHwgxtyWGSOisT1o9oCpo0Le+R2COiefCdoHOCPUH+lS+bCHZd+6UnIODgVjTOqT7HV3DscszYIPoMevercV6mDHKTFux8xwxB7Z9/51Snfcl07bFzzWV5xJG2RwqFsA5HY1bh2eam8kMDt27s4OKzZN+VedvMRh8pUZOfQ+lRrcRvOoME0LKCBng4x0OeuOuatTtuQ4X2NeWQoMSvF56/NtP8AEo7DNV2vIgqSyoRu/wCWez9fpUP20M25osSnADt82R7elEauG82WWNoz0Vjk+vXtVuo2/dJVNJe8PWV0eYyAhVAZiBuU8cDFE1xIRsURhCmcZ3DNU7i/k3ukge39B1Uj/wCvUHyC32eWZN3O5TwG69qyc+iNFDq0TW9xb2wZA80W7JRxyuc8jHaq2o7VuI3liYSZwJomwrZ/hYdxUM98wjklaFS+M4TruXtn3GeaSS8F9pSSRzP1DphsFPYilzLYpxdyG3uWK3FtITFPC5ZY0O4Fd3Y+mR3q1NfJhTIgk3DaCW5LHoMenb61iWziON5ZSFMEzI5DfOwPOD7Hj86TzEu4JCpCyxuTGFJHGOCQeR/jU89tUVypuxuNdXptGSS7kjRCWzgeYR1HHb0pbfUWuIoFWeR4zFvcucDnpn/AVi3N6q6TPc3DHz0ikHPchc9PyrMsbq6trOwjeaR40XHlA4ByM/jSlUaGqaZ0wuSIWkiBZ5JDtKDqOn9KyLx1iUzTFSY8s+eef7g759/wqndXtytoBDtUbcBgcbc9h7471juZXkiCzgxx8quPlDf3vp6e/NQ6nQpQ6k1zqGpynzLiGOQsNqxKpwmOdgxxx71UbUTFvNzZNAGGBKu8rH78d6raheyCMqhSSKL/AJaBwqoD/tev0rjdR1u5upmt7TVW+U4EjzB0QH+EZAGaIRbd2OTSVjrH8T2ts/yzmIJzJGXOMdMjIIJ74qKfxFZXIU2E5klkPKIBnb36GvM9R1WPbG0k0RKkEkxAIeT93BGe9Y1z4mV5WllkikuI2EafuVRAuP59gRXTGhcwlVS1R7MusW7utsyzXLR8FMqVXjqrDmsXVbiCGVZLG4uLJzwnmgtGo9QwBrzix8XmUm3ktreEMOVhi6v7njjoSOlaR8X6hJKJVj3WQ5Akj3pkDGWXjgZ78VsqFupzuv5M6qWbU7S3We9T7RFKP9fFOH2n+9gYIX3PrU1lrrSy4t47ppSCsiNGWicDkKSc/l+tcCupOxa9nupQXULlZ8Me2ewwPQV1Njd6vJbwmd4ba0K4HmMkiyY7DByzH68ZxWkaZlOp3Ne9GoX9hNeXKBGjfbIixMVZOgbDY2/qKiWa7tojLpkkF4sj5kguVGX+UdEJzkf7J5qvOJDbSSw6VZxoqgs5SQkZGTgMQM9SPTFcqdSjvvPktZblrhwFZGhDw4x18tVxnPT0Naci7GKqN9ToNWu7C78vbY23nkmJlbeAfXar8gDnpnFV7e5tIYxZ2dzFamRQMCcxgf7oOQwP55rBJjWNJvsd/JLtxKzMIE9cZ+YgccgAVPp+p3ixbJ7Kxayi3SrJKGbKkfdyOeT6EVPJ0Rrz6XNqS7mWERajKWtEG5vIA3PITwSueAB7/hWlpurpNA1pez2sqNj5nRt6g9Acj5enHb3rm4be2u47b9yE3AyTRQsz49FBZSCe+ckVn3MVtcTPBPBcxWQOIzKxWQe52gjPXngVMqfSxUZdbncS6XEsrgacroc4UptkIPflsMD6Vmalp0cMctrcWBWJ9rGB0kgEfOMq/fn6isyR7zTLALpGp3Go2EbCNYbjDhSOSuMBx+Ax61cuNVZbVP7Q0aKB9gJczsRnPY5BAHBP5Vn7LXQv2r3MK+k0u2Gy4M0svRYWG8g/7LjD/wBKyLvVIbuQEPd74gRF5+SYl77ZO/8AwKtpNRBlchIo4mX5sruy31JPHf1rImu7hy8UPkCEkjCIxH5U+W25alzbEaX0U6Ik94zBgVRvsxZR3IIAwfqKSVoINsttfxrH/EsisA30XoPqKe9v5SAf2giyEj5FJUE/7RzkfhVi1sWjjMrXFtvjOWg2Ev7bWwckj86NAdxLW/MqHyriJSpwAOR74fr+BqVo0Z9wjdeOGRigB9Tj/wCtV6Nbb7KPs+nuZ2OEk8s5lPXPqB78VK2m3eo2xeV/s9uEBARcD8T35o5khWb0bMyykChmfEyDqrNgntwT0qG9tlf95Hjg4cdDn3FXyLaKIJCRK5OM4BX6gVEzqHYocOyYAxxXTDVHHP3ZHNeILZDpkzgkMIycfhX6KV+emuwtLpV1MF2hYmBAGABg1+hdNbFJ3PFf2rH8vwVoDbC+NaT5QcZ/0a4r5nuZZCXlmWMK/BBb5ce4FfTf7U52+DfD5xuxrScf9utzXyzqDyiR498QB6KcfMfTPrTauiW/eQxbqCEs5lt3Ucbdp6+oAHIFV7vUlnWOOQbooxtVh+7J/D0oWOSby43JhDkhdrqufbk/1q7FoMTwuPMSOcEDZMxCt34PSudtR3OuMXIwoJHtyzxO6uDhQev16dq1bXUxE2Li2ackgl2lJZT6Z5yKs/2RPb3J3QsImG5GE2V9x7/lWsuio0Za1jlLyjGxiuefT1+vNRKomaKn8igb61lQq8KRyhsC4MjspHYf54+lbtrbW8zMkMiNdTADbKdgKjpjnpVWxsLrTIA7xSRhlIf91kAepHrU1rbOkTz+XJLbMcb7ckbD7qwIx+lCcJdSWprzOu02SKNo7IpbsIiW8iO0O/g5OQAcnqc8Z9ahvtQkWR/Kt5Z45CRHJEolKgnoFzxx6iq9jcXEo/0QxpKBt/1gimPfg9APbkcVQaRorpGTzfMjb96yHD4zyQ33Tg45BxzWnIuhz8zv7xaS7YqBBO6SSfIEulXahB7g4HT06VNLPqdg0lpDLDfWsgBMltb/ALtS3O3OcD0PFV4bldQnjgitpHvMt8p2AyADqUPX6gjmsx3mTzBKHiaNSH8iIA55yG5+n5Ci07f1/X4j5qb6GtNe6tJbtJBpEeI+AAQhG4ANnaOnsapJdaokUc02nuEdT/y1VlHYkeh/CqNtrFqbFrcuIHjGWunnILPkYDAjA44z+lQT6lLgxQ7NRmJ3F4Z96sCOeOg+uKGpW1BNJ6I1Z7gTxeQ+lTKzLuy91vjGMclAASPr0rPvNTnWQRiVYfLQFIoIvMbrnBxwo+uax7wSqshuUV0Xn5dxC59eMfnVFZJ0hK/v44cb1KKQCvqOmaLIq39f0zT/ALSurx9pkwAMsZGCr19euMnOBUU10GkxeSbiwAZ4m37sdKzJLlcBYpSUBJRZG2gevyjpmnWslrNLmOWS3nAyHCgx574HORQ0xpo011ee3G6NpxAMKqmUlPfIP58VsWOsvH8/757ccvlf3cZPoc5xXLuZHid0ZrgjADLHtP8AvYzmrcLbZBcLNdo4AR/3YH4MAMf41jOKZvCTWqPS9F8QTRoYlMN3bnqsxEmP++eR+tdJp96jGOaGBktnXCq5EkR/3XHK/jmvKdNujbBjZ3MTseGhlj+YnPVDjiuig1mNV8p4YoXJPIkKn3DADDfWuWpT7G8Z9z0qDVtojhuFe3eUeWTKQ4Vu2HHYj/CqU2o+UzRApKo4mjJwwbHyujDofeuTbVZYkaK68i406RcOseCwXt1OTjrip5bmKeJbW4D7gMwXBACyqOucdD0yKxlF9TaFkbP9r38MADvJJJGuMMdpcf38960bHVPtduuZ3Krw3m4yh9/QVz9tfIyJjMDxnkzDLIT2J6FD1Bx7HFa0ViLhluIihuVO5JrdOD/sup//AFVMosrmidLbzRAhR5bNjduJ4Ye3WrsF4ThYwQ567hlCPqOlcLf3Vy2RBbKJ1OcbCvI9unPSrFhrJu4D5bRRyIQZYmzmP2B/rU7LQXLfc9EhlkI2vFwD90nOP8atwzHyzn5gDna3X8q5iyvy6qrBY8D+MnJH4da0ILosdwZSCOg4wKpMRcN3GuXXACMVIHoa0UclQmWPdMnr75rmpHWUCMMFlDnGO+Ofyq3DchApyWgYZHP3T3X8KafcUl2Ntb4DYJFwjYCsTj8/enT/ADwGNJAgQ8IRkt71kXEu1MSY2n5wx5J9vyqaKWWEqUwc8AnqB6H396ObuLlL8coY5KkBsE+ZySR/KmXKNasGgzv28MTwR3U+3p6VA0371pFbC/xHHOff+VSGeLJDFiq8nAyBTTHa5btdRlmSRt6oBgMG+VkI6jH+c1YlkjuImjuLx5VPKoq/N+fXNYrBWInsJAZgcEvyPofarMF4JAQAAwOGUqRt+jd6tSdtSHFdDRVvLO6AS7VIDA9/wpsxIO+J1EqnkO2W9cEVF9qmVgD5hPQDPy/nURkcyu4IPGCHIJP0oFZj7uRG8t2lMiPkOenXkdfeooIW5aORYXbK8twV9SKjuH83y1GGI+bY3HP8qy5xcJLEJAuwuzrgnt0zQ3bVlJdDVklaOTCqJzIMNtHOR9axrO62SyKm1ZN+zBTGG7Aj3H6irF1I0tu9wi48siRipwQO4/EZqjK4a7ZyoMMqbDnqf7p/nSctdBJaDZGC3tw07Lbliqs2N2GA4z2Pp+FQ6fcJ9qPngB88spyCH5VievXIx2zUlvKbea5VEYRHYCM5J+Wqs6rDcQ+cu5JYzGpXhSOoBx+P6UW6j02LeoRp9iuvPVGjw4CvnHSq8l0IY7eWRx5axhjHtyfu9M1U1nVltIrBblxIu7dISvO0DG7HfGc1R1a9WaPZbzxNEDnKn5XHYk0OKWoJt6FtrnzLcIsgn+Y7ccKAeSPfHT8Kwdb1Z5iqLtVFI82dD8i/7I9Sf0rOmvljVY5HMhB+SMHhPX65rA1fU52kMUZRVALYbCkfh2J9aUVd3La5dxNT1PdeNHHBbTHbgTnLbB6BemfauZ1K/EMREDZYtk7zhye/Sm6rqET4jtchs5KOc59ef61hzTJbORIgYgZXD9Pp7e1dVOLRz1JLoQXs9zMpRnhCY3EZxj8fWswBVYnygS3ccmrE3ztsxke/T61FKbeMABjvwCWjOUb0H1HeulI52+xIJ49o3IqN0yRx9T/9ataYW8Rjk07xBDOvV1S1eHbx907sbh2xWVLKh27WhYHBMjLt/D61HK8SMvntbOTkgwSKcY9ew/GrSsZy13ZsQ6npdhNA/wBjFw4++kyKY1P+woOMHvmrcd3DLds9tPHEx5ULEcIeuAuflH41zEt1EX3QSIQR1cA5xUbSR7yROvP3ip/Tmq1ZFonaXC3uqhZb77TMtuSFLMTkZ4wCeOv1qpJHGJAqr9ndxgKvmBiewznArnIBHtyk0qs2AAWwW+mOtXbeS0Eu+Zpsj+Fn449aG0Cg7WsbNx+7gLRmEyQkrCGIbD9wVHUn1xz61f0+K4vbxJBLJLcSZ3MYQV3Hg/KccfhVC21SNARFMySN08q2U49MnGfx7VXNrdXzyyzGWVm4LOx59c4wPzpe1SGqDfkakdxY6TBIravKJoWKxQowd2cNyfSNfbnOOlaUniFDB5EU01/GqgiKdwIYye4VQC/ryRg1h2ugz7y8UVoEUZzGQfz71q2fhbKrJOTCP4mY/Lnvgms5V30LjhYdWUzfXlxeZ+02xRQdsZttsZP90gHJH1NJaaPezbmsfMMhONhXJyec5Oc/TsK6ux0KxijQxvLvOVOeffNasErIBFHeQ7fugZC7frWEqrZ0KnFbHIx+HzbY/tSeRdvRFbbkn2xVv7PZW8bgeVL6KuSVB9SRiulNtFC+HWXzT8xDKOG9M/1NCs+4OEjZRxwcBj7nvWfN3Ltc5aWJ3bZBpcb2/UhiGb/voDio4NPuluAYttq75KjzPNc+wFdXdzyR24KWtu2MdXwM+pIHOKzLr7TeQBZIreGOP5sJyWPqSecU02JoqW8Bit5JxMZgmQ5lOxo+eQfX2HFWZyl/C+2eR7UIF+Y7VPH3QPT3rMktHdl86R5hGxICnAXv9KuW7kQt5k0sTsclCAW//VitFqzKWiIZ4FhUKVQA/L8o4Ge2KofZyJ33bFLJxt/StNVF1P5VvlQc5kPp3qvcRolwETIRVyGJ611w2OCbvIxtQgU6Hqm8nAtpSB7hCa+86+E/FMZ/4R67kjZRiGTcO5BU192VcdikeL/tUuI/BmgO27C6yp+Xr/x63NfLskEd3ciMojRvyxV8fN268V9R/tTf8id4f5I/4nK8jr/x63NfNRtgjuGK7T8w9/8A6/tQ9hN2kQ2lta29wBJbG5tycOhwJF9xnj8OldBY21sdwsJNsK/MYpYsMvPcfpms2LaOriVenl/dYj29atrpkNwwaKaSJyOC7YZfbjg1xT1O6Bu20FpIGgO63ZuAC3yhu2D/AJNSyaEIUiaNhufJwi7hnuNh/pWfG1zbxRxamqzRoflkQfMB/WtvS9QRDttHLMr7lLPuU+vynpn2rncWdMWQ6aLi32D97CoY/eYkDnAO1s5HX6VrjTkMjxoQjynaBAyqjHtuB/mPyqutxdRsGURzxjO4Z2lfYZ6596vsVuLfasZKZBIHIP454P0pKdtwcOqKw8Pw3MTmWzU3lvyWKbt4zyCOnHJFYV54b1FP3cKSyQbsiMnKD34PFdc7zybM/PIq/K7MQ4HbJHBHv+dFtcytvChGO3LRs21mPqOxx68Uc/RCs0eYS6dfS+afIjn8pudpAkT3C9D05qXUTe3cMNvNDcQ+RjYJoJHBb3bBP4Zx0r0C9Y3Eix3cKGRfullXcw7/ADrVKSzgWWRUSZkIHG4ED6nqRW1Ou47mc6MZdDy+5jvLbUZJP7QtUaLDbkCjr0wOp+hpYNaeF57e7WN1ZCxnjjRioJycjvz6HI9K7m88Mm+QLEttCqE43qrZz2J4rnrn4e3pVvJSNmXqVGAa1jiO6IeGi9pHPieGK6OVtboIcHyeGfI4PXP6e1Z0l+8s2Ul2yY24CncoHpnoK6aXwhqluP37iIY3BlYMFx/u81Qj0pApFw9zIitgSRr8ue3Xp+NaKvGXQzeHad73MoMyjMszrGRkhV25Oc8n1qe3f75US4HRkAKj0yOOKu3FhO774JZZp8Z+dFOfx6DNVptNvFbfPD5m3kqZSn+FLmTEotDru8VIzh5FiAGFVBk/8CA/QVXaadYkuLedodw2Mskm5m5/zzUMnnh/MWNLdCOApyCfXJqvMJbh45JSQo43LHgY/ln3osh2ZbE5ico53oCcnbtJb0HfFaseqOWVbwtNgdZG3FR7Dp0rCUMsrFULHGAz85B9aRmSOApJBliciQnp6VLimWro6eHUYoQXtSVgOQiGM/r/AJ4q7baofKWMxywsTuRgSwX3x0z/AI1xazPEYhvkTaSQvQH6D19zWnb6rOqSLIS8UmC0anG/HTJ9PpWcqa6GsZM7m01a7jnVy8i3SIRHNjaSvfcP4hz0rZt9Rsmk3RG4hv8AP+ujYoM+uehHtivPItRjM3lyjaDzlTkKo5wCf5mraa0hRlRZHdj8i/wgevrWMqZaknuem2Wo/bVZLq4eVoTlxjfuJ9+op7eQkjPp8JSWM/u5G5PPXr/DXEaXqDXLCIhY2AXLEAlQe2B147V0EN3HcqXaTEKq25I8jju3J5/xrJwZopI6Sz1NXOxCsV0hBJn3YUex7j3FdDFqD/YzM0JRs4Mh+YD8u31rg7W4SRLctKVjQAc4IGeQT7gD86talr5ikSMMVypQuvBZfTHes7WLtfY6yS82+URNHlZCVIOeD1J9uRV+3kaKZlLglmyxxgexHvXA2erkRNHMyKV4IIxx2INb1lewi3G6VGQc4J4PvjtipaYrHV20hkhZCSQcjPp9PepYnZrJCrfvFHrwcdQw/Csa0vCrsNxKt82cYz61aWZCxC4GTkknOT/9ekgNH7Q6jaYRIH6sh4P1z396njuNm3ykkz/dYEfqazVwUJTCoOQM/dP0plxcsIZMbi209OAeO/pVXsBuLcnafNKByM44I/8ArUwybpQqsoYDjHII9AB396xUuY9y8jeyAjptHHFRyZRfMt38o9/K43eop8yEonQG5dVVXh2dvmw38ulJFexlAY9yZ6mTpn0rKs5A0IMTBiRz5rHd+Iz1q0sxRSVG5X5MYA498U7isXXuirFUlj+iGqjYEibXDsMklz69fpVabccu52N0xjBNQTsu5d+G5IyODUuTHYviRPM2xMJOpJBxge4PWqTMsYEe4SNEfl5OWT0P0/pWVd3SxviV2TBypZhuB9KqNqMu7cWAKr0I7HpT5kxcrNia4hiVrvc8SFc5HzZx0rMGqzSSusVuscTfdJbIz/ETz+grAk1ECArIxYnfnDYX1zXKLeOtnOjONgferMcEqTkkj61pF3Dl6m34l1F5dRiYkEsDCq5xuUEHv0zzTkv2gEly9ughEmREOijHc9647V9ajmkjBVZimSjtwe3JrKvfEEzqEAXGCDnJIHbmtFAXNZWR1Ora4twy+V5MMZXayleM56+ua5vVnMFkpkaQsclGUE7sd89M47VivLIrPtdtr44Y5x9DT4IZTkKZlBPzMrEZ9/rWkVGJEuZlBpiY9uWG47txGAw7f/qoMBk+8jKcAbh0x6kVtCFLaNmupAIRzlz0rMeS41a5MOnK0FsRhnY4J9/pWqkZ8jexmXFzbwNIskpeV12sF+Yis4mSWRvIKwQZxudSQv1PPNdfbeHYdKYPdxR3MhAPkupw+ewPrjnNRy2lxfTR2dhamFppSBFDnA25I47n1NaRkmY1LLRHCsjkMzOTwD+dRSKY3wEI+UEhhk/X2rt9T8O/Y0h+2MkUzZD5I2sM8Ee31rnbu3cTmWPDMScsprpjFvU5JVY3sjKghaWRQFAHTLHA/Op5LdIAruW2BjgjoT7dzTXhfbnaylPvE0S20pCkZYnnFVyhcI2fImBUBDwq+vbjvSxi4uJHdWZjnJA9fp6VPaW7mTa43Z4ArUt7J7K6E0WSF6K3cf0NHLcHJpXK+gyX8F2I4XYGUmPDNt/DPY1tx6hqclsrgtMwfYWds4J6bh7kED3r0DwJa6Prttc2+u6VLLAz71uLdtskLEYJz1q9qfwxEN8zadf3S2TJtaKbEnmHqPnUZGccE5wcDoc1LjcxddXsedR32sJZQ5iRfMmZQrOPvD6cgY454p7+J9YgRFi05UQnkDcysfcHP510ureBJrLyi96DO4DJJJwGIGSjDqHHPTOR054rnrma60eHzvJkVZwCkgXd/wACz74xxWTidEKtxU8XzfalN9ZyovAIAwBjqSB1x7VrWfiS3vMqjea6fL5Ug5z2wR1rPTVo4kiMiRSKn8LqcOOOMdm+lLJp+n6jCJY9ke/7jxfLyO1YyjbdHRCpc6m11R5TGWVQ+zAWRslh25zz/MVdt7wNIjGaMBjgqX3FTjqew+leezw3WkR+d5/mR9Dlv4fU+jZ7itbSLqbUYTIJw6KnzEyKWz2OO47etRyJ6o057aHYvcrkMXXg/Ltfhfr/AIVBJIvzPv8AOGc7920/l1rL066S4hcSMAUBAwAcn6Zq3Fy6mDaqyD7rgMT7kDGKSgPmJN7OCw/dxldqL1LH6D+dU5cKPncAEbSqc59s1daKVpAJSAB/H2A9cngZqrNCYVWSTCAcq3RnPsPT3rSCOech8M7RQ7n2F24IIxgeg9aTicgyKAQOGzilji+QDOVIzkjk0+VA0a4A56Y7V0R2OWaszI8T25Oh6kSMAW0jDH+6a+5K+KNdXHhfVvM5b7LNt/74Nfa9VEtHjP7Umf8AhD9AwM/8Tlf/AElua+c5LdbuzAiQ78nI/vDHX619H/tQf8il4e/7DK/+ktzXzvYzNA8jLH5qkHlhx/8AWpsTWpl28L7xGZBsQ5/ecn6VbRo5OEZvMBzg5H5Gr97aR3yRy26KJcbuCOQf6g1QhDgsNmFT74HYeo9/rXPUV9jopStuXobgqmx3lwPuoTnBrQtmt3+eSMKcYLp95ffjr/Sswws21owzg9N/ylvYc1OVIVgkTNxuYI3K/wCI96wcDpVQ6G2neYsuRIqKMSjDFRnqSOav+eBE0iyGNQQd24EH2/8A11w82qRIQYJFYY3lGAAPr1H86yJ/ECed5dioaZFwD5eSgz/Pnil7JMr2jvZHoa6skJbdJtAb5gPlbJ+v/wCqo31tXQ+dLF5J43Mw3L2Gcf59K87FrquoNm9m8lPur3cr6Zq1F4fQuolmkMaHcqq2OfX3P1qOSK3NOZnXz+KdNgeNTLbmRG+XLngjqOBVE+LTLNFFaQyzMR5m2H5dvPXmsyHT7OydQI1jjRSSznPXgnPvVq4ubKGbCCG3YgMyxnCjjj8xVxpp7GUqliyfFUojdntZEY5IiXEhk75OOn5/hVeTxRdx2Zu5LGeSAsIjtBKhyfuAnHJH5VjXPit3R7XT0Nukkq9DkoBxkE9z+grntUvLyaV4S+fLOFIbKfUHoep5raNFb2MJVZHZXXiWVIVK2KSRvI24RvkEgdN3oPas0a1cXzxv9mAEvLL5xAKdjgd65h5b+e2ZYURbSFAOGxtH9T9OantbK/bHlyMqTMqnAHTtz7VaorsQ6rNmWW/Wed7do4vJIbyw5OwE45PGTzVSS2e4utk91I0xBAcoXLsBk8E8Vu6J4evrrU7rfOhlij8xXuLlIhJlTwSwI464xz7da52zsNRjvvL86IvChZGX5l5POfTP9BVukyFXTe5oaPpFvc3YfU9U8qBXCELEXkxj04H9OK1rrws01rPNpmoXE8EZKt5yKAVHUjB9azbf7el8kl1FDOZTklgUHy9Pp6VZ0u7T7SEnj+zxrn5WJOGOTjI6jp1rOUWt0bxm27ple68JaxbbZrOQOjf6shfnb1wo/pVNtL1EAtPZNOoyN68ZI69a7fTfFMyQRxElAsJZsHDbSfmG4c4xxxU+ox2N7IDABDCoRW5JwR1JHpk9881zzbidFOV9GjziCeEK++BxsOwEr3PvVmHT45B5j5YYLExsOAOwzXoF/wCHIZ4mbTIFMW/EsIGFx6qO49+vPpWFqfh+Sxie5sAgtFkELFshCMZHB5Bx+tQqiNnBdDjPsU26RcDAGWJPHrioVaffxG0RH8Q4J/z/AFrq7CaO73L5KpKuS27jjsSDViW1hnVI4V3MwwQOfYZ9Kp1GtCFBdTmo9SuUifkDIwCgwR2NWbXVXV9zoSI0Kg5zx71rS+Hl+zssY/0jHBJ+Uc/SqkvhmVYiVljPGSB1pc8RqFyax1uaILtZSUG6Ta3BI4/E9K0ZtaF4YHZm2q/UkAHI61z76RcqqmSJlLcqSMZHrmlWwuYQuRnB+XHWpdmXytHT2V+du8T5IY7CTnvj8q6qx1KKOFgNjHZg4HUV5pD58B3PHgEkkAA4rSg1OTGzaSe6FR8p9qzlFMpXPUrfVBIg8osGwM5Xk1bh1AOApbnrycCvPLHU7kpGQ0YVuMl8EfhW3ZyS3ZIZk3Y5559u/NYygWkjtBqflEZAfIycHBq3HPJJGxOME5CgZ4xXNQRXCqW85FyOOck+1a9nCqSB1eMtjkZI5/AdazaBpW0NW32whQmSoACrtIbP41bUqhznbJ2BAGPYVQCuUjbeQhZSDy34H2rZjtsRl5A6hj821Dx7dKuNjKXmMklLgK4O0ddrcn8qf5wy3lxkE+oA4/rQ0aAYyMYO3e3OPpVeQJtYMoB6HGTgetDbDQjuLpslCeG5IPT/AOvWbLd4Un5lJHJ6DNF3OY2xljnuVxx9Kwru5VM4VmbncuOKz3NFHQuXVxG4ydplXkbuRXOalehpSwZ8HsuQFP1/z0qrqF5KXEQQISQcZP3f54rJvonm5mZAX6Ii8/l2raMR7FO91FYS0YlDRls7FJ49eTWLc33mLshjC9RzyR/hXQR6WZVSS4G1Og46/wCFWo9KXcWSEH3HH4mtk0jNnFG3ubhhkfL0BPXFX7Xw/M8QdvuN3/nXYW2kqZAhACjA9CPerwto7ZQMMwUHOD29/ek6gJHLwaVBEIWUDf0OVz/+uo9UlttPjMv3UYYJx1PsPWte4dkdwE+UnIU459/YU2y0KSdkvb0jaGOxCuRtxy2OmOcU4vqxOJy1ho514Ga7lMYT5kifoR7+9dPaeQkJs50ii8tPkLJ87Ff4Q3b+vetq5tINgjitAfcCk0vTH1K5tLNVBRpMmUqDtAB4PvSjPmkKtaEDM8O+H73xPqUaqzypHIo3OpJTKkkk+gGABXptn4H0vQlWaJS84jKtOfvse2PT1r0zwd4fttF0pIbeIKX+Zjjk59T3rB+Kjrpmgz3SoCUHCjpXqU4KyPnq1aU5NdD5f8XR2lxqV0I1YxbyF3HODnk1zcqRoP3aDC8cVp6hud3YgjqTWUxUfdIJrerO7sjfD01FaiRW/wBpODDvPdcZIFXr7QWsbWKWaNImkQuqY+YjOO351f8ACBgS+ikvNxjLgsQBkD0Fep/FHWfDeqaBZw6Lphtpo1CyShQGZcfd9+fetoUNFfqcVXHNSkl0/E8QgggXymiYMzfe5yB+NWIiWOMHHcnjNVNqwzyorHHVR0pwJZwMnA6ANXLUjyzaPRozVSmpLqdp4J1BbPW4H+4rHbx2Hv7V9I6fp9zDbpe2EnmKQAYjztHsa+S9PkZZFIOCCK+t/hjdSXWh27uSUaIZz6jitXZ2bOGtHlk7FXXtDe/gZxECjjEsLRBg1ef+KPAT/wBn+ZpsqzWMakTWU6ZKAnlkPU/ofc19DRKMA8VzfiiwLZNuNoI+YDp+VZTSjqVSk2rHxlq+kTaVclUJkhc/u3BPyN6HI4P1rItZZorxFSRVy43FwQq8/ecdh6kV7Z420hLgSxSoobOM+tecXnhOU6Vc3ZdSkMnllGcb2OM4A64x36VlzrS52wg5LTcdaX0dwzxmS1ilDY2B8qx9V46d6k03SoIbhgsQIRjITGNpYkfmBXK2MaNcJFiPevSOQct+PStu0Sc3n+iXjRbs7UmO38MnIrKaW6NoXXus6KFY5LqMmOJSMDfn/PNaMIZUKq3IOTnAPPpWVDHqQCtLLbs3Qggo2PXmrUpltlTdEyll+ZlwT+eax5jfl0Lk11JlcPmVcYwuAp9cd/xqncM06klt0inLMcnd6AVES83zozKuMDLDP5Cp4beNR8u5weRxjBrVPQycdbjowWEbeh59Kuw53KBtBLYqGMMGwqDdnkdaljAAZkOJAc8itoM5KqKfi9VPhzUsAAi0mHH+4a+0K+OPEIV/CeueYP3gs5m/HYa+x60iTHY8d/ae58KeHv8AsMr/AOktzXzhvaOQmMsATggfdI+lfR37Txx4U8Onr/xOV/8ASW5r55cF+AADU1JWNYRuxweP7KGX5nAwdvGRnuP60RW6SEOsqxybSQcnP0PrUSLsOSg49ulJHNGdxkwD2A4z9PQ1k3c1hFrQWSMIyq9ywUDJAG5ffA9apGQQr+5fc/OGB5I7ADtWhAEM2QxYkZwWAz9TUhtofLyBIT6nhdtZOVjZQuclqVtdS7Io5wnmD9+Y8Aeyir+jWdvaxBEjzIGxuJJJ9vap73akpAjyoxnb1/OobVJ7uQ4KW1ooIaZucD0H95j0qleeiJlamrs1QZpjLFEmREC7suSUUdWz2Fbmg6et3BJcTXEcWnpEZHmmBAUDgEkfd3dvpmue0sRPCUnuodNgkUmZbqYr5iryMAAlgTjp16DjJrJ1TWtS1ZI9JsBLBYzS/OjNhZ3/ALxUdgOw9K2jRjDWRzOrOq+WBreItYivDKNPjLabbfLG7ggynjgDsP51jWuk3V9EiLMFlGWeNfmbHUlvQdBzW5pfh6zmdYBcySRxcSE8KwHXHcc8D1rtdQ1KHT9DTTNNtlRtgU+UAOfQ46/jWcqsUztpYOpKySPLtN0cfahHNHkITIwByzHsCewqV7GKW/ihCZJO5vQD0/xrsdB0lnsL65kyJjtBGOe9M03Rh5kkrnax6HFXSn7nOxY2koVvZLpYyIdPM18lsqHyyC820DgfSu30Tw1HJJb+ZGkbli2DzhfT+VS6TpaRSFz8zNyxPU10sKvE6SkjBIVvYdqydVyZlyKOxesPAN1qyXKWdvbmPaMvJ8uxvb1Psaw5/AcNkJInjcXmcu2PmJ75Fd5oXiG50qJkt5EZWbcyOuQD7VmXuoPeXUssz7pWO4nHetG0ldMxXM3Y8y1HTBaMFZAyplTkdQaox6bbLfw+YvDjadowf8+1d9qlmlzlsjOKzbLTY3jxKm758L659qIz5ty7cuqPPL/w21tNO1i6p8jBieMHrx6ZqbwjrMdqQtxHIjPHhSw3B3BPJ9ua9Wm8JQT2tzdSSyRzH7jhs547jvXEWvh2NBcea/7gsQUC8jkZP1xXDUqOL5ZHuQo06sOeG6Ne3CaisctqNskiglQeBx2Pf6U+zsIri2mS4RYgykSxMxyp9fb61z8cF5otxbNEs01ud6gMuCAO4PcYroI2TULdGhdRu+Vjn73+FYSVtUS4NaM5DU/DkdwmyNH+0QlhHKG555HXtVbQIJ4lC6htjOAw3cK49Se30NegWEEcUmbldqqQRtPJA6c1FqNjbXAlmYKizHCMgCgN16ds+lOFTSzInFt6HNCNREzKq/OeSDSJEzoA0bAAE42n8Ku/YGtYvLlLKD2zwfT6fStGO0JCbXmSNhtY/fHH05/Opcl0LUWZ1jZpcRhp42AAPPTOenWqOoafCsQGza3qOcV2kVrOvNswliUYOxjkL7r1xUbwpJOfMVNp42yDHbt6GlzMi3U4610+FxkxrIeh3dPwNTx6NasoAUp2+7nHvXUm0NsJPKAZMZyRzVi2jMkALoVc9mHUVSmxOxydrpCQMQnlZPO4DaRXQ6faTRRtvijeIsF3BASp9vepJYR56qoUjOSG6GtrSbYLkAbhu4B5xjpScmyb2HWtqIoysaJuHBYL198etbdihWPIXbg5BAH61Nb26BUI6ntWhBEVIwASeQuKhKwXuRtaO0jOhxGY92Mkc/4+1aMlvE0jPIJGZh0EhOCfX3q1b2atFt2jeDtAz1Pc1otbCONli2K2f7uQM10RRzylbQ5ea1iYZ8lEXn+I5+p5qjLZs8YKoSCeoJ5/GuxFhFkMFYlSAd3Ofwp0kEbrKxH3MYXoMe1Q4X1ZamlsedXulkqD5iK27BAXn659Kxb/AEZSAsUbNx1cnJr0a7tVH3uVPI47+lZlzEFJYDn9ay5DT2jR51JoESI0kkSlmIAG3n60i6bDErFIFLHoQnT6iutvI9xb5faqkkXyYJwq8E960SsS5t7nKPalRxBhuMMRnA9QKdHaEupO4nqPet9oELMwZmJPDkUG3XHf5R1FQ5FJmHPEq58tcj1z1qjIjs8g37dwwcjGPoB1/CuiuYdgKso2E53Ef0qfT9CkuAJJOARnGRke/wBORSTu9DTRK7Od0fQVvbsm4SUWiDfIByxA/pmtGaaSG2Lpsa6m3bolXG1QcAHtz7V1GpWy2OnMGiCMMFVTICAcEf1/GuBu7hZNQWzsXeS7kfksMRov16lunHpWkm/hJj7/ALwiRzXd6Y7JMTDkocYU+pxXrfgPw5BYWkSyoX2ZLykY3sfvH6dvwrnvCmhR2awbcs0hLSyEcuf6c16rpUCGADbtPHHoK3p+6tjgxMnN76GnBEEjUA8dq4b4w2hn8JXGwbiOcH0rvQQowBWD4kt21LT5rdo8BgRk16EaiUbdTzpwuz5DkSJTJBLEDFICG9cVy2oWgtZ3Q/P3Vh0YV6P4s0WTR9WlRxiPJKkjgiuNvIxM7kjAA4OcYNXN6XN6TTMO3maFgCcY6e1aN1rEstpHbu4MaZIGO59+tZ0ilW8tiDzycdajwCSMY4/KtYYqUY8rRy1cuhUnzp2uMddzlm5Jp8SEdGxjtikjUngDJ7GnoMn0xWDlKcrs7owjSgoroXLBC0igdCeMV9c/Cu2Nn4at1kBBKAkE9zzXzn8OfD7arq8LSoxt42BbjgnsK+orREtLRI1XAHH41U5cvyOGa55WN0TAJuU8Z4rP1SUOuS/0qjb6gzOyqm5Adu7GADVe6LSSsc/4VyOq5u0TojS5VqcN4vt0mkMioCFJZj0yK4TVbS3urDc0bR3DMWVu+PevQNZmjnufKB/dL99v7+OwrntVW2kjLSSRRsTtG8/zFc9eq2+SJ6OGpcq55HjOv6BNFMJFVS5y6MR/n8qZo72s+LacrFcxtjJyd/Geg6j3r1B9LMdm+6VJYS2CcDk47D6elcbq3hSCRHkG0qrZjmVsEZ9utVGfKuVlzjzvmWjLNgtvvPlebGwPzKJt4Hrx6c1oNaRbWjUpIzdt2SfyrmbK1v7SdY3QSxgdcZY4/wDQq3LOKIysVLGT8RtPcYPSh90wj2YqwgNuCIWBwRkjP+NSRp5an7yg5PFXGj22zHc23O4DOf1pVXcqgrkD16GmqhMoFKJWRwxzg1YQ7X+QkE9R1psg3Bscc9BxSxhhkE8HjNb05anJWhZEPiOcN4X1gEgsLOZf/IZr7Kr4019VHhjXPMBDGymx9dhr7Lrpg7nMjxv9qH/kUfD3/YaX/wBJbmvn5IjJISDtA5zX0D+1Bz4S8PcZ/wCJ0vH/AG63NeAwEcqwwAelZVzooK7I2QtkK/bj3qGWNWUBwcDjcBjmrEihZx5WFXHRhn+XNOuDfNArW0MTLnAbJG38DXI5eZ2qNiK2SOEk5Zcd3HSpLl8WzMuwxouXIGDimJY6zIAWu4kDfd2Lkj8T3qpNoRglY3V7dXcznc0ZOFz6/T3ppw6sGqn2Y/eVN0LBxHI2SAVRPn3Z9uPyzVfVNZMQiiFiPtKcI074WMdsIvGfqSa1BeJFBPBZwgXAXl1QKsY9u9Y1tpUk8pe4DLEMEyH+In3raFW3woxnh+b+IxrWZuGji8s3N2TwoJwMj+L6egq0ujT6S3mTvvvWwEx1GeNo963tDht7RRZ6fOnnTNgnqq/jXVweG4EiPnOZJSP9afX61hUru+p3UKMY6lDwdZQyhIJG2mVtm89CR/h2rtrLQLeyDwuPMYt98DGfc1z1mg0+IwgZQ59s+/1rcgmUxHFw7MqgE5xkH+tYJ9T0XFyV4uwmqRwWNwiq48i5HksMcA/wn86590MLNG3ykNjFaOuXFkmmFLt3nmblRj7pHTntWVYXkV8iLOdsy8Bh/GP8f511Qqr4GcuKwkpwVaKvbc27SLG1lbn3rSt50MgWXO0H5gOuKy7VZPkUdc45q6sJD7s4Y8EjpSaszy2jSiaBrdz5jC4DY2cYI7e+as3r2rQwtbWzxXIG2TDEhsd+e59qqW0aJg4CnuatvNGRnIz/ACrRttWRjbUqxwSsjM6kg0y3eO3DvtAC87vYVqW0oERUjlqxNTlAVrZAuGILHqevQVC/dx5jpw9F4iooJHV6He2+p6YEZCeNzeh9MGi48NLIpnh2tI5+ZSOQPasrw7cQRK6wrhpGA8vPA+grsrAs+W3FlUcEnFczaqP3j1qtL2L9zRHH61aLpjWQMSERNyT1CkFePzripNC1FdWu5dBtp505ke3jGWx1OBXqWu2UN5chpUAYpt+bjvwc1DdwXGm6U2s2t20U4cRxxpwZM/ewe+OuKVOHvNdEc9WoopWWrPOWvBHPGt5DNa3CDHlzxlWH1B6fWtOzRY71RcGOZlbcka/Opz1PTkVe8S+H7jU9WtJ9ckeHUZkBaR2CFV/gBI7ex6Uul+HtQsNTtLW7idkuEZopYSGIXHylyPuqecH2olScm1FGbrRUE5MebURIdswmjwCIwowT2B+nvU8OlqygQWjhJiPvfNjp/EOevrxW7BC2nmW1uLcear7XbAYKvfA7g9a2tIRbe2uINkiPkNmNguUH9ayVNt2YnV0ujj5NMmtbhVZHCqeBLhWBPvUF5YLk790jg53Ocke1d4UKFIHkaUNyYZG7YJwSep61zN/bEE+Wy9DkEelKpHk2HCbnuYEkW0g8g+h54pNwVGVzjBwRjBFSXMiiYKqscnAJ75qY5KIJBlcjI61nF3HJWMC4cxXMbtjBJx/jXSaPGSi7CAcY2joK53UY9lyMBXi34Ge1dJpciKgEYPQFTnk8dTWhMlpodNaIoQdSfQetX7ZM4IHPU5rOspQyA4IP860oZAjAsw+Y/d9BRdE2Zq20TMMKSvX5s9Sa0Y0ygCMFx/Djkms2Jt5Rixx6A4/Cr4uVZWXYSgPbjP1NdFNrqc1VS6BJGYs7zncOgzkVXlIUblJAJxg1NKQpwCQ+eMNmqNwXBwUcOBuBX071M3bYIK5RvlEe7DfLtzwOR7VhzsFUZJOBWrfSkfOR8rc5/pWRO+cgABh2xmsL6nUo6amVd/fO3O3PXNVC7BCdpPOatXL9gfvdRVDdg7RyccmmmTYkijBbJOf8alMRbhCRyASewqKIhd205/iA/wDrVctNsmcfeHPHWpY4kSWqyToJWC55B6kY7gV3Wk6Wi2ZnMWElAd1KDCBegB9e5rAtI1WVMKpByMeuAeta00kq2EVpBtBuAWbqxVAvzH88Vvhkk22RiG2kkcf421CKMTPbPI6Q5XG7cXYn8j6+1YVpp8cVsY9gVZh5pZAGYsegJ5wa6XVdKdtGtZGtmhkdjL5z8hx2yO2RxiuduL2eJiyRjzPlAMRyOOORUVFu5OzNqT05YndeFpJ54VluHSV2faX3DJZRyMewrtbGRXbMXG04P0rxPS7i4tzPdSLKGkbKDbkk/XPH1rr7Hxu0EcaS2myQ4ViOQcdDW1OrFpczOWtQd/dPU1wVqOZAy/0rltO8WpKuXRZF7mJs7a2rbWbK4PyzbSezjFehTqQkjz6lKSWqOE+I3hePUbaQhCWxlSBkj3r5y8QaNc6XdPFMhKgkBgOtfZ8vlyo3Rh9a4LxV4NstVZyuYpupIHB+oqm3HbVGFOVnZnyXdxiaVnVCuBghR2qtJAqfNy3rXt+pfC+9Ny62dsZywzmM/wBDxXKXPw+1BXIFrPuztZSMYIpOpT3Z0pyex5wImHCgjPYf41veHvD0+o3USbCAxwB3PsK77Q/hnqE8imSFYUAHzScn8BXrPhPwZZaIm8DzbhsEyPyR9PShVU/4aIqOy95lbwB4Yi0W0ClA0h9vu/4/WuwjgkIIk+ck59MCrCmC3XMjqqj1OKy7/wAS2NuH+zfv26ZH3QfrSkoxXvsypqdR+4jRkVI0JbAUDvXH6xqqys0Ns2IgcO/Q49F9ag1DV7i7IaYr5faEdM+/rWFd3KhwZWcFJBG4KnCD1/CuCrib+7SPXoYW2tQNQuViiPAWNeAO31rk7+VZbsiKRJcg4EWFOPdjV65v4bzebeV47hPl2N398d6pF2WJDMVyGyFReD69elcsE7na1aJHaPJnAnMOzjD/AD7fUY4qWSAzkpKYSxGSApCyD1H+HWq0cpnuljwrockHocehPt1rWQDyjCuSX6hh39QfUVvOWpgo2MJ4msdwurcy2wORKvOB7/41JPAl5CkhJIwT5nRgPQnvWzJaNcQOjbiyMMr0Bz0/CsxNLlsnyoLKG5QHj60KQWuVI9MwgKzNJ6+malaJxCoZgc8sMYrRhKTkBTsY8sp4FQzB/MZTlhjse3rVX1JsZ5VA/wB0D+6M5x9aYFy5C4xwdvQ1PcAKy8HPbimPhhkZLevpWsGc9RXRmeJJW/4RnWgwBJs5sf8AfBr7Mr4y8Und4c1cN2s5sH/gBr7Nrvp7HC1Y8c/aeAPhPw6Ccf8AE6X/ANJbmvBbdHIZkOwDjPWvef2ocnwj4fx1/tlf/SW5rxOwiMkRdeOBwB1rDEvodWGXUWGAE7E25AySRzSiNijIcKx7AVOkiow4AZeD7io5p52ZltYWdz0LDpXBLVnoR0RG10yQGEhYzHks78AfWufu7+8u1kWxBaMnDyNwTWnJpsr3gN1J583Vlx8ufStM6WdpaQFWPCoq7QD6n1HtS0iaLuzjbbTJYycqXOeTg4Y/1Fai2sMNgY5JY3dmLeUYySx/2j6eg9q3JbVIbRwhZ5j8q+gJ9qoSWhjIkRiYlXaSB27k1rSqa2RhVhzas0vD9msCJJHJ5cOfnj3bSfU9MCuusr22YCLzIgnYE81xEF0nm4jZVZhgbV3YregAWGFmWbaoxsg/ib1Ynv7Cpn2Nqaujop7RZQVPzRpnao9/esPULRoNjOy4PChjWzZXphhLToIucLzuZ/wHNTXKRToTImMjA45Brn1R1U6rgzir2XbavHcZLk8ORyB6GslpfIBMeeOo9RXY3unsB5IQSx8lnk5P0rBuNEaaIm1kCDskh4/DvVqR3RxN0WtC8QCZFjlAZhxuPX6H3rqoJo5SdqS7ewK8mvPrHT5bG9EjIw5+bHIrpz8RrTRrXymgWWWM8ArgH3J9q7KDlN2PJx3soJS5dX2O80Wzsp13Xpu0GQFRYdxI75yeKsanaNPe7dNs3EYGFZ1AJ/AcVVsPiVZx+F9P1O5t7V45pnieWIgmFwMqrDOeR19Kqv46/tBLmSymu41BUwKsSjr94E+nXFehKi0tWkeBDEJ1Lxi/xKWvTXWnwvBNCqTAZyMk/jXNJPLcONz5Y4yPb61qXl5qeqky3MKLK42jJ/map2egyFcTzn72diDYMfWvHrytK17n1eCqRpwTaszXsbm3hZY3kzKANgjXLH/6/tXQJq9yItgQxH+Et1H1FZ1jYR2chjSONMHnYckcZ69a2Flt4SiM6YkAK5Utn29qxixV8RzaJFV9SvJMpNcyzBl6CEAfgTjNVb3Ub6eygtbeSTZbSF1UIVAbP3iScZ7cVqm1kvGcNNCyLz+9faox7Lz+dJc6LMiebcZlgLbDyMOMZHA749avmlG7RxOUW1cydTvdR1C6luNQuIluiAq7Ys7lx/L396k0n+2L5WtzcC0t7m6WWRIkWPeQRhQw5AHHy9K1rHS1nuDCt7bReVF5m8j5WXH3QfWprVFhtYJ7oJI0hPlKuM5HUMOw9/UVpGpNPmZhKMGuVG7eND9mdFhP2nJEjt944PC47VWtmlDhpFUGMjdkj5R7++a0YL4tATEge0YDFxKMux7AsOjf4VTniP7qaLbGH4EhQMVl/uyL6Hsfetqvv2kjCi3BcrH6pMhWOVbhFY/63CkbOepHTA/rWJdttl8pwGOMowOd3vmtm+luYDKl04dyWj2hBjJ52n145H1rmLyXG8DgbuO+P8RXHiGk7HTR1iZlwqiYsT0NORz1YE5H+TVYu7yYOPXPvVkMEUA9zj3NYpJGjM69jLzhAc4PUcfjV+1kbyQMncpwMDrVV8Fyei9jjH+fpVyzyHIJGQOuefwobKN/TziM9cnknvmtSCUBlbAJA+8K5/Tw7Fjt2jGMH/CtOz3FiAQDzwTnaKz5mPlRtwXJLoWQkg/xcfyq/HctuCmUBOSwj6mse2xGibmXJ5OK0bfEVuZGRpOcAYGa3ptmU4otRvK8ZWN2QFs/Nj9agneSIjL9B65zT0MiyYMTq3o2Nx/E1WvSTEzhdpDYyxwSK0ltczja5Wu3I2gYIByAR1+tc9cOd5Ugo69W/wAK1rhmjj8zHK9yeAKxbmVJmYFCEUdx/k1zSkdCWhnzOeACucY+tU2PIVQevY9RVu7kRRnOGI5wOfwrOXCSlD8p6jnJFWiGi4ONvqT681btnKsnr7d6qnAUHYTgdfT05qa3w4buP5Uak7GvbyHzfkBPJ5z0GOeauwYmkTbKsayIZCQSMqBjZ+J5x7VjwyFeFK5A6Yq7ZyfOgjVVwSHJIAIHQD0PHXvWlN2FPU6CWHyrZZGeRbVm2g47HHJHT1xWDqml2iXMIinhaPAAWTCjHduOCP8AGuuW7Roys1uZsqRjhjjP3SO317VxV7pwIaSOP7PHMWaIPyAoPU+n4V1VoxcbbmFBu/Yv3WiTGJEh8lxG4UrH91hjdkfQVHJo9xPGZRbxvEAcIBk4H8WKy4LuVCN4lhU4wrBvlXsSf88Vr6drkccbSsWG/p5TEY4x8ua517NvXQ2cakdncoahpN1ZgfZlNzJySbcEjOOQ309aS6lvrKwhnuY1WORtyRZ/eFRjJ9hmt6w182kMoSRmzkEFd29j6Y5zVO/B1iaK9aMQXMKhdiZYNj+LPr7e/Na+zha8GRzzvaS0MyDUp4oRM+6NS+wkkgDPrUg1e6Klo7lj82ChbJwPb096p6tMbCOztoIIGeVw1xJExJKgkgkHgjOB9BipL2/0yXTZhHbubyS5iXzsbPM3A5BI4UDrhfakk9uewOKevJubllrF/aTOpvLV3ZNxQtgKT03H19h3rHn16+BdyyMr87ivOff0rNu7+3t4YJzLbXIt0d549pV3PZGZevAyD2IxT7y8s/ItI44Vjn35a4BLo4K5+df9nIHXJrRyqOOktDP2UFLWNy7/AGzfFeJVRz1Gzp+tRDVb+VhGLxsk7QFAX86ykvbbXLe3nG/T2uYpBFIhCqSgOQwOeTg4HHSsfSPEkbSaZHPComt0ZbhsArcEnhiD/Ft4x2IPXNZP2nWehrGFO14wN+6muJ/MLs0ixfM5Yk4A6k/41BdXMFu8aXcqwo3Vjz1GRgDr26dM1gSavLbXUcb3EsTyN5KSl97hegQ8YK5xgn6GoLv7dal7W6aOaFk3h3Qb0BOcsBxj2GDisWlu3c6Ywl8KVia915QYgXMMsoIjVhjDeh9v1pmo6pHd6fA0cT+dgxyAuQTg4AGPQ5/OsWeAajP9naO3jhcZ+bhSwHHzdQDzz2NUtOlubS1ZZGDxiRsOTmRe3J/rQldXiauMYtcxJcySQ+W8crlgwBEh3DPoT1U/mKYszqjOf9XnaVIyVHYg06b54tkasrZyWJ4J9R71Nplk80fmHPuCeG+oq4aLUmprsatjahLuKX7wwc+orUEbbmZyScAptFJYxlmX5MsBtxitMRsg+ZQeceoFRzamciKKJyyuFbcF+bHao5FMsrKgy7c7QOuK00iVfmUFo9uMg/nTFjMZUxbQ2OSwzyD2poxfkYctujIMx4kz1HaqhQiVtp8xMjnGDitmWFAuSW8w5Kn0qk26KNcjcueSKtaCuZV4uJRs+UZwM85qqUVGIXKn+6egrTvCXLhE6e/Jqo6CRQ0UhcjjY/at4u5lMwfFeP8AhG9WYr96zl5H+4a+za+L/Fh2eHNVUgqDaS4/74NfaFehR2OCe54/+00u/wALeHF9daX/ANJbmvGdPY28floRzweOley/tNkDwt4cJOB/bS8/9utzXjFmQASU+X1zya58VujqwuzLHlbm8xOuduf/AK1WViwmSC2OhHFMt2YNhOOM7Rz+NXZomCxrGdyk7iduOK4ZHchltbKX2rwMZzVqS2kmOWJBQevBpINsrZXdhe3ritK0hCo4IypbJOf0Fc8mbXtqc3c2rQ/OcEnLHHfjiq+oxSLYiNcICOQOp710F1bq822UOIuvPb2zVK8szNukCssY4CnoRVRlYdubc4cq9k+37qkbif510dhqUjNGWj8xzhUVmwAPw6D+dLqdhFcfu8ZAXeeOnNYDLPpbI3Vsll56Ctr82xK03O2BcQCQThHO7dIz52KOuF6AehNQ22owFymlst6Cgc3JmLZPcE+vsK5iJxrAihudw0tOXjJwbkjn5v8AYz27967O2kjht0SErHbxqcKigAe3FDtH1BNvXoXodSluLaJZ1gCSDeSAd5x6e1CmCXaP3ahujZ61ziiW+uJlV2Fo/wAz5XaZAB90HqFH61M2I9SQhvI06G3y5Qnhu6jjggD9ahxu9TSNkrrqa1zYqsZWLzMD5iF96adKFwTvtYXLYwjLwv50kF/vubSFsI0oCc9ETHyqf9r3Nbt3rAt9JijmjVktyzqQuGcfxHPfaOcd+lOMX0YSm7bXKFh4U+0TRLa6WqiQhRiPgt9e1b58L3ullkmtmZuflX5iAOSQB296oeGvF11e4Oljzkt41W5KgQ7QWyiKe7jjJPQHvWtc+IZGMupWf2hJoCxdjJnzMcFc9uQcH26Vu6cbe83c5eepf3YqxVeyWLCTMwjeJnjIxgkdRz0x3/D1qrb3MV55lvaPH5kT4kJyAmMZB79Dn2q2Htmsn8uNpWaPckTuXwWHzPxyAR2J/Cua8MwSWutGGaSONJQVeaRQ3mNj5WA7vgAZHoM4rJxhFqxpGUmnzdDs4reG0uJPti+Q20eUpwxyTjJHoevYjNXZZm3vbzx+bHDHt2q2AuOmD3HfjvVLzEgvoJnRJLm3O3dN828H+9g8ntx0PNQ3N+SMPD5cYO5QeSvOevT/APVRKSirIiKcndlxGYCOaeKM7VJ3g4I54YZ5NJeXPkYdGdjLh2yR8wP3d2PWsW+vGjG/lpApJwmcDsSe+fTHSqMk89zBFNkm2kyFYNgSEfeUY5GPesrvY0VNNpmrf6rJLlEeM7zudAuNh7DjtgVY00tdKbidAPL+8Zm2kE9MetZlnA9xGss7RNGo2x564z7dcd66JI/OnQSOkAAU52fIWUf1ppNu7CTUVZF+1u0hykkcZVNynk5578cflzWjaanJJEYLmK2EMTDqw3lcfK7dsY4wapWdlsjU27QtNkbHHzbs/wAJ9D/k028MQkkSJcrgANuzg9z+f8q3UpQWpyOMZPQrXxENw2+Ql9vKEnIyODz0/wABXPXzguQc7u1XLk/vWcktIc5bPJPvWdMCH2nJyOp9a45Scnc6oq2hBArbgOM5wamn+UhQBupVCoQxbGONvemzMxfkEc49aBESKGkAGTuPGT09atW4Kk5GSDjjnAqsjnK84YDbV+04KsSMHj0zUtll+yLhwNwweQauQuGJDFgFzgrzkehrNjkEM/JIByeR1+lWbQMzMN2SBx2IzWdyrGpaXyOQyJkk4AArUjudqltjSIp/ibOD9B6ViaeFdgitgLyWPf6Vt2SqsJCED1ULgVtTbsZ1EiXfLcEMwdjwWLtuxjpjP1pFVk3ZfzOdxYkYH51J5BUiTcShA24bOD9KiuYWdzucEHoM8j6Vu77syTXQz7zayONmGHYnAz61z13Gz5K545x13Vv3AXPluWUAbMM2ePXPrmsuck43tjPH4fSuWauzeOiMi6UyxlSRu4J5yB9aoFPLKE5bPQ+taF8GaRRG2DnGOxqk+yeVWjTywF2n3Oev1q47EskjIZSARx+hqRPkyeMHg+3vimR4ViwPJPIxSj5nYj1xxTIsXshlXafbB61NbyFZUB/1ZGGC9SPT86qQN87A4IHJz2q7AAVLcYP3R3OapLqhX6HR2V5G88bzqHZEwXPPOMDj9KckBEcURj2ImUdyMKCTxz2BGM1jwSeUyrgsgIbBOP1rYguC6zQKUEzFWj809AD0B9RmumE77mEotaoi1TSBPbwSBlhkkBUujF1JHTIPpgCuX1S1uAw+0ZeeT5g0RGD77un+Heu7iMZkj81wxhlIKMMck8HI7YBqZLKG7syiRyNKFxG/I7nHfGK1dFVNtyY13T32PJt9xZTIDl2XGGGR5Sn+p9a27PxAfLiWJ2XYP4T2B7/UVtT+FYjFclZFgdcAlsj8x0wTnnFc1e6RcwQb5oJFUk4lTG3I4I4/rXNKlOnqjsVSnU3Fs59+o3V/Ewil4Qvt3ZQDGMH1/wDr06S8E95HGxQR7g7YfhgqfKCMYzk9frVKGNkgjMPm+YTkq+Mnjgg9KqGKSO6eae1l3EhAUGR+QrJSaWhXIm7kviDT7a50+X7GTC2DJMka8Y78e2azfDBMuhxXNxF5Vw4I3mQsQAdvToBgA96tXF1AhkbLxsQQ4xtJ9M5qhpU4GmxxrcIBGzZR+Rndnj86fNoVytJEGnW6RWlujS3Uhtr9ikmR5aKZCMbevO6q3iSKPSL22lssQKkoBkT52Of0IB4/CrKuUjZvNjYvLlR0xu4/HFUdVaZ444ScQ5+baR3789DTe40uZ6k2sLHPaGG5/eTO++SRlAIXrhR2PpSWex41klkLFSUYHglu5OPzoiVpwpUgoqgA7upHGTUWnWc8wmjt0wGfIwenGD/KlZ7Fc2hnzL5Lqgf9wM7QP4Aev68/nVK2SbzJjGAil9rMeg966d9Ed5RFJExEqkkt8uD2H1rT0XSVUv5igkAKR2HHGfWr2Rm59TB0zS5ADFKryMF3R5OOD6fSuli0kNHgjaFAG5e/HetSztFXeOflIC8Ddjrk+laAt/k44G48+neoeu5Dm+hQitVWMIpKAj7w5Ge1PCAIVZSDjnd0NXhFhxngKeCBwKayAADILE8ZqbdSCq0MaREBGXICk561VkQxx+WDgAYOOv1q+VDyIA37xsjBOBmmToWJTGQcE5q1rqiW+5kshz5jMpCHGT3FVZYiquEUnB6CtWaNfKymA3XaOg5qjcgK5COfm5YEVRJkkAp1GehDdcVSZEVtuckdj2q/cqpLPgswPHNUnkibaSnzHJOOtbQM5nPeK1X/AIRrWMvki0mwD2+Q19l18a+Ksf8ACO6xhelnNnP+4a+yq9Kj8JwT+I8g/aYGfDHhwYz/AMTpeP8At0ua8TilIJQAEEZZvT2r2z9pjH/CMeHNxIH9tLnH/Xrc14fAyrhpQAgb5RiufE/EdWG+E2LQvFEzsQM/J74q22HO2JyQQADn7vqMVTjwx3MF2tjaCea0E3BlWNUVD1Jrhkd0dS1b2zGOSVS7RJ/COMn2rRgYxqFZgJT2A5FRIg3Ls5C9wOB71diAileUKhOPvZycVg0XcrXMZeQCRR5ftSpEjQsqplehFXJ2Bw0rED/vke1SxQliCrq6A5HaoWg29Dmrqyk+0wmFRyp+XpkCsnWtMjubSXdHlvvZU4wPSu/aHerbkXjn/Gql1p6SxuNvOP4R1HpVxbTFzdzx9bW80afYC0sJUna3Uc9q27LVI54HQybVZSHYjoMda6XVtD88xAZ3r8yc8gd8+1czrOhtDbzTGN45QpwRx2610RtJpg5WTRfhm8mzE6SSEiMsGY7sYHHHpUL200KXCKQ0bPvZmbIztB2n1AyPrwKw9Ol1CGGCaRVniKbjsPPToacmt2+4KTKSfmZ2BwD32+2f5Ucu7ZXPqoxOpsrWZIjPJIWkLbmB5LH/AB6Vd1S8kMBjSAObbdJFMMlWAHKsp4OeRmsC3123lixI/wAo98YNWn1mPaVjlUE8EgjFYq6Nn72hD4JuJbTwhbyQKZJpiW3A9Sxxz/ntXT6fG4tWthIHEa42Mm0Fe6g/j1rkrW/hi062gWcQhQBtQjAGc1ci11Gcb5TIQMAgc06ilzMmnrBNHXaW5GlQRbmjjjyjhXyWK+v4YqjrinzrW8tzme2kBGTjC55U/WsWHWlZ2WJCctkZ4AqC4ub65jeGFUQY5+bJ/Cos+pSjdnYXF7AUbypAX+8rA/Ke2PxFMl1SMsVgk3BUPLk4J9MfnWHpujXWo28JDtuYbSrnaOO9dPb6YnlbSmBwiuvzMGAwef7p7gd6tQRjKSWhnGynkEc8x81Nu/ZHIWcL7nt9K3YbKO+vklnBe4baMR8IBwBkemOTTbOA5ZIpAkbyHODw4X3/AD5FdfpWkwSBFeZt10F3CNRsiHOFJ/iPFbU4c2xhUq8u5UewkneV5kCHgQmNdqEA5Jx/DgAVpafbW0sQkaRZcKR83ykMeTgdx021Pd2YSJ5EnaS4MpVC3yqAB8zAH8Kde3CzoVUjKR+WABkZGOje/rWjtBu5gm5pJFSRPLjKR/uzncVHQ/8A16y55AnmNsUhgRycGtFiojkJBzsGcHjrzn+nvXPanMWyRk7h0wOn+PFcdSXU6YIoyOVwATleQaaVEoyrKOf1p0G13AZfm+715yae4jVSyhQwzkf1rNaI0e5XCgsehlAOeOlMddwDkEKD82KeWPOQUYEDd6/SlOTlT0YnAPA5qbjImPloSfrnGQPXNXbVh5RUkDI+Udj9Kpk7kRWO0A/MMfzqe2f92FdeVJ47j6UhtE0nJUOuV9R2q7bSKsykrksOGPX2rPuFLRsVlChGG055x/WtK0mAJLIpCgsWA61NtSuhqaegKAkDjvjAA7CtqGUsirvVSeAeKwrGQyKqg4TG447Vt2mwIm5CWIxz8orpp9jGogZC16LnevCbAg6A+tPiTcjOejH5cdaYkTSk+XIAd2NgHUegNQ7JlkAhdiwPK4/Sr9SPIgvox5XOQc59D1rFlkUlkI+VG+9jgfSty/ZyW3IAWHPcgVz8wHILvyPYD8KwqKzNYbFK6EflO0TEDOCM8ms4jdLtU7ifvY7fjVi9LSwkDcNvCNjp+HpUW0IFZWyo9sHd3pRY2rbjgCowQPQNn8xTUkVmC7uFJPX9akiBcMcbQe4PWoJgVPy8EjuOn1qiUi0zAIWyck/5zU0cjmJSQMt78CqSFjjABBHSnmVgcqTtVcBT2NO4nE3YZo5EjjiAGxeQR+fNWQQgAyRjBBB53etYNtK0ew444yP51qxSiSRS3OfQ1XNfUXLY6a1njn8s7SbgtuYu2EYYx+pqwvlm5Zk+cSYkwH2iM9GGO446isGxkaKRQjYz97PQj0rUs3gk2NyGO7aB95TnII711UqtzmqU7als28UzQ7cEMoGQ2dxLd+f84qO8s3S72O8ZEqFwki4UEcH26evrUUMsCBGjTZcSBoy6gjcAePo1WCzSrExeKS5i++Jl6D6/r+FdHMmjKzRlXmmaWu2EoIAUDrLgrtx2Hb8KoDQ5UiTyJjOrg452lW79ev1rqboPhIG8t5Fy67F4b2wfWmNiX5oTgDDoAMbWHGOn4VEoRbLjUaRyUlnJE6h9oYAEeamc+p4yKy7HTFWGbFvbhiSxOBjPTj2rvrjYYY8Alecs55B7ggVRWxjMOTFgNkFgp4P9axcLbGqqaann9pokDyeVLaxNiTcBj24xVq50W0MWI4IU3cZ281166ciPgYUjIODnGOR9c80yWz3jBACjB4HSo5WkV7S7vc5Gz0qFYEYQRnOW+7twCT+VOgsoreeVY8gsc/Lxx7V1iW4W33k4HQ8c/lSLHmRnCsGxnoDxRyi5tzAazTaDxGoOTx1Pc/yptjalFdBl2wC2V9PSt54y0ZYnBII+7nFMeNYWUMDgDcvqRS5Q5uhR8gjawUDjJA7j3pxVi2DkFhg54zVuIIX2uxweODzVfBKkHk+ualpD3I0j2SA9MfpUDxBJGOSyZ3VZjbgA5Ax075qtMQzxlhtUd/pU+g9bkJVFYlhnnpnqKbIQFUEEMDgjvVxlUbWOGB/ixVG4lxPhkLLu3A9j6CnawtylcLsZwSApJII5rPljzJgHkD5ZOtal8R5aKWAw2Q2BjntVFpfm80qACmGC+3eqtZk30MSfzJCWVvLPTFZs4cglSBKTgj1rWvmjcKQo8z7p/oazZxtAONxHXHGK1gRPY57xSzN4c1gHjFpNn/vg19m18Z+K1U+GtYIJ3fZJcc9fkNfZlenR+E86e55B+0wQvhjw4WXcBrS8f9ulzXiFuN43noD07V7Z+04QPCvh0k4A1lef+3W5rw63fKId2WPQdvrWOIWtzqwz0NW1i33QxjYvG0dK6OxiiaYO65U8gdvpXN2kRyFkyE/hPr7V0Vm8ip5LouzsnXntXnVGd8VdGusYlVZE3BcliA2P1qeFUU+YpGJOSnbFVZoGFskCuoZztdBztPXr2rSjVFiiRIw7ovzOc8euKy20AgSNTMSEcrncd/I9sVf8uIbUiJDsMvgdKrGA7fNaJuct5QONvpmr2nW5CsHPzlcnn37/AMqSWtim9LkdtEGXfkso4571NsUJhcnIOc9hU0EZRJPLIyzdv4R3qaOFmA2Ljg5ODgjNOKJbMh4gZ1/dExqMknnj0qrqOnWt3ZMjqySfwvn7oPGD7VtyWpwWw3PPBzk9qruhk3Rv8sWcEhuT+FNNrcLX2OSl8Pwx6U8IJR0jGzjPtWdaeF45wi4VokQKMjk8V3E1skcOCCUBClsdOcjFOtbdILdVR8ZyTkdT603NjV0rnAS+DsvgRQyDON3AFJb+CYJVJNpF90s2H6Y9q9Qg8tg4bbkjkADmpjbwyDlABjoO1WtRe0aPI9L8GS3Pms0kG+GTyjuJzgAY7ehFb9n4EEYXe7NvGQFGQ3512el2gN/qDY4lkV1boc7cfnwOlayQgDZvU7fm35wTT+LVidRx0RwsPha3hdgxDKRxu4Gc+1akGiwxx7PJESg55GT9M11z6fGsgd3C7lxhh+tQS3EaQyQgZx93OCRju1Dh3J9o3sc5Faw2txIjuRu+aTsT7CnToyT/ACnllzliOFHb8sD8asTIp3CPyg8ZJRcjLk/5P5VHbxBp5l/dybgMsRuwByQD2yeKz20NbX1HWcMb3UYsUjmJf5SVKhM4GACcY5rpf9Gd2a5cFYpAsjoSsaAf881789c1jIUO0RW8XEjERp91WPAH4VrWlm5iuY7qcKyEAoo+XcTwfr71dOVrpamdSKer0JJ3U3JuYyZY3HAfqvQZI6ZHXApC4YvHu/dIDhRxj3PvSX8rPbogOUiGVGOBzzmoIQ8nmxlzGuwu7Fccdv6VLleVkJRtG7INRmjEawqTtCZL92Pf/wCtXM3Yw0ZVWHQDBzWteTxyqzk7ZDwVA4RccfnWcWLNkHcoPOR3rCbuzeKsRhN22UoMkYypx/k1HKvzqVOQeD3qSUByu0Hb1K9xUFw4DFQcPjkCpZSHISp5C7u3YCntll3BSBk4HfIpm0zAFJmADf3c9fb07VYBMkjxMCExuGP89aQbFabBkzhDnp7VHzKxUcjA3dhipZ4HZc+ZwgzkDGaqxuVlcsMsB07GhlIvRgAOrADjkds1bs0kGAwA3Dk5rOkkbLbnIJyM461ftWKqrAkr1OBnrUsaZr2j4C4Tbgc46CtmGR0CkHIA9f0xWHZIcKo3MF6k1qxMG+ZOh4GfWtabM5pE6XCoGKFvM5znGBSfbXjfDfKuOQByKhiYLkMUyT0AwT60+cuydiGHU88VqmyWkQ3t0X3Nty3oDzg981kz/OxjxtO75c8ZFXZodzFIyGAGW7VmzsvLAEBTtG7jnFYzbbLikloZ1yrwuzgKUPccjArPNusN0WUH95hjn1rWkAMbHL7ByQT/ACqrK5ZVUfeB7+n1oSE2BKqiCRFdwd2c8GmzlHkciERIQGUBt2D9etPgQuVbBCjpk9qaZgZnA2KqnI7k8VTeliEiKJSqE5JzyB71KiHcqjDMThieopjyELgjJboR1NOUAMXXJ56k5zUl7k8W0ysFQqo4DHpTA8yXQZc7dvKnpnPXPrUal84JUKeq44JNTqMsqfMQOoNFwsbVrIzYbPB71egZ45Q0LkYBIIODn0rHtZdsTttymeQK00bcsnJZshT7g960iRJGxBJEUVLjCuknmDcBtcN2NMmtFaJCJMBl4JPy5yflyOh96qQErHMjbmX5cgDpjv8AnVuR0nmufIBUMoYK2QK6VPQ53Fp3RDbXC2zpNbh4SB5cu9gy59gOmKl+0qJQDMHhkYF1Q4C+4744/rVcoPMkE7TvI43lYyMggep5qnLOYgDtLEjI6gYPUYx+vSjnsrFcibN22YyErkyZJZQ2Bx3b2/Gk+0RlmQPuKDiUE4PoPr2rHjun2hd+I06YfAwe2QOTStdokbRjc5LY+UYDY9O9PnRPs9S+kvmJuUFBx06ZHXBomZjG7qmPl6/XtVIXDyMCykEcbXbC4zwAOtOkkKIFWXe0mQxb+Ef0FLmHya2LD4cL6bQTx+GTUIAQkdSTkDsf/rVGJDuIJBZeVBOdw6nP+FSojtIqsw4PPuOv5Ur3YONtBZFLMyhsru5PYD/PaotpMj7ycqu05H605yRtAwyqSzc9+wxUc+0om/lmIJUdRRcEiHZsAdQdzEZJ7+uKYoLlVZcZPQDBP/1qnIGFTdldrZ7e9Rxtgwux6gn3B6Dj9ahlFUOPmJz13MvsOB+NQOu4sAParOFj4f5lHynA/WqjtsJbDHJPPt2xUPQZIxMJ6kqw4z14qm6g/KvOQMcdKsM5eIFht+baKpSytJLtDbdrEE/3vSm3oK2pXvI08jGMAg5z0H0rLlQxeYkbfMpBODWjcPHLOQpxGVOY+x9ax7iQM0nkgFeijPJFD3BXM++jUsxB24JIyec1nSyzxDJUlau3CKr5mYjzOjD+tUpRsDBmwvqOa3pszqWsYPif5/D2sNyV+yTEE9jsNfaNfFnitXTw9qjKcobSXj/gBr7Tr1KWx5ktWeO/tOgN4U8OqRkHWVH/AJK3NeHQqFYBPlKjgkZxX2Hrei6Vr1qtrrmmWOpWyOJFivLdJkVwCAwDAjOCRn3NYv8AwrjwP/0Jvhv/AMFcH/xNKpS5+ppTq8nQ+cbeRWhiIP70dGY8Z+laulmZJDJK5IjGQvqfevef+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDia5ZYK/2vwOqONsrcv4nlEACRiTLjeMsR3NW7ZRG6mU4QjMcanJJJr0z/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ian+z/734f8EX13+7+JxABW2jV1UBsnqdx5p1vl1ZI8Aqclzxn0H0rtf+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJp/Uf734ErF/3TjWKEOXkWMMDtAPU9qsRArJlmbcy4B6Aiuq/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImn9R/vfgP65/dOVucJwowCehPWqy25KgndsOcZwa7P/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mh4G/wBr8P8AggsZb7JxcsbMjohQjvJ2z9Kjjtzsx8rBuOn613H/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNT9QX834f8Ef1232TkUiihX/WEtkAgDirTLH5I2ru3HaSTjHHeuk/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImqWCt9r8BPGX6fic9FCI5gyhocjjAyAfpRJJFE8mTJEn3mHUD/AOtXQ/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E1Twf8Ae/D/AIJP1ry/E5k3aTxthw8hwwBJ4Hc8frWdfXC+csMxBCkFJV+4xPUDjp9emK7f/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mplgm/tfh/wS1jEvs/j/AMA4SFZ7y4LWitH8pTPUAE4zk9TxV2KCFW8pSPMwuY4htUepbnmuu/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JqfqHeX4f8ABG8d/d/EwIIIzNM0ix+RGCFCjA56Ed+v4061zLO0L4CuhZnJ69wK3f8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+Jp/Udve/An65voYk5jztTPkxj5mxkv7Vn3kzRx7rXhpiWeMnoM8ZPY/0rq/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaHgf734f8Eaxlvs/iefXbF0Zuh3EFR1OOpquGUyggsoYbQD1+tek/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNR/Zv8Ae/D/AIJf1/8Au/j/AMA8zY7JgBHkvjLHj2qEkEYcqzA88Yxz0r1L/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4ml/Zv978P+CH9of3fx/4B5xHHsby1JxtyB0H50sYdZAyswViO3+eetejf8K48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE0/7N/vfh/wRfXv7v4nnIl2DaRyck8cCs2eMG4yv3WX8zXrH/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TSeW/3vw/4I1j7fZ/H/AIB5RISoXaRyuefSr9rgYAJV+ARXpH/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNL+zP734f8Ef8AaH938f8AgHEwzr5mTnceAB3HrWlADw55HQY5xXSf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNNZbb7X4f8ABB5h/d/H/gGHGpAJb5ie5PSh1bcAzYHr2xW5/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TV/2f/e/D/gi+v8A938f+Acx8hGI2UgMckDpWdM3lI5c792eD19jXcf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNS8uv9r8P+CH1/8Au/j/AMA83dty+YNy/Xj9KhDJ5hGQWx6V6d/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE0LLv734f8ETx1/s/j/wDy60jY53jHy4znt1p5jQyANgsy/N9PXNenf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0f2d/e/D/gh9f/ALv4nmMkWxcoQACT6fhUUSF1QnoMk8V6n/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E0v7N/vfh/wQ+v/wB38TzKNlGTuxjOfbjtUyeazxcAlgTkfofevR/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaf9nf3vw/4IfXv7v4/wDAODtuJMyqWBOQQBWlbSbHw4woIU4PUZ7V1X/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNNZfb7X4f8EX17+7+P/AMUJIJ5AhyFOMevepolSSVT8wVlwoz93PXFan/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNafUv7xH1vyMtzJvEkhyV4DYwQMcfWoI5PIhR7tWO35kwcg+3sa2/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaPqf978A+t/3TnJLdzI0u1o4icjkAAn/ZqvNDIYHaGKVFPTIBJA7g+nWur/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JpfUb/a/Af1z+6cik5HzIy5PALfMw9x6fWpo5lDqdsjk9hjJI7kmuo/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AIml9Rf834D+uf3fxOXgkHklUKoM8lR1HpmrkMgKhFyC4wEz94j/AGjW5/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E01gn/ADfh/wAETxd/s/iYrkLGGyEOwknHUj+nao98by/Luw2NpPJY+341vf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0fUv734C+t+X4nMzJmVIy6l25Ptg96Y7bbdiQpzwWz0NdT/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TR9R/vfh/wAEPrfkcdIXKgQMGRj84Bxk9qheLny95AwVYjscZx7iu3/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJpfUP734D+uf3Tz2VysmMsOVHlrx0H/wBaq8qhHUMowzggZ6H/AAr0r/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4ml9Q/vfh/wQ+ueX4njdy+IBCQwnLvlyevfA9PTFZ0rpBKGD4Zh8qHse9e6/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNP6j/e/D/gj+uf3fxPn65IMagLhAd30FVZ2Rc4+4T+VfRf/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNaRwnL1M5YnmVrHyt4nbHhnVAgJBtJs+w2GvtOuV/4Vx4H/6E3w3/AOCuD/4muqrrirHKf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Right eye of a HIV patient with coexisting tubercular uveitis showing iris granuloma and hypopyon. Anterior chamber aspiration revealed acid-fast bacilli, confirming the diagnosis of tuberculosis.",
"    <br/>",
"    (Panel B) Severe form of immune recovery uveitis resulting in perforation of the right eye following highly active antiretroviral therapy (HAART) and antitubercular treatment. Iris is seen prolapsed through the perforation site at the limbus.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3401=[""].join("\n");
var outline_f3_20_3401=null;
var title_f3_20_3402="Tumor lysis syndrome: Prevention and treatment";
var content_f3_20_3402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor lysis syndrome: Prevention and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Ching-Hon Pui, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/20/3402/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/20/3402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21712030\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Catabolism of the nucleic acids to uric acid leads to hyperuricemia; the marked increase in uric acid excretion can result in the precipitation of uric acid in the renal tubules and acute renal failure. Hyperphosphatemia with calcium phosphate deposition in the renal tubules can also cause renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491545#H491545\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TLS is defined both by laboratory criteria (",
"    <a class=\"graphic graphic_table graphicRef59424 \" href=\"UTD.htm?19/28/19915\">",
"     table 1",
"    </a>",
"    ) and by clinical features (",
"    <a class=\"graphic graphic_table graphicRef72208 \" href=\"UTD.htm?20/59/21436\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TLS most often occurs after the initiation of cytotoxic therapy in patients with clinically aggressive and highly aggressive lymphomas (particularly the Burkitt subtype) and acute lymphoblastic leukemia. However, it can occur spontaneously and with other tumor types that have a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H9#H9\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover prevention and treatment of TLS. The definition, classification, pathogenesis, risk factors, etiology, and clinical presentation are covered in detail elsewhere, as are issues related to treatment of the particular malignancies that are associated with TLS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Tumor lysis syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the complications of acute myeloid leukemia\", section on 'Tumor lysis syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712037\">",
"    <span class=\"h1\">",
"     CLINICAL IMPACT OF TLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential severity of complications from TLS necessitates preventive measures in patients who are at high or intermediate risk for this complication (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 3",
"    </a>",
"    ) and prompts immediate treatment in the event that TLS does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H13#H13\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical impact of TLS during treatment was addressed in a retrospective series of 772 consecutive patients undergoing induction chemotherapy for acute myeloid leukemia (AML) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical TLS (but not laboratory TLS) was associated with a significantly higher risk of death during induction therapy (79 percent [30 of 39 patients] versus 23 percent in those without evidence of clinical TLS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H3#H3\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Cairo-Bishop definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major causes of death in patients with clinical TLS were hemorrhage and renal failure, and clinical TLS was considered a major cause of death in 19 of the 772 patients (2 percent). In addition to an increase in mortality, the development of TLS is also associated with higher rates of treatment-related complications and costs, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of data from the Health Care Utilization project on 600,000 patients treated for a hematologic malignancy, patients who developed acute renal failure requiring dialysis had a significantly longer hospital stay (21 versus 7 days) and fivefold higher total cost per discharge than did those who did not develop renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a multicenter European analysis of 788 patients undergoing induction treatment for newly diagnosed or recurrent acute lymphoblastic leukemia (ALL), AML, or non-Hodgkin lymphoma (NHL) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/4\">",
"       4",
"      </a>",
"      ]. The costs incurred by patients who had hyperuricemia and TLS were significantly higher than those of patients who had hyperuricemia but without TLS.",
"     </li>",
"     <li>",
"      A separate European analysis demonstrated the cost-effectiveness of preventing hyperuricemia and TLS with prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/5\">",
"       5",
"      </a>",
"      ]. The incremental cost of prevention was divided by the average number of life-years saved to produce the incremental cost-effectiveness ratio (ICER), which represents the estimated cost per life-year saved. For pediatric patients, who have high life expectancies, the ICER per life-year saved ranged from 425 to 3054 Euros, depending upon the country. For adults, the ICER ranged from 23,794 to 41,383 Euros with NHL or ALL to close to 100,000 Euros with AML, largely due to the limited life expectancy of these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data provide support for routine prophylaxis of TLS in patients at intermediate or high risk for this complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H13#H13\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21715371\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712044\">",
"    <span class=\"h2\">",
"     IV hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive intravenous (IV) hydration is the cornerstone of preventing TLS and is recommended prior to therapy in all patients at intermediate or high risk for TLS (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of IV hydration is induction of a high urine output to minimize the likelihood of uric acid precipitation in the tubules. However, IV hydration can lead to potentially dangerous fluid overload in patients with underlying renal insufficiency or cardiac dysfunction (particularly if the patient is in an edematous state). Prior to initiation of IV hydration, reversible forms of renal insufficiency (eg, volume contraction, hypercalcemia, urinary tract obstruction) should be corrected.",
"   </p>",
"   <p>",
"    A 2008 International Expert Panel on TLS recommended that both children and adults at risk for TLS initially receive 2 to 3",
"    <span class=\"nowrap\">",
"     L/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day of IV fluid (or 200",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day in children weighing &le;10 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. Urine output should be monitored closely and maintained within a range of 80 to 100",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per hour (2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for both children and adults, 4 to 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour if &le;10 kg). Diuretics can be used to maintain the urine output, if necessary, but should not be required in patients with relatively normal renal and cardiac function.",
"   </p>",
"   <p>",
"    The choice of hydration fluid depends upon the clinical circumstances. The expert panel suggests the initial use of 5% dextrose one-quarter normal (isotonic) saline [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with hyponatremia or volume depletion, isotonic saline should be the initial hydration fluid. Due to the risk of hyperkalemia and hyperphosphatemia with calcium phosphate precipitation once tumor breakdown begins, potassium and calcium should be withheld from the hydration fluids, at least initially.",
"   </p>",
"   <p>",
"    There are no guidelines that address the optimal duration of hydration, which should depend on the tumor burden, the type of chemotherapy used (some regimens induce tumor lysis syndrome several days later), the drug sensitivity of the tumor, the patient&rsquo;s ability to drink, and renal function. IV hydration should be continued at least until tumor burden (as indicated by blast cell count as well as liver and spleen size in patients with leukemia, and serum LDH level or tumor size in those with solid tumors) is largely resolved, there is no evidence of significant tumor lysis (as indicated by serum uric acid and phosphorus level), and patient can drink adequately with good urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712051\">",
"    <span class=\"h2\">",
"     Urinary alkalinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of urinary alkalinization with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is unclear and controversial. In the past, alkalinization to a urine pH of 6.5 to 7.0 or even higher was recommended to convert uric acid to the more soluble urate salt, thereby diminishing the likelihood of uric acid precipitation in the tubules.",
"   </p>",
"   <p>",
"    However, this approach has fallen out of favor for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no data demonstrating the efficacy of this approach. In addition, the only available experimental study suggested that hydration with saline alone is as effective as alkalinization in minimizing uric acid precipitation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alkalinization of the urine has the potential disadvantage of promoting calcium phosphate deposition in the kidney, heart, and other organs in patients who develop marked hyperphosphatemia once tumor breakdown begins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, the expert panel concluded that use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    was only indicated in patients with metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. The panel could not reach a consensus regarding alkalinization in patients who will receive treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    but suggested that high serum phosphate levels preclude the use of sodium bicarbonate in such patients. Alkalinization of the urine is not required in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H21712072\">",
"     'Rasburicase'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21715509\">",
"    <span class=\"h2\">",
"     Hypouricemic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712058\">",
"    <span class=\"h3\">",
"     Allopurinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    is a hypoxanthine analog that competitively inhibits xanthine oxidase, blocking the metabolism of hypoxanthine and xanthine to uric acid (",
"    <a class=\"graphic graphic_figure graphicRef79178 \" href=\"UTD.htm?21/22/21869\">",
"     figure 1",
"    </a>",
"    ). Allopurinol effectively decreases the formation of new uric acid and reduces the incidence of obstructive uropathy in patients with malignant disease at risk for TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, there are several limitations to its use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because it acts by decreasing uric acid formation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      does not reduce the serum uric acid concentration before treatment is initiated. Thus, for patients with preexisting hyperuricemia (serum uric acid &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [446",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      is the preferred hypouricemic agent (see",
"      <a class=\"local\" href=\"#H21712072\">",
"       'Rasburicase'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      increases serum levels of the purine precursors hypoxanthine and xanthine, which may lead to xanthinuria, deposition of xanthine crystals in the renal tubules, and acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491586#H491586\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Xanthinuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      also reduces the degradation of other purines, dose reductions of 65 to 75 percent are needed in patients being treated with 6-mercaptopurine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      has the potential to interact with a number of other drugs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , and thiazide diuretics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712065\">",
"    <span class=\"h4\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    dose in adults is 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every eight hours (maximum 800 mg per day). In children, the dose is 50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every eight hours (maximum 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses every eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose must be reduced by 50 percent in the setting of renal failure.",
"   </p>",
"   <p>",
"    Among patients who are unable to take oral medications, IV&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    can be administered at a dose of 200 to 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, in one to three divided doses (maximum dose 600 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Treatment is generally initiated 24 to 48 hours before the start of induction chemotherapy. It is continued for up to three to seven days afterward until there is normalization of serum uric acid and other laboratory evidence of tumor lysis (eg, elevated serum LDH levels).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712072\">",
"    <span class=\"h3\">",
"     Rasburicase",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    for lowering serum uric acid levels is to promote the degradation of uric acid by the administration of urate oxidase (uricase), which catalyzes oxidation of uric acid to the much more water-soluble compound allantoin (",
"    <a class=\"graphic graphic_figure graphicRef79178 \" href=\"UTD.htm?21/22/21869\">",
"     figure 1",
"    </a>",
"    ). Urate oxidase is present in most mammals but not humans.",
"   </p>",
"   <p>",
"    The identification and cloning of the gene encoding urate oxidase in Aspergillus flavus enabled the development of recombinant urate oxidase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    (Elitek, Fasturtek outside the United States). Rasburicase is expressed in a modified strain of Saccharomyces cerevisiae to minimize the risk of contaminant-related allergic reactions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     Rasburicase",
"    </a>",
"    is well tolerated, rapidly lowers serum uric acid, and is effective in preventing and treating hyperuricemia and tumor lysis syndrome (TLS) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/7,13-19\">",
"     7,13-19",
"    </a>",
"    ]. This rapid reduction in serum uric acid is in contrast to the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , which decreases uric acid formation and therefore does not acutely reduce the serum uric acid concentration.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    for the prevention of TLS in children can be illustrated by the following prospective data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study included 131 patients under the age of 21 who were undergoing induction chemotherapy for hematologic malignancies considered high-risk for TLS (B-ALL or other ALL, advanced stage NHL, or AML) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       Rasburicase",
"      </a>",
"      was administered at a dose of 0.15 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once or twice daily for five to seven days.",
"      <br/>",
"      <br/>",
"      Among the 65 patients with hyperuricemia at presentation, the median serum uric acid concentration rapidly decreased from an average of 9.7 to 1.0",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (577 to 59",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Serum phosphate concentrations decreased to normal within 48 hours, and significant reductions in serum creatinine occurred after 24 hours. No patient required dialysis or developed other clinical consequences of TLS, and there were no adverse events with rasburicase.",
"     </li>",
"     <li>",
"      The superiority of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      was shown in a trial of 52 children with high-risk lymphoma or leukemia or any childhood lymphoma or leukemia with a pretreatment serum uric acid concentration &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (476",
"      <span class=\"nowrap\">",
"       micromol/L);",
"      </span>",
"      patients were randomly assigned to prophylactic rasburicase (0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over 30 minutes daily) or allopurinol (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day in three divided doses), each for five to seven days [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Rasburicase therapy was associated with a much greater reduction in serum uric acid four hours after the first dose (86 versus 12 percent reduction in serum levels) and had an earlier onset of action. Serum creatinine levels steadily declined in patients treated with rasburicase, while they",
"      <strong>",
"       increased",
"      </strong>",
"      over the four days of therapy in the allopurinol group. No patient receiving rasburicase required dialysis, compared to one in the allopurinol group. Severe hemolysis developed in one rasburicase-treated patient who had no evidence of glucose-6-phosphate dehydrogenase (G6PD) deficiency.",
"     </li>",
"     <li>",
"      A Cochrane review evaluating the benefit of urate oxidase for prevention and treatment of TLS in children with cancer included the above randomized trial, and three controlled but not randomized studies comparing outcomes in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      versus urate oxidase (two of which used uricozyme, a nonrecombinant form of urate oxidase derived from Aspergillus flavus, and the other,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/20\">",
"       20",
"      </a>",
"      ]. The frequency of normalization of uric acid was significantly higher with urate oxidase (relative risk [RR] 19.09, 95% CI 1.28 to 285.41), as was the area under the curve of uric acid. One single controlled clinical trial reported significantly lower mortality due to TLS (RR 0.05, 95% CI 0.00 to 0.89) and a lower incidence of renal failure (RR 0.13, 95% CI, 0.05 to 0.35) with urate oxidase as compared to allopurinol.",
"      <br/>",
"      <br/>",
"      Based upon the single randomized trial showing no significant difference in mortality or renal failure between urate oxidase and allopurinol [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/7\">",
"       7",
"      </a>",
"      ], the authors concluded that although urate oxidase might be effective in reducing serum uric acid, it is still unclear whether this translates into a reduction in mortality or renal failure. However, it should be noted that the randomized trial was a small study, included very few high risk patients, and did not have statistical power to detect differences in mortality or risk of renal failure. We believe that the available data represents high-quality evidence supporting the use of rasburicase rather than allopurinol for children with high-risk conditions. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two prospective trials have addressed the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The French Groupe d'Etude des Lymphomes de l'Adulte administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      to 100 patients with aggressive NHL who were considered at high risk for TLS; 11 percent had hyperuricemia at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/15\">",
"       15",
"      </a>",
"      ]. Rasburicase was begun one day before or on day 1 of the start of combination chemotherapy, at a dose of 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day, and was continued for a total of three to seven days.",
"      <br/>",
"      <br/>",
"      Control of uric acid was obtained within four hours of the first dose in all patients and was maintained throughout the period of observation. No patient had an increase in serum creatinine, and serum concentrations of potassium, phosphate, and calcium were also well controlled. Overall tolerance to the drug was excellent, although three patients discontinued treatment early because of a grade 3 increase in liver enzymes.",
"     </li>",
"     <li>",
"      In the only phase III trial to compare",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      , 280 adults with hematologic malignancies at risk for TLS (mainly AML) were randomly assigned to rasburicase alone (0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily on days 1 to 5), rasburicase (0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily on days 1 to 3) plus oral allopurinol (300 mg daily on days 3 to 5) or allopurinol alone (300 mg daily on days 1 to 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/21\">",
"       21",
"      </a>",
"      ]. Compared to allopurinol alone, normalization of serum uric acid (&le;7.5",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      at days 3 to 7 was achieved by a significantly higher percentage of patients receiving rasburicase alone (87 versus 66 percent, p = 0.001); the response rate was also higher for rasburicase plus allopurinol (78 percent) than for allopurinol alone, but the difference was not statistically significant (p = 0.06). Both rasburicase groups were also superior to allopurinol alone in time to control serum uric acid (median time, 4 hours with rasburicase with or without allopurinol versus 27 hours with allopurinol alone). &nbsp;",
"      <br/>",
"      <br/>",
"      The incidence of laboratory TLS was significantly lower with rasburicase as compared to allopurinol alone (41 versus 21 percent, p = 0.003) and tended to be lower with the addition of rasburicase to allopurinol (27 versus 21 percent with allopurinol alone, p = 0.054). The incidence of clinical TLS (defined by changes in two or more laboratory parameters [hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia], and at least one of the following events occurring within seven days of treatment [renal",
"      <span class=\"nowrap\">",
"       failure/injury,",
"      </span>",
"      need for renal dialysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase in serum creatinine &gt;1.5 times the upper limit of normal, arrhythmia, seizure]) was 3 percent in each of the rasburicase groups versus 4 percent with allopurinol alone. The percentage of patients who experienced acute kidney injury was 2 percent with rasburicase alone, 2 percent with allopurinol alone, and 5 percent with combined therapy. It should be noted that the study was not designed to demonstrate a reduction in clinical or laboratory TLS and that only 15 percent of the patients had aggressive B-cell malignancies.",
"      <br/>",
"      <br/>",
"      No drug-related life-threatening events or deaths occurred in the study. Drug-related events reflecting potential hypersensitivity were reported by five patients, four in the rasburicase arm, and one in the rasburicase plus allopurinol arm; most were grade 1 or 2, but one patient had a grade 3 hypersensitivity reaction that led to treatment discontinuation on day 1. Otherwise, the adverse event profiles were similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the available evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    decreases morbidity and laboratory TLS, which can be regarded as an indicator of the risk for clinical TLS, which is in turn, a risk factor for higher hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/22\">",
"     22",
"    </a>",
"    ]. The evidence is stronger for use in children with high risk conditions than in adults. Based upon these data, Rasburicase is approved for use in both children and adults by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712079\">",
"    <span class=\"h4\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMA and FDA dosing guidelines both recommend a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    dose of 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily for up to five (FDA) or seven (EMA) days. The expert consensus panel provided alternative dose recommendations based upon risk stratification (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"     table 3",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H13#H13\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Risk stratification'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk patients or a baseline uric acid level &gt;7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (446",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Intermediate-risk patients with baseline uric acid &le;7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are reasonable dosing guidelines.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     Rasburicase",
"    </a>",
"    is supplied in vials containing 1.5 or 7.5 mg. We generally round the dose to the closest number of vials.",
"   </p>",
"   <p>",
"    Doses are generally administered once daily, although if tumor lysis is massive, an increase to twice daily dosing may be needed. The average duration of therapy is two days, but can vary from one to seven days. There are no guidelines from regulatory agencies or expert groups on this point, and the length of treatment has generally been based on clinical judgement, depending on tumor burden, type of cancer and anticancer treatment, and blood uric acid levels following the first dose.",
"   </p>",
"   <p>",
"    Responses are dose-related. In a phase I study, a single dose of 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    was effective in reducing plasma uric acid concentration, while all healthy volunteers treated with doses &gt;0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    had undetectable plasma uric acid concentration within four hours after administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these data, several small uncontrolled retrospective case series have suggested that lower doses (0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shorter duration therapy (even in a single dose) can be effective in some patients and minimizes cost [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/18,24-30\">",
"     18,24-30",
"    </a>",
"    ]. In some of these studies, adults were treated with a single 3 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/18,28\">",
"     18,28",
"    </a>",
"    ]. The utility of a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    was shown in a randomized trial comparing rasburicase (0.15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    given as a single dose versus daily dose for five consecutive days in 80 adult patients at high to intermediate risk of TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/19\">",
"     19",
"    </a>",
"    ]. Only six (all at high risk) of the 40 patients randomly assigned to the single dose arm required a second dose of rasburicase on day 4 because of uric acid levels &gt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and no patient in either group developed renal insufficiency. Rasburicase was well tolerated, with one case of methemoglobinemia and hemolysis in a single patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency.",
"   </p>",
"   <p>",
"    Based upon these data, single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    may be used in patients at intermediate risk (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or lower) or high risk (0.2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    of TLS. However, we would recommend that these patients receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    after rasburicase treatment. Moreover, uric acid levels should be monitored closely and additional doses of rasburicase given if and when hyperuricemia recurs. It is also imperative that serum uric acid levels be measured accurately (with the sample placed on ice while awaiting assay) in patients treated with rasburicase, particularly when a single low dose is used. (See",
"    <a class=\"local\" href=\"#H21712086\">",
"     'Contraindications and restrictions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21712093\">",
"     'Monitoring guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712086\">",
"    <span class=\"h4\">",
"     Contraindications and restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    label carries a black box warning about anaphylaxis, hemolysis, hemoglobinuria, methemoglobinemia, and interference with serum uric acid measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       Rasburicase",
"      </a>",
"      is",
"      <strong>",
"       CONTRAINDICATED",
"      </strong>",
"      in pregnant or lactating women and in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, because",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , a byproduct of uric acid breakdown, can cause severe hemolysis and methemoglobinemia in patients with the enzyme deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients being considered for rasburicase (especially males) who have the potential for G6PD deficiency by virtue of a history of prior drug-induced hemolytic anemia or",
"      <span class=\"nowrap\">",
"       racial/ethnic",
"      </span>",
"      background (African-American, Mediterranean, or Southeast Asian descent) should undergo screening with available semiquantitative tests. If the screening test is positive, definitive testing using measurement of red blood cell NADPH formation is recommended.",
"      <br/>",
"      <br/>",
"      The diagnosis of G6PD deficiency is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       Rasburicase",
"      </a>",
"      within blood samples will cause enzymatic degradation of uric acid ex vivo if the blood samples are left at room temperature, resulting in spuriously low serum uric acid concentrations, and hence missing the diagnosis of ongoing TLS. Blood samples for determination of uric acid concentrations should be collected in a prechilled tube, immediately placed on ice, and the assay completed within four hours, if possible [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21712093\">",
"       'Monitoring guidelines'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712093\">",
"    <span class=\"h2\">",
"     Monitoring guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine output and serial assays of electrolytes and serum uric acid are the key factors to monitor in patients who are at risk for TLS. Urine output and fluid balance should be recorded and assessed frequently.",
"   </p>",
"   <p>",
"    Although not evidence-based, the 2008 International Expert Panel guidelines made the following recommendations for monitoring in patients at high risk of TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not necessary for all patients to undergo induction therapy in an intensive care unit (ICU) setting. However, patients at high risk of developing TLS (particularly those with advanced Burkitt",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma)",
"      </span>",
"      should be in a position to be readily transferred to an ICU before chemotherapy is started. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H13#H13\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children and adults at high risk for developing TLS should be tested for laboratory and clinical TLS parameters (serum concentrations of uric acid, phosphate, potassium, creatinine, calcium and lactate dehydrogenase [LDH], as well as fluid input and urine output) four to six hours after the initiation of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For all patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      (hence deemed at high risk for TLS), serum uric acid should be reevaluated four hours after administration of the first dose, and every 6 to 12 hours (depending on the risk and degree of tumor lysis) thereafter until normalization of serum LDH and uric acid levels. As noted above, blood samples for uric acid in patients treated with rasburicase should be collected in a prechilled tube, immediately placed on ice, and the assay completed within four hours, if possible (See",
"      <a class=\"local\" href=\"#H21712086\">",
"       'Contraindications and restrictions'",
"      </a>",
"      above.) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Adults at intermediate risk for TLS should be monitored for at least 24 hours after completion of chemotherapy. For multiagent regimens, monitoring should be maintained for 24 hours after administration of the final agent of the first cycle of therapy. If rasburicase is not used initially, serum electrolytes should be measured eight hours after chemotherapy, and the patient might require a one night hospital stay. If TLS has not occurred within 72 hours of multiagent chemotherapy, the likelihood of TLS is very low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others suggest an algorithmic approach to monitoring and management based upon the estimated risk for or presence of TLS (",
"    <a class=\"graphic graphic_algorithm graphicRef63724 \" href=\"UTD.htm?23/2/23592\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712100\">",
"    <span class=\"h1\">",
"     TREATMENT OF ESTABLISHED TLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite appropriate preventive measures, approximately 3 to 5 percent of patients develop laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical evidence of TLS, despite the prophylactic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    . In addition, TLS can occur spontaneously prior to the onset of chemotherapy, primarily in patients with non-Hodgkin lymphoma (NHL) or acute leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H12#H12\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Spontaneous TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with or develop TLS during therapy should receive intensive supportive care with continuous cardiac monitoring and measurement of electrolytes, creatinine, and uric acid every four to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"     33",
"    </a>",
"    ]. Effective management of these cases involves the combination of treating specific electrolyte abnormalities, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    at 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (if it was not given initially) with repeated doses as necessary, attempting to wash out the obstructing uric acid crystals with fluids with or without a loop diuretic, and the appropriate use of renal replacement therapy. Early consultation with an expert in renal medicine is advisable. (See",
"    <a class=\"local\" href=\"#H21712114\">",
"     'Indications for renal replacement therapy'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712107\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;General guidelines for management of electrolyte abnormalities associated with TLS were provided by the 2008 International Expert Panel [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines are valid for children, but some modification is needed in adults (eg, adults with hyperkalemia who have EKG changes related to hypocalcemia are generally given 1000 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    rather than 100 to 200",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    a typical dosing regimen for children), Modified guidelines for adults and children are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef70281 \" href=\"UTD.htm?4/30/4590\">",
"     table 4",
"    </a>",
"    ). Briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia is the most dangerous component of TLS because it can cause sudden death due to cardiac dysrhythmias. Patients should limit potassium and phosphate intake during the risk period for TLS. In addition, frequent measurement of serum potassium (every four to six hours [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"       33",
"      </a>",
"      ]), continuous cardiac monitoring, and the administration of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"       sodium polystyrene sulfonate",
"      </a>",
"      are recommended in patients with TLS and acute kidney injury. Glucose plus insulin or beta-agonists can be used as temporizing measures, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      may be used to reduce the risk of cardiac dysrhythmia. If needed, hemodialysis and hemofiltration effectively removes potassium. (See",
"      <a class=\"local\" href=\"#H21712114\">",
"       'Indications for renal replacement therapy'",
"      </a>",
"      below.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Symptomatic hypocalcemia should be treated with calcium at the lowest doses required to relieve symptoms. To avoid calcium-phosphate precipitation, most symptomatic acutely hypocalcemic patients with hyperphosphatemia due to TLS (particularly if the calcium phosphate product is &gt;60 mg",
"      <sup>",
"       2",
"      </sup>",
"      per dL",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"       33",
"      </a>",
"      ]) should not be treated with calcium until hyperphosphatemia is corrected. In most situations, clinicians should use other oral phosphate binders, even though there are no good studies demonstrating efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/34\">",
"       34",
"      </a>",
"      ]. However, patients with severe symptoms of hypocalcemia (eg, tetany or cardiac arrhythmia) should be considered for calcium replacement regardless of the phosphate level. Asymptomatic patients with hypocalcemia do not require treatment.",
"     </li>",
"     <li>",
"      Despite treatment with a hypouricemic agent, hyperphosphatemia remains a major problem in TLS and can cause acute kidney injury. Strategies aimed at lowering serum phosphate levels (aggressive hydration and phosphate binder therapy) should be used in conjunction with control of uric acid in patients who have established TLS or who are at high risk of developing TLS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491579#H491579\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Hyperphosphatemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific issues pertaining to management of hyperkalemia, hyperphosphatemia, and hypocalcemia in adults are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link\">",
"     \"Overview of the causes and treatment of hyperphosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712114\">",
"    <span class=\"h2\">",
"     Indications for renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite optimal care, severe acute kidney injury develops in some patients, requiring renal replacement therapy. The need for dialysis during induction therapy for high-risk hematologic malignancies has substantially declined since the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    . In one retrospective series, for example, only 2 of 57 children undergoing induction therapy for Burkitt lymphoma or B-ALL who received prophylactic urate oxidase therapy required dialysis during induction therapy, and none died from renal failure or other metabolic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/35\">",
"     35",
"    </a>",
"    ]. This compares favorably to a 1996 report from the United States Pediatric Oncology Group, in which 21 percent of children with advanced Burkitt lymphoma treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , hydration, and urinary alkalinization required hemodialysis during induction chemotherapy, and 5 percent died following a",
"    <span class=\"nowrap\">",
"     metabolic/renal",
"    </span>",
"    complication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In countries where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    is available, hyperuricemia is seldom an indication for dialysis after induction therapy for a hematologic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. However, despite the use of rasburicase, approximately 1.5 percent of children and 5 percent of adults require dialysis during induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for renal replacement therapy are similar to those in patients with other causes of acute kidney injury, although somewhat lower thresholds are used for patients with TLS because of potentially rapid potassium release and accumulation, particularly if urine output is low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=see_link\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the indications for renal replacement therapy in patients with TLS are [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe oliguria or anuria",
"     </li>",
"     <li>",
"      Persistent hyperkalemia",
"     </li>",
"     <li>",
"      Hyperphosphatemia-induced symptomatic hypocalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis for complete recovery of renal function is excellent if dialysis is initiated early to rapidly reduce serum uric acid and phosphate concentrations. Oliguria due to acute uric acid nephropathy responds quickly to hemodialysis with initiation of a diuresis usually occurring as the serum uric acid concentration falls below 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (595",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/37\">",
"     37",
"    </a>",
"    ]. Hemodialysis is efficient in removing uric acid; the clearance is about 70 to 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and serum uric acid levels fall by about 50 percent with each six hour treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/37\">",
"     37",
"    </a>",
"    ]. Peritoneal dialysis is much less efficient with uric acid clearances below 10",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Depending upon the dialyzer and blood flow, phosphate clearance usually ranges from 60 to 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with hemodialysis. The phosphate burden in these patients can vary from 2 to 7 grams per day; as a result, it is frequently necessary to perform hemodialysis at 12 to 24 hour intervals.",
"   </p>",
"   <p>",
"    Continuous renal replacement therapies such as arteriovenous hemodialysis (CAVHD) with a high dialysate flow rate, continuous venovenous hemofiltration (CVVH), and continuous venovenous hemodialysis (CVVHD) may be better tolerated and are also effective in cases of acute kidney injury from TLS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The phosphorus clearance with CAVHD, for example, can reach 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at a dialysate flow rate of four liters per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/39\">",
"     39",
"    </a>",
"    ]. This can lead to the removal of up to 10 grams of phosphorus per day without the rebound hyperphosphatemia often seen after intermittent hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712129\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis and the release of large amounts of potassium, phosphate, and uric acid into the systemic circulation. Deposition of uric acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium phosphate crystals in the renal tubules can result in acute renal failure, which is usually anuric. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491545#H491545\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TLS is observed most frequently in patients with aggressive and highly aggressive lymphomas (particularly the Burkitt subtype) and mature B-cell acute lymphoblastic leukemia following the initiation of cytotoxic therapy, although it may also occur spontaneously",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in other tumor types with a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H9#H9\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Etiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumor-related and patient-related factors can be used to estimate the risk of TLS in individual patients (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H13#H13\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The best treatment is prevention. Our recommendations for prevention and management are based upon a disease-specific estimated risk of TLS (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 3",
"      </a>",
"      ) and follow those of an expert panel on prevention and treatment of tumor lysis syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/42\">",
"       42",
"      </a>",
"      ]. A simplified algorithmic approach to risk stratification and management of TLS is presented in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef63724 \" href=\"UTD.htm?23/2/23592\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712136\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712151\">",
"    <span class=\"h3\">",
"     Hydration and urinary alkalinization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients at high or intermediate risk of TLS, we recommend aggressive fluid hydration (2 to 3",
"      <span class=\"nowrap\">",
"       L/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) to achieve a urine output of at least 80 to 100",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per hour (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If there is no evidence of acute obstructive uropathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypovolemia, a loop diuretic may be used to maintain the urine output, if necessary. (See",
"      <a class=\"local\" href=\"#H21712044\">",
"       'IV hydration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that urinary alkalinization is of benefit, and there are potential harms, especially when phosphate levels are elevated. We recommend that IV administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      not be used in the absence of metabolic acidosis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There is no indication for urinary alkalinization in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H21712051\">",
"       'Urinary alkalinization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712159\">",
"    <span class=\"h3\">",
"     Hypouricemic agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       High-risk",
"      </strong>",
"      &mdash; For the initial management of pediatric and adult patients at high risk for TLS (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 3",
"      </a>",
"      ), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21712072\">",
"       'Rasburicase'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      All patients (especially males) with the potential for glucose-6-phosphate dehydrogenase (G6PD) deficiency by virtue of their",
"      <span class=\"nowrap\">",
"       racial/ethnic",
"      </span>",
"      background (African, Mediterranean, Southeast Asian ancestry) or prior history of hemolytic reaction to a drug should be screened for G6PD deficiency prior to administration of rasburicase. If the screening test is positive, definitive testing (ie, measurement of red blood cell NADPH formation) is recommended. We recommend not using rasburicase in patients with G6PD deficiency (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21712086\">",
"       'Contraindications and restrictions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We recommend a single dose of rasburicase (0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      rather than multiple day therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, if single dose therapy is used, allopurinol treatment should also be given, uric acid levels must be monitored closely and additional doses of rasburicase given when and if hyperuricemia recurs. Blood samples for uric acid should be collected in a prechilled tube, immediately placed on ice, and the assay completed within four hours, if possible. (See",
"      <a class=\"local\" href=\"#H21712079\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Intermediate-risk",
"      </strong>",
"      &mdash; For the initial management of adult and pediatric patients at intermediate risk for TLS (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 3",
"      </a>",
"      ), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      as long as pretreatment uric acid levels are not elevated (ie, &lt;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [476",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, administration of a single dose of rasburicase is a reasonable alternative in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21712058\">",
"       'Allopurinol'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend rasburicase rather than allopurinol if pretreatment uric acid levels are &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (476",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21712175\">",
"       'Management of established TLS'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      If rasburicase is used, we recommend a single dose (0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      3 or 6 mg) rather than multiple day therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, if single dose therapy is used, uric acid levels should be monitored closely and additional doses of rasburicase given when hyperuricemia recurs. Blood samples for uric acid should be collected in a prechilled tube, immediately placed on ice, and the assay completed within four hours, if possible. (See",
"      <a class=\"local\" href=\"#H21712079\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Low-risk",
"      </strong>",
"      &mdash; For patients with a low risk of TLS, we suggest a watch and wait approach with hydration and close monitoring rather than prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712167\">",
"    <span class=\"h3\">",
"     Posttreatment monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at high risk for TLS should receive intensive supportive care with continuous cardiac monitoring, close monitoring of urine output and fluid balance, and frequent serial measurement of electrolytes, creatinine, and uric acid. (See",
"      <a class=\"local\" href=\"#H21712093\">",
"       'Monitoring guidelines'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For children and adults at intermediate or high risk of developing TLS, measurement of serum levels of uric acid, phosphate, potassium, creatinine, calcium and LDH should be assessed four to six hours after the initial administration of chemotherapy, and every 6 to 12 hours thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?3/20/3402/abstract/1,33\">",
"       1,33",
"      </a>",
"      ]. Evidence of TLS or a rising level of uric acid should prompt immediate therapeutic intervention. (See",
"      <a class=\"local\" href=\"#H21712100\">",
"       'Treatment of established TLS'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For all patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      , blood samples for uric acid should be collected in a prechilled tube, immediately placed on ice, and the assay completed within four hours, if possible. (See",
"      <a class=\"local\" href=\"#H21712086\">",
"       'Contraindications and restrictions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adult patients at intermediate risk not receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      , electrolyte levels should be determined eight hours after chemotherapy and monitored for at least 24 hours after completion of the first cycle of chemotherapy (24 hours after administration of the final agent for multiagent regimens). (See",
"      <a class=\"local\" href=\"#H21712093\">",
"       'Monitoring guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21712175\">",
"    <span class=\"h2\">",
"     Management of established TLS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present with or develop TLS during therapy should receive intensive nursing care with continuous cardiac monitoring and measurement of electrolytes, creatinine, and uric acid every four to six hours. Effective management involves the combination of treating specific electrolyte abnormalities (",
"      <a class=\"graphic graphic_table graphicRef70281 \" href=\"UTD.htm?4/30/4590\">",
"       table 4",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute renal failure, the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      (if it was not given initially), attempting to wash out the obstructing uric acid crystals with a loop diuretic and intravenous fluids, and the appropriate use of renal replacement therapy. (See",
"      <a class=\"local\" href=\"#H21712100\">",
"       'Treatment of established TLS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for renal replacement therapy include (see",
"      <a class=\"local\" href=\"#H21712114\">",
"       'Indications for renal replacement therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe oliguria or anuria",
"     </li>",
"     <li>",
"      Persistent hyperkalemia",
"     </li>",
"     <li>",
"      Hyperphosphatemia-induced symptomatic hypocalcemia",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/1\">",
"      Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/2\">",
"      Montesinos P, Lorenzo I, Mart&iacute;n G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/3\">",
"      Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 2008; 8:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/4\">",
"      Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/5\">",
"      Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 11:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/6\">",
"      Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977; 59:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/7\">",
"      Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/8\">",
"      KRAKOFF IH, MEYER RL. PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR. JAMA 1965; 193:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/9\">",
"      McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/10\">",
"      Keuzenkamp-Jansen CW, DeAbreu RA, B&ouml;kkerink JP, et al. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 1996; 18:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/11\">",
"      Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000; 18:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/12\">",
"      Feusner J, Farber MS. Role of intravenous allopurinol in the management of acute tumor lysis syndrome. Semin Oncol 2001; 28:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/13\">",
"      Bertrand Y, Mechinaud F, Brethon B, et al. SFCE (Soci&eacute;t&eacute; Fran&ccedil;aise de Lutte contre les Cancers et Leuc&eacute;mies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. J Pediatr Hematol Oncol 2008; 30:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/14\">",
"      Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/15\">",
"      Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21:4402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/16\">",
"      Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/17\">",
"      Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/18\">",
"      Hummel M, Reiter S, Adam K, et al. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/19\">",
"      Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 2012; 23:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/20\">",
"      Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010; :CD006945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/21\">",
"      Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol 2010; 28:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/22\">",
"      Darmon M, Guichard I, Vincent F, et al. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 2010; 51:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/23\">",
"      Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998; 77 Suppl 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/24\">",
"      Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/25\">",
"      Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/26\">",
"      McDonnell AM, Lenz KL, Frei-Lahr DA, et al. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006; 26:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/27\">",
"      Giraldez M, Puto K. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 2010; 85:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/28\">",
"      Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 2011; 46:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/29\">",
"      Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008; 28:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/30\">",
"      Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009; 34:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/31\">",
"      Sonbol MB, Yadav H, Vaidya R, et al. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol 2013; 88:152.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information for rasburicase available online at file://products.sanofi-aventis.us/elitek/elitek.html (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/33\">",
"      Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/34\">",
"      Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/35\">",
"      Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol 2001; 38:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/36\">",
"      Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/37\">",
"      Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/38\">",
"      Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/39\">",
"      Pichette V, Leblanc M, Bonnardeaux A, et al. High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994; 23:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/40\">",
"      Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 1994; 8:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/41\">",
"      Tan HK, Bellomo R, M'Pis DA, Ronco C. Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration. Int J Artif Organs 2001; 24:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/20/3402/abstract/42\">",
"      Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17050 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3402=[""].join("\n");
var outline_f3_20_3402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21712129\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21712030\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21712037\">",
"      CLINICAL IMPACT OF TLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21715371\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712044\">",
"      IV hydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712051\">",
"      Urinary alkalinization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21715509\">",
"      Hypouricemic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21712058\">",
"      - Allopurinol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21712065\">",
"      Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21712072\">",
"      - Rasburicase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21712079\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21712086\">",
"      Contraindications and restrictions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712093\">",
"      Monitoring guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21712100\">",
"      TREATMENT OF ESTABLISHED TLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712107\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712114\">",
"      Indications for renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21712129\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712136\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21712151\">",
"      - Hydration and urinary alkalinization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21712159\">",
"      - Hypouricemic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21712167\">",
"      - Posttreatment monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21712175\">",
"      Management of established TLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/17050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17050|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/2/23592\" title=\"algorithm 1\">",
"      Algorithm for risk assessment TLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17050|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/22/21869\" title=\"figure 1\">",
"      Uric acid pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/17050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/28/19915\" title=\"table 1\">",
"      Cairo-Bishop define TLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/59/21436\" title=\"table 2\">",
"      Cairo-Bishop TLS grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22701\" title=\"table 3\">",
"      TLS risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/30/4590\" title=\"table 4\">",
"      Mgmt electrolyte abn TLS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=related_link\">",
"      Overview of the causes and treatment of hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=related_link\">",
"      Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_20_3403="Muscle relaxants chronic pain";
var content_f3_20_3403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscle relaxants for chronic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclobenzaprine",
"       </td>",
"       <td>",
"        10 mg&nbsp;three times daily&nbsp;(10 to 40 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carisoprodol (Soma)",
"       </td>",
"       <td>",
"        350 mg three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baclofen (Lioresal)",
"       </td>",
"       <td>",
"        5 mg once a day, titrated gradually to 5 to 10 mg three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methocarbamol (Robaxin)",
"       </td>",
"       <td>",
"        1500 mg four times daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3403=[""].join("\n");
var outline_f3_20_3403=null;
var title_f3_20_3404="Differential diagnosis of pediatric limp etiology by gait";
var content_f3_20_3404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of limp by gait abnormality in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of limp",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antalgic gait",
"      </td>",
"      <td>",
"       Most common; short stance phase caused by pain in the weight-bearing extremity",
"      </td>",
"      <td>",
"       Fracture (including toddler or Salter I fracture), soft tissue injury, transient synovitis, osteomyelitis, septic arthritis, foreign body in forefoot, osteochondritis dissecans, tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trendelenberg gait",
"      </td>",
"      <td>",
"       Downward pelvic tilt during the swing phase caused by weakness or spasm in the contralateral gluteus medius muscle",
"      </td>",
"      <td>",
"       Legg-Calv&eacute;-Perthes, slipped capital femoral epiphysis, developmental dysplasia of the hip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Steppage gait",
"      </td>",
"      <td>",
"       Seen with a foot drop; presents with exaggerated hip and knee flexion during the swing phase to clear the dropped foot from the floor",
"      </td>",
"      <td>",
"       Neurologic diseases which cause loss of dorsiflexion of the ankle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toe-walking gait",
"      </td>",
"      <td>",
"       Child walks on his/her toes caused by heel pain or by increased flexor muscle tone in the lower leg",
"      </td>",
"      <td>",
"       Mild cerebral palsy, Sever disease, heel foreign body, idiopathic, toddler calcaneal fx",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vaulting gait",
"      </td>",
"      <td>",
"       The knee is hyperextended and locked at the end of the stance phase of the gait and the child vaults over the extremity",
"      </td>",
"      <td>",
"       Limb length discrepancy or abnormal knee mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stooping gait",
"      </td>",
"      <td>",
"       Patient shuffles with hip flexed due to irritation of the psoas muscle by intraabdominal inflammation.",
"      </td>",
"      <td>",
"       Appendicitis, pelvic inflammatory disease, psoas muscle abscess",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    See Figure 1 for detailed description of the gait cycle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3404=[""].join("\n");
var outline_f3_20_3404=null;
var title_f3_20_3405="Pros and cons of buprenorphine substitution therapy in pregnancy";
var content_f3_20_3405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pros and cons of buprenorphine substitution therapy in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pros",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Lower risk of overdose.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Fewer drug interactions.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Ability to be treated on an outpatient basis without the need for daily visits to a licensed treatment program.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Dosing of buprenorphine is similar to that in nonpregnant women.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Evidence suggesting less severe neonatal withdrawal.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Insurance in the United States may cover buprenorphine prescribed by a private physician in an office setting, while not covering methadone prescribed at a substance abuse treatment center.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Only limited data are available on pregnancy outcomes after first trimester exposure.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Lack of long-term neurodevelopmental outcome data.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Clinically important patient dropout rate due to dissatisfaction with the drug.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          More difficult induction protocol with the potential risk of precipitated withdrawal.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Increased risk of diversion* (especially the single agent formulation Subutex).",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Less stringent structure of some office-based treatment programs.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          <span style=\"font-family: 'calibri','sans-serif'; font-size: 11pt; mso-fareast-font-family: calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'times new roman'; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">",
"           Reports of maternal hepatic dysfunction and elevated transaminases",
"          </span>",
"          .&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Effects of buprenorphine are only partially reversible by naloxone.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          The maximum daily dose of buprenorphine is 32 mg, due to a ceiling effect, which may not be sufficient in all women (usually those requiring more than 140 mg per day of methadone).",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The combination of buprenorphine and naloxone (Suboxone) is not used during pregnancy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070.",
"       </li>",
"       <li>",
"        Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012; 35:441.",
"       </li>",
"       <li>",
"        Jones HE, Kaltenbach K, Heil SH, et&thinsp;al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3405=[""].join("\n");
var outline_f3_20_3405=null;
var title_f3_20_3406="Hip arthritis in HH";
var content_f3_20_3406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip arthritis in hemochromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 212px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hip radiograph from a patient with hereditary haemochromatosis. The most prominent abnormality is a zone of subchondral radiolucency in the superior pole with some adjacent sclerosis. There is also modest overall hyaline cartilage thinning and minor osteophytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John S Axford, BSc, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3406=[""].join("\n");
var outline_f3_20_3406=null;
var title_f3_20_3407="Interstitial pulmonary edema";
var content_f3_20_3407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Pleural fluid accumulation in interstitial pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the mechanism of pleural fluid accumulation in interstitial pulmonary edema. Lung interstitial liquid can move into the pleural space along a pressure gradient and across leaky pleural membranes (heavy solid arrow). Lymphatic fluid removal is able to increase, but not sufficiently to prevent fluid accumulation in the pleura.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_20_3407=[""].join("\n");
var outline_f3_20_3407=null;
